

## APPLICATION FOR FEDERAL ASSISTANCE

**SF 424 R&R**

		<b>3. DATE RECEIVED BY STATE</b>	<b>State Application Identifier</b>
<b>1. TYPE OF SUBMISSION</b> <input type="radio"/> Pre-application <input checked="" type="radio"/> Application <input type="radio"/> Changed/Corrected Application		<b>4. a. Federal Identifier</b> <b>b. Agency Routing Identifier</b> <b>c. Previous Grants.gov Tracking ID</b>	
<b>2. DATE SUBMITTED</b>	<b>Applicant Identifier</b>		
<b>5. APPLICANT INFORMATION</b>		<b>Organizational DUNS:</b> 046705849	
Legal Name: The Regents of the University of California, Irvine Department: Division: Street1: 5171 California Avenue, Suite 150 Street2: City: Irvine County/Parish: Orange State: CA: California Province: Country: USA: UNITED STATES ZIP / Postal Code: 92697-7600			
Person to be contacted on matters involving this application Prefix: First Name: Middle Name: Last Name: Suffix: Maria Diaz			
Position/Title: Contract and Grant Officer Street1: 5171 California Avenue, Suite 150 Street2: City: Irvine County/Parish: Orange State: CA: California Province: Country: USA: UNITED STATES ZIP / Postal Code: 92697-7600			
Phone Number: (949) 824-3172		Fax Number: (949) 824-2094	Email: mgdiaz1@uci.edu
<b>6. EMPLOYER IDENTIFICATION NUMBER (EIN) or (TIN):</b> 1-952226406-A1			
<b>7. TYPE OF APPLICANT:</b> H: Public/State Controlled Institution of Higher Education Other (Specify): <input checked="" type="radio"/> Small Business Organization Type <input type="radio"/> Women Owned <input type="radio"/> Socially and Economically Disadvantaged			
<b>8. TYPE OF APPLICATION:</b> <input checked="" type="radio"/> New <input type="radio"/> Resubmission <input type="radio"/> Renewal <input type="radio"/> Continuation <input type="radio"/> Revision		If Revision, mark appropriate box(es). <input type="radio"/> A. Increase Award <input type="radio"/> B. Decrease Award <input type="radio"/> C. Increase Duration <input type="radio"/> D. Decrease Duration <input type="radio"/> E. Other(specify):	
Is this application being submitted to other agencies? <input type="radio"/> Yes <input checked="" type="radio"/> No		What other Agencies?	
<b>9. NAME OF FEDERAL AGENCY:</b> National Institutes of Health		<b>10. CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER:</b> TITLE:	
<b>11. DESCRIPTIVE TITLE OF APPLICANT'S PROJECT:</b> Advancing predictive physical modeling through focused development of model systems to drive new modeling innovations			
<b>12. PROPOSED PROJECT:</b> Start Date 07/01/2017		<b>13. CONGRESSIONAL DISTRICT OF THE APPLICANT:</b> Ending Date 06/30/2022 CA-045	

**14. PROJECT DIRECTOR/PRINCIPAL INVESTIGATOR CONTACT INFORMATION**

Prefix: First Name: DAVID Middle Name: Last Name: MOBLEY Suffix:  
 Position/TITLE: Assistant Professor Organization Name: The Regents of the University of California, Irvine  
 Department: PHARMACEUTICAL SCIENCE Division: DEPARTMENT OF PHARMACEUTICAL S  
 Street1: 3134B Natural Sciences 1 Street2:  
 City: Irvine County/Parish: Orange State: CA: California  
 Province: Country: USA: UNITED STATES ZIP / Postal Code: 92697-7600  
 Phone Number: (949) 824-6383 Fax Number: (949) 824-2949 Email: dmobley@uci.edu

**15. ESTIMATED PROJECT FUNDING**

a. Total Federal Funds Requested	\$1,962,858.00
b. Total Non-Federal Funds	\$0.00
c. Total Federal & Non-Federal Funds	\$1,962,858.00
d. Estimated Program Income	\$0.00

**16. IS APPLICATION SUBJECT TO REVIEW BY STATE EXECUTIVE ORDER 12372 PROCESS?**

- a. YES  THIS PREAPPLICATION/APPLICATION WAS MADE AVAILABLE TO THE STATE EXECUTIVE ORDER 12372 PROCESS FOR REVIEW ON: DATE:
- b. NO  PROGRAM IS NOT COVERED BY E.O. 12372; OR  PROGRAM HAS NOT BEEN SELECTED BY STATE FOR REVIEW

**17. By signing this application, I certify (1) to the statements contained in the list of certifications\* and (2) that the statements herein are true, complete and accurate to the best of my knowledge. I also provide the required assurances \* and agree to comply with any resulting terms if I accept an award. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties. (U.S. Code, Title 18, Section 1001)**

I agree

*The list of certifications and assurances, or an Internet site where you may obtain this list, is contained in the announcement or agency specific instructions.*

**18. SFLLL or other Explanatory Documentation. File Name: Mime Type:****19. Authorized Representative**

Prefix: First Name: Maria Middle Name: Last Name: Diaz Suffix:  
 Position/TITLE: Contract and Grant Officer Organization Name: The Regents of the University of California, Irvine  
 Department: Division:  
 Street1: 5171 California Avenue, Suite 150 Street2:  
 City: Irvine County/Parish: Orange State: CA: California  
 Province: Country: USA: UNITED STATES ZIP / Postal Code: 92697-7600  
 Phone Number: (949) 824-3172 Fax Number: (949) 824-2094 Email: mgdiaz1@uci.edu

**Signature of Authorized Representative**

**Date Signed**

**20. Pre-application File Name: Mime Type:****21. Cover Letter Attachment File Name: coverletter1005723917.pdf Mime Type: application/pdf**

Center for Scientific Review  
National Institutes of Health  
6701 Rockledge Drive  
Bethesda, MD 20892-7710

To Whom It May Concern:

Attached please find my R01 proposal, "Advancing predictive physical modeling through focused development of model systems to drive new modeling innovations", in response to PA-16-160.

**Please assign this application to the following:**

Institutes/Centers:

National Institute of General Medical Sciences – NIGMS

Scientific Review Groups:

Macromolecular Structure & Function D Study Section – MSFD

I am comfortable having anyone in this general area review my proposal. This proposal is at the interface of computational chemistry, thermodynamics and physical chemistry, medicinal chemistry, and supramolecular chemistry.

It is important to note that this work as a complement to the existing NIH funded Drug Design Data Resource (D3R) in that the work proposed here will help ensure that computational methods become suitable to apply in the D3R Grand Challenges.

Thank you very much for your help, and please don't hesitate to contact me if there are any questions or problems.

Sincerely,

David L. Mobley  
Associate Professor  
Department of Pharmaceutical Sciences and Department of Chemistry  
University of California, Irvine  
Irvine, CA 92697  
949-385-2436  
[dmobley@uci.edu](mailto:dmobley@uci.edu)

## **Project/Performance Site Location(s)**

### Project/Performance Site Primary Location

Organization Name: The Regents of the University of California Irvine

Province: \* Country: USA: UNITED STATES \* Zip / Postal Code: 92697-3958

DUNS Number: 046705849 \* Project/Performance Site Congressional District: CA-045

## Project/Performance Site Location 1

Organization Name: Memorial Sloan Kettering Cancer Center

\* City: New York      County:      \* State: NY: New York  
\* Country: USA: UNITED      \* Zip / Postal Code:

Province: STATES 10065-6007

Environ Biol Fish (2010) 91:1–10  
DOI 10.1007/s10641-010-9999-0

## Project/Performance Site Location 2

Organization Name: The Administrators of the Tulane Educational Fund

\* Street1: 6823 St Charles Street2:  
\* City: New Orleans County: \* State: LA: Louisiana  
\* Zip / Postal Code: \* Country: USA: UNITED

Province: **STATES** County: **DELAWARE** Zip Code: **70118-5665**

---

Digitized by srujanika@gmail.com

## Project/Performance Site Location 3

Organization Name: University of Maryland College Park

Province: **Alberta** County: **Calgary** Zip: **20742-5141**  
**STATES**

#### Additional Methods

## RESEARCH & RELATED Other Project Information

1. * Are Human Subjects Involved? <input type="radio"/> Yes <input checked="" type="radio"/> No		
1.a. If YES to Human Subjects		
Is the Project Exempt from Federal regulations? <input type="radio"/> Yes <input type="radio"/> No		
If yes, check appropriate exemption number		
Exemption Number: _ 1 _ 2 _ 3 _ 4 _ 5 _ 6		
If no, is the IRB review Pending? <input type="radio"/> Yes <input type="radio"/> No		
IRB Approval Date:		
Human Subject Assurance Number		
2. * Are Vertebrate Animals Used? <input type="radio"/> Yes <input checked="" type="radio"/> No		
2.a. If YES to Vertebrate Animals		
Is the IACUC review Pending? <input type="radio"/> Yes <input type="radio"/> No		
IACUC Approval Date:		
Animal Welfare Assurance Number		
3. * Is proprietary/privileged information <input type="radio"/> Yes <input checked="" type="radio"/> No included in the application?		
4.a.* Does the Project have an Actual or Perceived Impact – positive or negative – on the environment? <input type="radio"/> Yes <input checked="" type="radio"/> No		
4.b. If yes, please explain:		
4.c. If this project has an actual or potential impact on the environment, has an exemption been authorized or an environmental assessment (EA) or environmental impact statement (EIS) been performed? <input type="radio"/> Yes <input type="radio"/> No		
4.d. If yes, please explain:		
5.a.* Is the research performance site designated, or eligible to be designated, as a historic place? <input type="radio"/> Yes <input checked="" type="radio"/> No		
5.b. If yes, please explain:		
6.a.* Does this project involve activities outside the U.S. or partnership with International Collaborators? <input type="radio"/> Yes <input checked="" type="radio"/> No		
6.b. If yes, identify countries:		
6.c. Optional Explanation:		
7. Project Summary/Abstract	Abstract1005646846.pdf	Mime Type: application/pdf
8. Project Narrative	Project_Narrative1005646847.pdf	Mime Type: application/pdf
9. Bibliography & References Cited	References1005723865.pdf	Mime Type: application/pdf
10. Facilities & Other Resources	Facilities_Resources_Combined_R11005724160.pdf	Mime Type: application/pdf
11. Equipment	Equipment1005724131.pdf	Mime Type: application/pdf

## PROJECT SUMMARY / ABSTRACT

This work seeks to advance quantitative methods for biomolecular design, especially for predicting biomolecular interactions, via a focused series of community blind prediction challenges. Physical methods for predicting binding free energies, or “free energy methods”, are poised to dramatically reshape early stage drug discovery, and are already finding applications in pharmaceutical lead optimization. However, performance is unreliable, the domain of applicability is limited, and failures in pharmaceutical applications are often hard to understand and fix. On the other hand, these methods can now typically predict a variety of simple physical properties such as solvation free energies or relative solubilities, though there is still clear room for improvement in accuracy. In recent years, blind prediction challenges have played a key role in driving innovations in prediction of physical properties and binding, especially in the form of the SAMPL series of challenges. Here, we will continue and extend SAMPL prediction challenges to include new physical properties, more complicated host-guest binding data, and application to biomolecular systems. Carefully selected systems and novel experimental data will provide challenges of gradually increasing complexity spanning between systems which are now tractable to those which are marginally out of reach of today’s methods but still slightly simpler than those covered by the Drug Design Data Resource (D3R) series of challenges on existing pharmaceutical data. We will work with D3R to run blind challenges on the data we generate and to ensure it is designed to maximally benefit the field.

In **Aim 1**, we will collect new measurements on partitioning, distribution, and protonation of drug-like compounds, in collaboration with partners in the pharmaceutical industry. In **Aim 2**, we leverage our expertise in host-guest binding to generate new data on host-guest binding in cucubiturils and deep cavity cavitands. And in **Aim 3**, we use high-throughput robotic experiments to generate new protein-ligand binding data of biological relevance. **Aim 4** focuses on using this data to run blind SAMPL challenges, motivating the community to test, understand, and improve these methods. We will also run reference calculations with the latest techniques.

This work will ensure the continued success of SAMPL challenges which have already driven considerable innovation in the field and been the focus of more than 90 different publications (each typically cited 5-50 times) since their inception around 2007, and will play a key role in driving the next several generations of improvements in computational techniques for molecular design. The research proposed here will lead to significant improvements in the predictive power of physical models for drug discovery, molecular design and the prediction of physical properties.

## **PROJECT NARRATIVE**

Physical methods for designing small molecule therapeutics are poised for a breakthrough, allowing molecular design for targeted treatment of diseases, personalized medicine, and rapid drug development. However, careful stress testing and improvement of these methods is necessary to make them sufficiently reliable and robust for the enormous range of problems they can potentially solve. Here, we will generate new experimental data on carefully selected and tailored systems, using it to drive a series of blind community challenges which will engage the community in testing and improving these methods, preparing the methods to have the dramatic impacts on human health that they promise.

## Full List of SAMPL References

- [1] Monroe, J. I. and Shirts, M. R.: Converging free energies of binding in cucurbit[7]uril and octa-acid host–guest systems from SAMPL4 using expanded ensemble simulations. *J Comput Aided Mol Des.* 28(4): 401–415, March 2014.
- [2] Muddana, H. S., Yin, J., Sapra, N. V., Fenley, A. T., and Gilson, M. K.: Blind prediction of SAMPL4 cucurbit[7]uril binding affinities with the mining minima method. *J Comput Aided Mol Des.* 28(4): 463–474, February 2014.
- [3] Gallicchio, E., Chen, H., Chen, H., Fitzgerald, M., Gao, Y., He, P., Kalyanikar, M., Kao, C., Lu, B., Niu, Y., Pethe, M., Zhu, J., and Levy, R. M.: BEDAM binding free energy predictions for the SAMPL4 octa-acid host challenge. *J Comput Aided Mol Des.* 29(4): 315–325, March 2015.
- [4] Mikulskis, P., Cioloboc, D., Andrejić, M., Khare, S., Brorsson, J., Genheden, S., Mata, R. A., Söderhjelm, P., and Ryde, U.: Free-energy perturbation and quantum mechanical study of SAMPL4 octa-acid host–guest binding energies. *J Comput Aided Mol Des.* 28(4): 375–400, April 2014.
- [5] Hsiao, Y.-W. and Söderhjelm, P.: Prediction of SAMPL4 host–guest binding affinities using funnel metadynamics. *J Comput Aided Mol Des.* 28(4): 443–454, February 2014.
- [6] Bhakat, S. and Söderhjelm, P.: Resolving the problem of trapped water in binding cavities: Prediction of host-guest binding free energies in the SAMPL5 challenge by funnel metadynamics. *J Comput Aided Mol Des.* 2016.
- [7] Pal, R. K., Haider, K., Kaur, D., Flynn, W., Xia, J., Levy, R. M., Taran, T., Wickstrom, L., Kurtzman, T., and Gallicchio, E.: A combined treatment of hydration and dynamical effects for the modeling of host-guest binding thermodynamics: The SAMPL5 blinded challenge. *Journal of Computer-Aided Molecular Design.* 2016.
- [8] Yin, J., Henriksen, N. M., Slochower, D. R., and Gilson, M. K.: The SAMPL5 Host-Guest Challenge: Binding Free Energies and Enthalpies from Explicit Solvent Simulations. *J Comput Aided Mol Des.* 2016.
- [9] Bosisio, S., Mey, A. S. J. S., and Michel, J.: Blinded predictions of host-guest standard free energies of binding in the SAMPL5 challenge. *J Comput Aided Mol Des.* 2016.
- [10] Tofoleanu, F., Lee, J., Pickard IV, F. C., König, G., Huang, J., Baek, M., Seok, C., and Brooks, B. R.: Absolute binding free energy calculations for octa-acids and guests. *J Comput Aided Mol Des.* 2016.
- [11] Mobley, D. L., Wymer, K. L., Lim, N. M., and Guthrie, J. P.: Blind prediction of solvation free energies from the SAMPL4 challenge. *J Comput Aided Mol Des.* 28(3): 135–150, March 2014.
- [12] Muddana, H. S., Fenley, A. T., Mobley, D. L., and Gilson, M. K.: The SAMPL4 host–guest blind prediction challenge: An overview. *J Comput Aided Mol Des.* 28(4): 305–317, March 2014.
- [13] Sullivan, M. R., Sokkalingam, P., Nguyen, T., Donahue, J. P., and Gibb, B. C.: Binding of carboxylate and trimethylammonium salts to octa-acid and TEMOA deep-cavity cavitands. *J Comput Aided Mol Des.* pp 1–8, July 2016.
- [14] Deng, N., Forli, S., He, P., Perryman, A., Wickstrom, L., Vijayan, R. S. K., Tiefenbrunn, T., Stout, D., Gallicchio, E., Olson, A. J., and Levy, R. M.: Distinguishing Binders from False Positives by Free Energy Calculations: Fragment Screening Against the Flap Site of HIV Protease. *J. Phys. Chem. B.* 119(3): 976–988, January 2015.
- [15] Li, L., Dill, K. A., and Fennell, C. J.: Testing the semi-explicit assembly model of aqueous solvation in the SAMPL4 challenge. *J Comput Aided Mol Des.* 28(3): 259–264, January 2014.
- [16] Paranhewage, S. S., Gierhart, C. S., and Fennell, C. J.: Predicting water-to-cyclohexane partitioning of the SAMPL5 molecules using dielectric balancing of force fields. *J Comput Aided Mol Des.* pp 1–7, August 2016.
- [17] Klamt, A., Eckert, F., Reinisch, J., and Wichmann, K.: Prediction of cyclohexane-water distribution coefficients with COSMO-RS on the SAMPL5 data set. *J Comput Aided Mol Des.* pp 1–9, July 2016.

- [18] Tielker, N., Tomazic, D., Heil, J., Kloss, T., Ehrhart, S., Güssregen, S., Schmidt, K. F., and Kast, S. M.: The SAMPL5 challenge for embedded-cluster integral equation theory: Solvation free energies, aqueous pKa, and cyclohexane–water log D. *J Comput Aided Mol Des.* pp 1–10, August 2016.
- [19] König, G., Pickard, F. C., Huang, J., Simmonett, A. C., Tofoleanu, F., Lee, J., Dral, P. O., Prasad, S., Jones, M., Shao, Y., Thiel, W., and Brooks, B. R.: Calculating distribution coefficients based on multi-scale free energy simulations: An evaluation of MM and QM/MM explicit solvent simulations of water-cyclohexane transfer in the SAMPL5 challenge. *J Comput Aided Mol Des.* pp 1–18, August 2016.
- [20] Luchko, T., Blinov, N., Limon, G. C., Joyce, K. P., and Kovalenko, A.: SAMPL5: 3D-RISM partition coefficient calculations with partial molar volume corrections and solute conformational sampling. *J Comput Aided Mol Des.* pp 1–13, September 2016.
- [21] Santos-Martins, D., Fernandes, P. A., and Ramos, M. J.: Calculation of distribution coefficients in the SAMPL5 challenge from atomic solvation parameters and surface areas. *J Comput Aided Mol Des.* pp 1–8, September 2016.
- [22] Perryman, A. L., Santiago, D. N., Forli, S., Santos-Martins, D., and Olson, A. J.: Virtual screening with AutoDock Vina and the common pharmacophore engine of a low diversity library of fragments and hits against the three allosteric sites of HIV integrase: Participation in the SAMPL4 protein–ligand binding challenge. *J Comput Aided Mol Des.* 28(4): 429–441, February 2014.
- [23] König, G., Pickard, F. C., Mei, Y., and Brooks, B. R.: Predicting hydration free energies with a hybrid QM/MM approach: An evaluation of implicit and explicit solvation models in SAMPL4. *J Comput Aided Mol Des.* 28(3): 245–257, February 2014.
- [24] Voet, A. R. D., Kumar, A., Berenger, F., and Zhang, K. Y. J.: Combining in silico and in cerebro approaches for virtual screening and pose prediction in SAMPL4. *J Comput Aided Mol Des.* 28(4): 363–373, January 2014.
- [25] Park, H.: Extended solvent-contact model approach to SAMPL4 blind prediction challenge for hydration free energies. *J Comput Aided Mol Des.* 28(3): 175–186, February 2014.
- [26] Rustenburg, A. S., Dancer, J., Lin, B., Feng, J. A., Ortwine, D. F., Mobley, D. L., and Chodera, J. D.: Measuring experimental cyclohexane–water distribution coefficients for the SAMPL5 challenge. *bioRxiv.* 063081 pp, July 2016.
- [27] Reinisch, J. and Klamt, A.: Prediction of free energies of hydration with COSMO-RS on the SAMPL4 data set. *J Comput Aided Mol Des.* 28(3): 169–173, January 2014.
- [28] Muddana, H. S., Sapra, N. V., Fenley, A. T., and Gilson, M. K.: The SAMPL4 hydration challenge: Evaluation of partial charge sets with explicit-water molecular dynamics simulations. *J Comput Aided Mol Des.* 28(3): 277–287, January 2014.
- [29] Manzoni, F. and Söderhjelm, P.: Prediction of hydration free energies for the SAMPL4 data set with the AMOEBA polarizable force field. *J Comput Aided Mol Des.* 28(3): 235–244, March 2014.
- [30] Sandberg, L.: Predicting hydration free energies with chemical accuracy: The SAMPL4 challenge. *J Comput Aided Mol Des.* 28(3): 211–219, February 2014.
- [31] Brini, E., Paranhewage, S. S., Fennell, C. J., and Dill, K. A.: Adapting the semi-explicit assembly solvation model for estimating water-cyclohexane partitioning with the SAMPL5 molecules. *J Comput Aided Mol Des.* pp 1–11, September 2016.
- [32] Kamath, G., Kurnikov, I., Fain, B., Leontyev, I., Illarionov, A., Butin, O., Olevanov, M., and Pereyaslavets, L.: Prediction of cyclohexane–water distribution coefficient for SAMPL5 drug-like compounds with the QMPFF3 and ARROW polarizable force fields. *J Comput Aided Mol Des.* pp 1–12, September 2016.
- [33] Diaz-Rodriguez, S., Bozada, S. M., Phifer, J. R., and Paluch, A. S.: Predicting cyclohexane/water distribution coefficients for the SAMPL5 challenge using MOSCED and the SMD solvation model. *J Comput Aided Mol Des.* pp 1–11, August 2016.

- [34] Kenney, I. M., Beckstein, O., and Iorga, B. I.: Prediction of cyclohexane–water distribution coefficients for the SAMPL5 data set using molecular dynamics simulations with the OPLS-AA force field. *J Comput Aided Mol Des.* pp 1–14, August 2016.
- [35] Calderaru, O., Olsson, M. A., Riplinger, C., Neese, F., and Ryde, U.: Binding free energies in the SAMPL5 octa-acid host–guest challenge calculated with DFT-D3 and CCSD(T). *J Comput Aided Mol Des.* pp 1–20, September 2016.
- [36] Genheden, S. and Essex, J. W.: All-atom/coarse-grained hybrid predictions of distribution coefficients in SAMPL5. *J Comput Aided Mol Des.* pp 1–8, July 2016.
- [37] Chung, K.-C. and Park, H.: Extended solvent-contact model approach to blind SAMPL5 prediction challenge for the distribution coefficients of drug-like molecules. *J Comput Aided Mol Des.* pp 1–15, July 2016.
- [38] Koziara, K. B., Stroet, M., Malde, A. K., and Mark, A. E.: Testing and validation of the Automated Topology Builder (ATB) version 2.0: Prediction of hydration free enthalpies. *J Comput Aided Mol Des.* 28(3): 221–233, January 2014.
- [39] Yin, J., Henriksen, N. M., Slochower, D. R., Shirts, M. R., Chiu, M. W., Mobley, D. L., and Gilson, M. K.: Overview of the SAMPL5 host–guest challenge: Are we doing better? *J Comput Aided Mol Des.* pp 1–19, September 2016.
- [40] Bannan, C. C., Burley, K. H., Chiu, M., Shirts, M. R., Gilson, M. K., and Mobley, D. L.: Blind prediction of cyclohexane–water distribution coefficients from the SAMPL5 challenge. *J Comput Aided Mol Des.* pp 1–18, September 2016.
- [41] Lee, J., Tofoleanu, F., Pickard, F. C., König, G., Huang, J., Damjanović, A., Baek, M., Seok, C., and Brooks, B. R.: Absolute binding free energy calculations of CBClip host–guest systems in the SAMPL5 blind challenge. *J Comput Aided Mol Des.* pp 1–15, September 2016.
- [42] Jones, M. R., Brooks, B. R., and Wilson, A. K.: Partition coefficients for the SAMPL5 challenge using transfer free energies. *J Comput Aided Mol Des.* pp 1–10, September 2016.
- [43] Pickard, F. C., König, G., Tofoleanu, F., Lee, J., Simmonett, A. C., Shao, Y., Ponder, J. W., and Brooks, B. R.: Blind prediction of distribution in the SAMPL5 challenge with QM based protomer and pKa corrections. *J Comput Aided Mol Des.* pp 1–14, September 2016.
- [44] Cao, L. and Isaacs, L.: Absolute and relative binding affinity of cucurbit[7]uril towards a series of cationic guests. *Supramolecular Chemistry.* 26(3-4): 251–258, March 2014.
- [45] Muddana, H. S. and Gilson, M. K.: Prediction of SAMPL3 host–guest binding affinities: Evaluating the accuracy of generalized force-fields. *J Comput Aided Mol Des.* 26(5): 517–525, January 2012.
- [46] Gibb, C. L. D. and Gibb, B. C.: Binding of cyclic carboxylates to octa-acid deep-cavity cavitand. *J Comput Aided Mol Des.* 28(4): 319–325, November 2013.
- [47] Klimovich, P. V. and Mobley, D. L.: Predicting hydration free energies using all-atom molecular dynamics simulations and multiple starting conformations. *Journal of Computer-Aided Molecular Design.* 24(4): 307–316, April 2010.
- [48] Mobley, D. L., Liu, S., Cerutti, D. S., Swope, W. C., and Rice, J. E.: Alchemical prediction of hydration free energies for SAMPL. *Journal of Computer-Aided Molecular Design.* 26(5): 551–562, PMC3583515, May 2012.
- [49] Muddana, H. S., Varnado, C. D., Bielawski, C. W., Urbach, A. R., Isaacs, L., Geballe, M. T., and Gilson, M. K.: Blind prediction of host–guest binding affinities: A new SAMPL3 challenge. *J Comput Aided Mol Des.* 26(5): 475–487, February 2012.
- [50] Skillman, A. G.: SAMPL3: Blinded prediction of host–guest binding affinities, hydration free energies, and trypsin inhibitors. *J Comput Aided Mol Des.* 26(5): 473–474, May 2012.
- [51] Newman, J., Dolezal, O., Fazio, V., Caradoc-Davies, T., and Peat, T. S.: The DINGO dataset: A comprehensive set of data for the SAMPL challenge. *J Comput Aided Mol Des.* 26(5): 497–503, December 2011.

- [52] Gallicchio, E., Deng, N., He, P., Wickstrom, L., Perryman, A. L., Santiago, D. N., Forli, S., Olson, A. J., and Levy, R. M.: Virtual screening of integrase inhibitors by large scale binding free energy calculations: The SAMPL4 challenge. *J Comput Aided Mol Des.* 28(4): 475–490, February 2014.
- [53] Klamt, A. and Diedenhofen, M.: Blind prediction test of free energies of hydration with COSMO-RS. *J Comput Aided Mol Des.* 24(4): 357–360, April 2010.
- [54] Fennell, C. J., Kehoe, C. W., and Dill, K. A.: Modeling aqueous solvation with semi-explicit assembly. *PNAS.* 108(8): 3234–3239, February 2011.
- [55] Ellingson, B. A., Skillman, A. G., and Nicholls, A.: Analysis of SM8 and Zap TK calculations and their geometric sensitivity. *J Comput Aided Mol Des.* 24(4): 335–342, April 2010.
- [56] Surpateanu, G. and Iorga, B. I.: Evaluation of docking performance in a blinded virtual screening of fragment-like trypsin inhibitors. *J Comput Aided Mol Des.* 26(5): 595–601, December 2011.
- [57] Purisima, E. O., Corbeil, C. R., and Sulea, T.: Rapid prediction of solvation free energy. 3. Application to the SAMPL2 challenge. *J Comput Aided Mol Des.* 24(4): 373–383, April 2010.
- [58] König, G. and Brooks, B. R.: Predicting binding affinities of host-guest systems in the SAMPL3 blind challenge: The performance of relative free energy calculations. *J Comput Aided Mol Des.* 26(5): 543–550, December 2011.
- [59] Kehoe, C. W., Fennell, C. J., and Dill, K. A.: Testing the semi-explicit assembly solvation model in the SAMPL3 community blind test. *J Comput Aided Mol Des.* 26(5): 563–568, December 2011.
- [60] Kumar, A. and Zhang, K. Y. J.: Computational fragment-based screening using RosettaLigand: The SAMPL3 challenge. *J Comput Aided Mol Des.* 26(5): 603–616, January 2012.
- [61] Meunier, A. and Truchon, J.-F.: Predictions of hydration free energies from continuum solvent with solute polarizable models: The SAMPL2 blind challenge. *J Comput Aided Mol Des.* 24(4): 361–372, March 2010.
- [62] Genheden, S., Martinez, A. I. C., Criddle, M. P., and Essex, J. W.: Extensive all-atom Monte Carlo sampling and QM/MM corrections in the SAMPL4 hydration free energy challenge. *J Comput Aided Mol Des.* 28(3): 187–200, February 2014.
- [63] Beckstein, O., Fourrier, A., and Iorga, B. I.: Prediction of hydration free energies for the SAMPL4 diverse set of compounds using molecular dynamics simulations with the OPLS-AA force field. *J Comput Aided Mol Des.* 28(3): 265–276, February 2014.
- [64] Coleman, R. G., Sterling, T., and Weiss, D. R.: SAMPL4 & DOCK3.7: Lessons for automated docking procedures. *J Comput Aided Mol Des.* 28(3): 201–209, February 2014.
- [65] Hogues, H., Sulea, T., and Purisima, E. O.: Exhaustive docking and solvated interaction energy scoring: Lessons learned from the SAMPL4 challenge. *J Comput Aided Mol Des.* 28(4): 417–427, January 2014.
- [66] Reinisch, J., Klamt, A., and Diedenhofen, M.: Prediction of free energies of hydration with COSMO-RS on the SAMPL3 data set. *J Comput Aided Mol Des.* 26(5): 669–673, May 2012.
- [67] Kulp, J. L., Blumenthal, S. N., Wang, Q., Bryan, R. L., and Guarnieri, F.: A fragment-based approach to the SAMPL3 Challenge. *J Comput Aided Mol Des.* 26(5): 583–594, January 2012.
- [68] Klamt, A. and Diedenhofen, M.: Some conclusions regarding the predictions of tautomeric equilibria in solution based on the SAMPL2 challenge. *J Comput Aided Mol Des.* 24(6-7): 621–625, April 2010.
- [69] Fu, J., Liu, Y., and Wu, J.: Fast prediction of hydration free energies for SAMPL4 blind test from a classical density functional theory. *J Comput Aided Mol Des.* 28(3): 299–304, March 2014.
- [70] Hamaguchi, N., Fusti-Molnar, L., and Wlodek, S.: Force-field and quantum-mechanical binding study of selected SAMPL3 host-guest complexes. *J Comput Aided Mol Des.* 26(5): 577–582, February 2012.
- [71] Colas, C. and Iorga, B. I.: Virtual screening of the SAMPL4 blinded HIV integrase inhibitors dataset. *J Comput Aided Mol Des.* 28(4): 455–462, January 2014.

- [72] Ellingson, B. A., Geballe, M. T., Wlodek, S., Bayly, C. I., Skillman, A. G., and Nicholls, A.: Efficient calculation of SAMPL4 hydration free energies using OMEGA, SZYBK1, QUACPAC, and Zap TK. *J Comput Aided Mol Des.* 28(3): 289–298, March 2014.
- [73] Sulea, T. and Purisima, E. O.: Predicting hydration free energies of polychlorinated aromatic compounds from the SAMPL-3 data set with FiSH and LIE models. *J Comput Aided Mol Des.* 26(5): 661–667, December 2011.
- [74] Geballe, M. T., Skillman, A. G., Nicholls, A., Guthrie, J. P., and Taylor, P. J.: The SAMPL2 blind prediction challenge: Introduction and overview. *J Comput Aided Mol Des.* 24(4): 259–279, May 2010.
- [75] Ribeiro, R. F., Marenich, A. V., Cramer, C. J., and Truhlar, D. G.: Prediction of SAMPL2 aqueous solvation free energies and tautomeric ratios using the SM8, SM8AD, and SMD solvation models. *J Comput Aided Mol Des.* 24(4): 317–333, April 2010.
- [76] Skillman, A. G., Geballe, M. T., and Nicholls, A.: SAMPL2 challenge: Prediction of solvation energies and tautomer ratios. *J Comput Aided Mol Des.* 24(4): 257–258, April 2010.
- [77] Gallicchio, E. and Levy, R. M.: Prediction of SAMPL3 host-guest affinities with the binding energy distribution analysis method (BEDAM). *J Comput Aided Mol Des.* 26(5): 505–516, February 2012.
- [78] Mikulskis, P., Genheden, S., Rydberg, P., Sandberg, L., Olsen, L., and Ryde, U.: Binding affinities in the SAMPL3 trypsin and host-guest blind tests estimated with the MM/PBSA and LIE methods. *J Comput Aided Mol Des.* 26(5): 527–541, December 2011.
- [79] Geballe, M. T. and Guthrie, J. P.: The SAMPL3 blind prediction challenge: Transfer energy overview. *J Comput Aided Mol Des.* 26(5): 489–496, April 2012.
- [80] Guthrie, J. P.: SAMPL4, a blind challenge for computational solvation free energies: The compounds considered. *J Comput Aided Mol Des.* 28(3): 151–168, April 2014.
- [81] Nicholls, A., Wlodek, S., and Grant, J. A.: SAMPL2 and continuum modeling. *J Comput Aided Mol Des.* 24(4): 293–306, April 2010.
- [82] Soteras, I., Orozco, M., and Luque, F. J.: Performance of the IEF-MST solvation continuum model in the SAMPL2 blind test prediction of hydration and tautomerization free energies. *J Comput Aided Mol Des.* 24(4): 281–291, March 2010.
- [83] Lawrenz, M., Wereszczynski, J., Ortiz-Sánchez, J. M., Nichols, S. E., and McCammon, J. A.: Thermodynamic integration to predict host-guest binding affinities. *J Comput Aided Mol Des.* 26(5): 569–576, February 2012.
- [84] Sulea, T., Hogues, H., and Purisima, E. O.: Exhaustive search and solvated interaction energy (SIE) for virtual screening and affinity prediction. *J Comput Aided Mol Des.* 26(5): 617–633, December 2011.
- [85] Beckstein, O. and Iorga, B. I.: Prediction of hydration free energies for aliphatic and aromatic chloro derivatives using molecular dynamics simulations with the OPLS-AA force field. *J Comput Aided Mol Des.* 26(5): 635–645, December 2011.
- [86] Benson, M. L., Faver, J. C., Ucisik, M. N., Dashti, D. S., Zheng, Z., and Merz, K. M.: Prediction of trypsin/molecular fragment binding affinities by free energy decomposition and empirical scores. *J Comput Aided Mol Des.* 26(5): 647–659, April 2012.
- [87] Kast, S. M., Heil, J., Güssregen, S., and Schmidt, K. F.: Prediction of tautomer ratios by embedded-cluster integral equation theory. *J Comput Aided Mol Des.* 24(4): 343–353, March 2010.
- [88] Mobley, D. L., Bayly, C. I., Cooper, M. D., and Dill, K. A.: Predictions of Hydration Free Energies from All-Atom Molecular Dynamics Simulations. *J Phys Chem B.* 113: 4533–4537, January 2009.
- [89] Newman, J., Fazio, V., Caradoc-Davies, T., Branson, K., and Peat, T. S.: Practical Aspects of the SAMPL Challenge: Providing an Extensive Experimental Data Set for the Modeling Community. *Journal of Biomolecular Screening.* 14(10): 1245, January 2009.

- [90] Klamt, A., Eckert, F., and Diedenhofen, M.: Prediction of the Free Energy of Hydration of a Challenging Set of Pesticide-Like Compounds†. *J Phys Chem B*. January 2009.
- [91] Guthrie, J. P.: A Blind Challenge for Computational Solvation Free Energies: Introduction and Overview. *J Phys Chem B*. 113(14): 4501–4507, January 2009.
- [92] Marenich, A. V., Cramer, C. J., and Truhlar, D. G.: Performance of SM6, SM8, and SMD on the SAMPL1 Test Set for the Prediction of Small-Molecule Solvation Free Energies. *J. Phys. Chem. B*. 113(14): 4538–4543, April 2009.
- [93] Sulea, T., Wanapun, D., Dennis, S., and Purisima, E. O.: Prediction of SAMPL-1 Hydration Free Energies Using a Continuum Electrostatics-Dispersion Model. *J. Phys. Chem. B*. 113(14): 4511–4520, April 2009.
- [94] Nicholls, A., Wlodek, S., and Grant, J. A.: The SAMP1 Solvation Challenge: Further Lessons Regarding the Pitfalls of Parametrization. *J. Phys. Chem. B*. 113(14): 4521–4532, April 2009.
- [95] Nicholls, A., Mobley, D. L., Guthrie, J. P., Chodera, J. D., Bayly, C. I., Cooper, M. D., and Pande, V. S.: Predicting Small-Molecule Solvation Free Energies: An Informal Blind Test for Computational Chemistry. *J. Med. Chem.* 51(4): 769–779, February 2008.
- [96] Chamberlin, A. C., Cramer, C. J., and Truhlar, D. G.: Performance of SM8 on a Test To Predict Small-Molecule Solvation Free Energies. *J. Phys. Chem. B*. 112(29): 8651–8655, July 2008.

## Bibliography and References Cited

- [97] Mobley, D. L. and Klimovich, P. V.: Perspective: Alchemical free energy calculations for drug discovery. *J. Chem. Phys.* 137(23): 230901, January 2012.
- [98] Christ, C. D. and Fox, T.: Accuracy Assessment and Automation of Free Energy Calculations for Drug Design. *J. Chem. Inf. Model.* 54(1): 108–120, January 2014.
- [99] Deng, N., Forli, S., He, P., Perryman, A., Wickstrom, L., Vijayan, R. S. K., Tiefenbrunn, T., Stout, D., Gallicchio, E., Olson, A. J., and Levy, R. M.: Distinguishing Binders from False Positives by Free Energy Calculations: Fragment Screening Against the Flap Site of HIV Protease. *J. Phys. Chem. B.* 119(3): 976–988, January 2015.
- [100] Sherborne, Bradley, : Opening the lid on FEP. *J Comput Aided Mol Des.* 2016.
- [101] Wang, L., Wu, Y., Deng, Y., Kim, B., Pierce, L., Krilov, G., Lupyan, D., Robinson, S., Dahlgren, M. K., Greenwood, J., Romero, D. L., Masse, C., Knight, J. L., Steinbrecher, T., Beuming, T., Damm, W., Harder, E., Sherman, W., Brewer, M., Wester, R., Murcko, M., Frye, L., Farid, R., Lin, T., Mobley, D. L., Jorgensen, W. L., Berne, B. J., Friesner, R. A., and Abel, R.: Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field. *J Am Chem Soc.* 137(7): 2695–2703, February 2015.
- [102] Christ, C. D. Binding affinity prediction from molecular simulations: A new standard method in structure-based drug design?, May 2016.
- [103] Cui, G. Affinity Predictions with FEP+: A Different Perspective on Performance and Utility, May 2016.
- [104] Verras, A. Free Energy Perturbation at Merck: Benchmarking against Faster Methods, May 2016.
- [105] Schnieders, M. J., Baltrusaitis, J., Shi, Y., Chattree, G., Zheng, L., Yang, W., and Ren, P.: The Structure, Thermodynamics, and Solubility of Organic Crystals from Simulation with a Polarizable Force Field. *J. Chem. Theory Comput.* 8(5): 1721–1736, May 2012.
- [106] Park, J., Nessler, I., McClain, B., Macikenas, D., Baltrusaitis, J., and Schnieders, M. J.: Absolute Organic Crystal Thermodynamics: Growth of the Asymmetric Unit into a Crystal via Alchemy. *J. Chem. Theory Comput.* 10(7): 2781–2791, July 2014.
- [107] Liu, S., Cao, S., Hoang, K., Young, K. L., Paluch, A. S., and Mobley, D. L.: Using MD Simulations To Calculate How Solvents Modulate Solubility. *Journal of Chemical Theory and Computation.* 12(4): 1930–1941, February 2016.
- [108] Leonis, G., Steinbrecher, T., and Papadopoulos, M. G.: A Contribution to the Drug Resistance Mechanism of Darunavir, Amprenavir, Indinavir, and Saquinavir Complexes with HIV-1 Protease Due to Flap Mutation I50V: A Systematic MM–PBSA and Thermodynamic Integration Study. *J. Chem. Inf. Model.* 53(8): 2141–2153, August 2013.
- [109] Lee, C. T., Comer, J., Herndon, C., Leung, N., Pavlova, A., Swift, R. V., Tung, C., Rowley, C. N., Amaro, R. E., Chipot, C., Wang, Y., and Gumbart, J. C.: Simulation-Based Approaches for Determining Membrane Permeability of Small Compounds. *J. Chem. Inf. Model.* 56(4): 721–733, April 2016.
- [110] Comer, J., Schulten, K., and Chipot, C.: Calculation of Lipid-Bilayer Permeabilities Using an Average Force. *J Chem. Theory Comput.* 10(2): 554–564, February 2014.
- [111] Liu, S., Wu, Y., Lin, T., Abel, R., Redmann, J. P., Summa, C. M., Jaber, V. R., Lim, N. M., and Mobley, D. L.: Lead optimization mapper: Automating free energy calculations for lead optimization. *J Comput Aided Mol Des.* 27(9): 755–770, September 2013.
- [112] Mikulskis, P., Genheden, S., and Ryde, U.: A Large-Scale Test of Free-Energy Simulation Estimates of Protein–Ligand Binding Affinities. *J. Chem. Inf. Model.* 54(10): 2794–2806, October 2014.
- [113] Homeyer, N., Stoll, F., Hillisch, A., and Gohlke, H.: Binding Free Energy Calculations for Lead Optimization: Assessment of Their Accuracy in an Industrial Drug Design Context. *J. Chem. Theory Comput.* 10(8): 3331–3344, August 2014.

- [114] Shirts, M. R., Mobley, D. L., and Brown, S. P. Free-energy calculations in structure-based drug design. In Merz, , Kenneth MJ., Ringe, D., and Reynolds, C. H. (Eds.): Drug Design: Structure and Ligand-Based Approaches. Cambridge University Press, January 2010.
- [115] Lim, N. M., Wang, L., Abel, R., and Mobley, D. L.: Sensitivity in binding free energies due to protein reorganization. Journal of Chemical Theory and Computation. July 2016.
- [116] Rocklin, G. J., Boyce, S. E., Fischer, M., Fish, I., Mobley, D. L., Shoichet, B. K., and Dill, K. A.: Blind Prediction of Charged Ligand Binding Affinities in a Model Binding Site. J. Mol. Biol. 425(22): 4569–4583, November 2013.
- [117] Nuzzo, R.: How scientists fool themselves –and how they can stop. Nature. 526(7572): 182–185, October 2015.
- [118] Mobley, D. L., Graves, A. P., Chodera, J. D., McReynolds, A. C., Shoichet, B. K., and Dill, K. A.: Predicting absolute ligand binding free energies to a simple model site. J. Mol. Biol. 371(4): 1118–1134, August 2007.
- [119] Boyce, S. E., Mobley, D. L., Rocklin, G. J., Graves, A. P., Dill, K. A., and Shoichet, B. K.: Predicting ligand binding affinity with alchemical free energy methods in a polar model binding site. J. Mol. Biol. 394(4): 747–763, December 2009.
- [120] Gathiaka, S., Liu, S., Chiu, M., Yang, H., Stuckey, J. A., Kang, Y. N., Delproposto, J., Dunbar, J. B., Carlson, H. A., Burley, S., Walters, W., Amaro, R. E., Feher, V., and Gilson, M. K.: D3R Grand Challenge 2015: Evaluation of Protein-Ligand Pose and Affinity Prediction. J Comput Aided Mol Des. 2016.
- [121] Nicholls, A., Mobley, D. L., Guthrie, J. P., Chodera, J. D., Bayly, C. I., Cooper, M. D., and Pande, V. S.: Predicting Small-Molecule Solvation Free Energies: An Informal Blind Test for Computational Chemistry. J. Med. Chem. 51(4): 769–779, February 2008.
- [122] Nicholls, A., Wlodek, S., and Grant, J. A.: The SAMP1 Solvation Challenge: Further Lessons Regarding the Pitfalls of Parametrization. J. Phys. Chem. B. 113(14): 4521–4532, April 2009.
- [123] Mobley, D. L., Bayly, C. I., Cooper, M. D., and Dill, K. A.: Predictions of Hydration Free Energies from All-Atom Molecular Dynamics Simulations. J Phys Chem B. 113: 4533–4537, January 2009.
- [124] Geballe, M. T., Skillman, A. G., Nicholls, A., Guthrie, J. P., and Taylor, P. J.: The SAMPL2 blind prediction challenge: Introduction and overview. J Comput Aided Mol Des. 24(4): 259–279, May 2010.
- [125] Geballe, M. T. and Guthrie, J. P.: The SAMPL3 blind prediction challenge: Transfer energy overview. J Comput Aided Mol Des. 26(5): 489–496, April 2012.
- [126] Mobley, D. L., Wymer, K. L., Lim, N. M., and Guthrie, J. P.: Blind prediction of solvation free energies from the SAMPL4 challenge. J Comput Aided Mol Des. 28(3): 135–150, March 2014.
- [127] Muddana, H. S., Fenley, A. T., Mobley, D. L., and Gilson, M. K.: The SAMPL4 host–guest blind prediction challenge: An overview. J Comput Aided Mol Des. 28(4): 305–317, March 2014.
- [128] Bannan, C. C., Burley, K. H., Chiu, M., Shirts, M. R., Gilson, M. K., and Mobley, D. L.: Blind prediction of cyclohexane–water distribution coefficients from the SAMPL5 challenge. J Comput Aided Mol Des. pp 1–18, September 2016.
- [129] Yin, J., Henriksen, N. M., Slochower, D. R., Shirts, M. R., Chiu, M. W., Mobley, D. L., and Gilson, M. K.: Overview of the SAMPL5 host–guest challenge: Are we doing better? J Comput Aided Mol Des. pp 1–19, September 2016.
- [130] Ignjatović, M. M., Calderaru, O., Dong, G., Muñoz-Gutierrez, C., Adasme-Carreño, F., and Ryde, U.: Binding-affinity predictions of HSP90 in the D3R Grand Challenge 2015 with docking, MM/GBSA, QM/MM, and free-energy simulations. J Comput Aided Mol Des. pp 1–24, August 2016.
- [131] Deng, N., Flynn, W. F., Xia, J., Vijayan, R. S. K., Zhang, B., He, P., Mentes, A., Gallicchio, E., and Levy, R. M.: Large scale free energy calculations for blind predictions of protein–ligand binding: The D3R Grand Challenge 2015. J Comput Aided Mol Des. pp 1–9, August 2016.

- [132] Sunseri, J., Ragoza, M., Collins, J., and Koes, D. R.: A D3R prospective evaluation of machine learning for protein-ligand scoring. *J Comput Aided Mol Des.* pp 1–11, September 2016.
- [133] Ellingson, B. A., Skillman, A. G., and Nicholls, A.: Analysis of SM8 and Zap TK calculations and their geometric sensitivity. *J Comput Aided Mol Des.* 24(4): 335–342, April 2010.
- [134] Ellingson, B. A., Geballe, M. T., Wlodek, S., Bayly, C. I., Skillman, A. G., and Nicholls, A.: Efficient calculation of SAMPL4 hydration free energies using OMEGA, SZYBKI, QUACPAC, and Zap TK. *J Comput Aided Mol Des.* 28(3): 289–298, March 2014.
- [135] Mobley, D. L., Liu, S., Cerutti, D. S., Swope, W. C., and Rice, J. E.: Alchemical prediction of hydration free energies for SAMPL. *Journal of Computer-Aided Molecular Design.* 26(5): 551–562, PMC3583515, May 2012.
- [136] Fennell, C. J., Wymer, K. L., and Mobley, D. L.: A Fixed-Charge Model for Alcohol Polarization in the Condensed Phase, and Its Role in Small Molecule Hydration. *J. Phys. Chem. B.* 118(24): 6438–6446, June 2014.
- [137] Paranhewage, S. S., Gierhart, C. S., and Fennell, C. J.: Predicting water-to-cyclohexane partitioning of the SAMPL5 molecules using dielectric balancing of force fields. *J Comput Aided Mol Des.* pp 1–7, August 2016.
- [138] Sulea, T. and Purisima, E. O.: Predicting hydration free energies of polychlorinated aromatic compounds from the SAMPL-3 data set with FiSH and LIE models. *J Comput Aided Mol Des.* 26(5): 661–667, December 2011.
- [139] Li, L., Dill, K. A., and Fennell, C. J.: Testing the semi-explicit assembly model of aqueous solvation in the SAMPL4 challenge. *J Comput Aided Mol Des.* 28(3): 259–264, January 2014.
- [140] Brini, E., Paranhewage, S. S., Fennell, C. J., and Dill, K. A.: Adapting the semi-explicit assembly solvation model for estimating water-cyclohexane partitioning with the SAMPL5 molecules. *J Comput Aided Mol Des.* pp 1–11, September 2016.
- [141] Klamt, A., Eckert, F., Reinisch, J., and Wichmann, K.: Prediction of cyclohexane-water distribution coefficients with COSMO-RS on the SAMPL5 data set. *J Comput Aided Mol Des.* pp 1–9, July 2016.
- [142] Mobley, D. L. and Gilson, M. K.: Predicting binding free energies: Frontiers and benchmarks. *bioRxiv.* 074625 pp, September 2016.
- [143] Muddana, H. S., Yin, J., Sapra, N. V., Fenley, A. T., and Gilson, M. K.: Blind prediction of SAMPL4 cucurbit[7]uril binding affinities with the mining minima method. *J Comput Aided Mol Des.* 28(4): 463–474, February 2014.
- [144] Yin, J., Henriksen, N. M., Slochower, D. R., and Gilson, M. K.: The SAMPL5 Host-Guest Challenge: Binding Free Energies and Enthalpies from Explicit Solvent Simulations. *J Comput Aided Mol Des.* 2016.
- [145] Muddana, H. S., Sapra, N. V., Fenley, A. T., and Gilson, M. K.: The SAMPL4 hydration challenge: Evaluation of partial charge sets with explicit-water molecular dynamics simulations. *J Comput Aided Mol Des.* 28(3): 277–287, January 2014.
- [146] Yin, J., Fenley, A. T., Henriksen, N. M., and Gilson, M. K.: Toward Improved Force-Field Accuracy through Sensitivity Analysis of Host-Guest Binding Thermodynamics. *The Journal of Physical Chemistry B.* 119(32): 10145–10155, August 2015.
- [147] Nielsen, J. E., Gunner, M. R., and García-Moreno E., B.: The pKa Cooperative: A collaborative effort to advance structure-based calculations of pKa values and electrostatic effects in proteins. *Proteins.* 79(12): 3249–3259, December 2011.
- [148] Janin, J.: Assessing predictions of protein–protein interaction: The CAPRI experiment. *Protein Science.* 14(2): 278–283, February 2005.
- [149] Moult, J., Fidelis, K., Kryshtafovych, A., Schwede, T., and Tramontano, A.: Critical assessment of methods of protein structure prediction (CASP) —round x. *Proteins.* 82: 1–6, February 2014.

- [150] Coleman, R. G., Sterling, T., and Weiss, D. R.: SAMPL4 & DOCK3.7: Lessons for automated docking procedures. *J Comput Aided Mol Des.* 28(3): 201–209, February 2014.
- [151] Reinisch, J., Klamt, A., and Diedenhofen, M.: Prediction of free energies of hydration with COSMO-RS on the SAMPL3 data set. *J Comput Aided Mol Des.* 26(5): 669–673, May 2012.
- [152] Beauchamp, K. A., Behr, J. M., Rustenburg, A. S., Bayly, C. I., Kroenlein, K., and Chodera, J. D.: Towards Automated Benchmarking of Atomistic Forcefields: Neat Liquid Densities and Static Dielectric Constants from the ThermoML Data Archive. *Journal of Physical Chemistry B.* 119(40): 12912–12920, September 2015.
- [153] Bannan, C. C., Calabró, G., Kyu, D. Y., and Mobley, D. L.: Calculating Partition Coefficients of Small Molecules in Octanol/Water and Cyclohexane/Water. *Journal of Chemical Theory and Computation.* 12(8): 4015–4024, August 2016.
- [154] Wang, K., Chodera, J. D., Yang, Y., and Shirts, M. R.: Identifying ligand binding sites and poses using GPU-accelerated Hamiltonian replica exchange molecular dynamics. *J Comput Aided Mol Des.* 27(12): 989–1007, December 2013.
- [155] Pickard, F. C., König, G., Tofoleanu, F., Lee, J., Simmonett, A. C., Shao, Y., Ponder, J. W., and Brooks, B. R.: Blind prediction of distribution in the SAMPL5 challenge with QM based protomer and pKa corrections. *J Comput Aided Mol Des.* pp 1–14, September 2016.
- [156] Rustenburg, A. S., Dancer, J., Lin, B., Feng, J. A., Ortwine, D. F., Mobley, D. L., and Chodera, J. D.: Measuring experimental cyclohexane-water distribution coefficients for the SAMPL5 challenge. *bioRxiv.* 063081 pp, July 2016.
- [157] Bhatnagar, N., Kamath, G., and Potoff, J. J.: Prediction of 1-octanol–water and air–water partition coefficients for nitro-aromatic compounds from molecular dynamics simulations. *Physical Chemistry Chemical Physics.* 15(17): 6467, 2013.
- [158] Kollman, P. A.: Advances and continuing challenges in achieving realistic and predictive simulations of the properties of organic and biological molecules. *Accounts of Chemical Research.* 29(10): 461–469, 1996.
- [159] Muddana, H. S., Varnado, C. D., Bielawski, C. W., Urbach, A. R., Isaacs, L., Geballe, M. T., and Gilson, M. K.: Blind prediction of host–guest binding affinities: A new SAMPL3 challenge. *J Comput Aided Mol Des.* 26(5): 475–487, February 2012.
- [160] Bhakat, S. and Söderhjelm, P.: Resolving the problem of trapped water in binding cavities: Prediction of host-guest binding free energies in the SAMPL5 challenge by funnel metadynamics. *J Comput Aided Mol Des.* 2016.
- [161] Henriksen, N. M., Fenley, A. T., and Gilson, M. K.: Computational Calorimetry: High-Precision Calculation of Host–Guest Binding Thermodynamics. *Journal of Chemical Theory and Computation.* 11(9): 4377–4394, September 2015.
- [162] Ma, D., Glassenberg, R., Ghosh, S., Zavalij, P. Y., and Isaacs, L.: Acyclic cucurbituril congener binds to local anaesthetics. *Supramolecular Chemistry.* 24(5): 325–332, May 2012.
- [163] Cao, L. and Isaacs, L.: Absolute and relative binding affinity of cucurbit[7]uril towards a series of cationic guests. *Supramolecular Chemistry.* 26(3-4): 251–258, March 2014.
- [164] She, N., Moncelet, D., Gilberg, L., Lu, X., Sindelar, V., Briken, V., and Isaacs, L.: Glycoluril-Derived Molecular Clips are Potent and Selective Receptors for Cationic Dyes in Water. *Chem. Eur. J.* pp n/a–n/a, August 2016.
- [165] Cao, L., Šekutor, M., Zavalij, P. Y., Mlinarić-Majerski, K., Glaser, R., and Isaacs, L.: Cucurbit[7]uril-Guest Pair with an Attomolar Dissociation Constant. *Angew. Chem. Int. Ed.* 53(4): 988–993, January 2014.
- [166] Liu, S., Ruspic, C., Mukhopadhyay, P., Chakrabarti, S., Zavalij, P. Y., and Isaacs, L.: The Cucurbit[n]uril Family: Prime Components for Self-Sorting Systems. *Journal of the American Chemical Society.* 127(45): 15959–15967, November 2005.

- [167] Mock, W. L. and Shih, N. Y.: Structure and selectivity in host-guest complexes of cucurbituril. *The Journal of Organic Chemistry*. 51(23): 4440–4446, November 1986.
- [168] Assaf, K. I. and Nau, W. M.: Cucurbiturils: From synthesis to high-affinity binding and catalysis. *Chem Soc Rev.* 44(2): 394–418, January 2015.
- [169] Moghaddam, S., Yang, C., Rekharsky, M., Ko, Y. H., Kim, K., Inoue, Y., and Gilson, M. K.: New Ultrahigh Affinity Host-Guest Complexes of Cucurbit[7]uril with Bicyclo[2.2.2]octane and Adamantane Guests: Thermodynamic Analysis and Evaluation of M<sub>2</sub> Affinity Calculations. *Journal of the American Chemical Society*. 133(10): 3570–3581, March 2011.
- [170] Shetty, D., Khedkar, J. K., Park, K. M., and Kim, K.: Can we beat the biotin–avidin pair?: cucurbit[7]uril-based ultrahigh affinity host–guest complexes and their applications. *Chem. Soc. Rev.* 44(23): 8747–8761, 2015.
- [171] Biedermann, F., Uzunova, V. D., Scherman, O. A., Nau, W. M., and De Simone, A.: Release of High-Energy Water as an Essential Driving Force for the High-Affinity Binding of Cucurbit[n]urils. *J. Am. Chem. Soc.* 134(37): 15318–15323, September 2012.
- [172] Isaacs, L.: Stimuli Responsive Systems Constructed Using Cucurbit[n]uril-Type Molecular Containers. *Acc. Chem. Res.* 47(7): 2052–2062, July 2014.
- [173] Vinciguerra, B., Zavalij, P. Y., and Isaacs, L.: Synthesis and Recognition Properties of Cucurbit[8]uril Derivatives. *Org. Lett.* 17(20): 5068–5071, October 2015.
- [174] Lucas, D., Minami, T., Iannuzzi, G., Cao, L., Wittenberg, J. B., Anzenbacher, P., and Isaacs, L.: Templated Synthesis of Glycoluril Hexamer and Monofunctionalized Cucurbit[6]uril Derivatives. *J. Am. Chem. Soc.* 133(44): 17966–17976, November 2011.
- [175] Ma, D., Zhang, B., Hoffmann, U., Sundrup, M. G., Eikermann, M., and Isaacs, L.: Acyclic Cucurbit[n]uril-Type Molecular Containers Bind Neuromuscular Blocking Agents In Vitro and Reverse Neuromuscular Block In Vivo. *Angew. Chem. Int. Ed.* 51(45): 11358–11362, November 2012.
- [176] Ma, D., Hettiarachchi, G., Nguyen, D., Zhang, B., Wittenberg, J. B., Zavalij, P. Y., Briken, V., and Isaacs, L.: Acyclic cucurbit[n]uril molecular containers enhance the solubility and bioactivity of poorly soluble pharmaceuticals. *Nat Chem.* 4(6): 503–510, June 2012.
- [177] Zhang, B. and Isaacs, L.: Acyclic Cucurbit[n]uril-type Molecular Containers: Influence of Aromatic Walls on their Function as Solubilizing Excipients for Insoluble Drugs. *J. Med. Chem.* 57(22): 9554–9563, November 2014.
- [178] Gilberg, L., Zhang, B., Zavalij, P. Y., Sindelar, V., and Isaacs, L.: Acyclic cucurbit[n]uril-type molecular containers: Influence of glycoluril oligomer length on their function as solubilizing agents. *Org. Biomol. Chem.* 13(13): 4041–4050, 2015.
- [179] Sigwalt, D., Moncelet, D., Falcinelli, S., Mandadapu, V., Zavalij, P. Y., Day, A., Briken, V., and Isaacs, L.: Acyclic Cucurbit[n]uril-Type Molecular Containers: Influence of Linker Length on Their Function as Solubilizing Agents. *ChemMedChem.* 11(9): 980–989, May 2016.
- [180] Zhang, B., Zavalij, P. Y., and Isaacs, L.: Acyclic CB[n]-type molecular containers: Effect of solubilizing group on their function as solubilizing excipients. *Org. Biomol. Chem.* 12(15): 2413–2422, 2014.
- [181] Ma, D., Zavalij, P. Y., and Isaacs, L.: Acyclic Cucurbit[n]uril Congeners Are High Affinity Hosts. *J. Org. Chem.* 75(14): 4786–4795, July 2010.
- [182] Ko, Y. H., Kim, E., Hwang, I., and Kim, K.: Supramolecular assemblies built with host-stabilized charge-transfer interactions. *Chem. Commun.* (13): 1305–1315, 2007.
- [183] Barrow, S. J., Kasera, S., Rowland, M. J., del Barrio, J., and Scherman, O. A.: Cucurbituril-Based Molecular Recognition. *Chem. Rev.* 115(22): 12320–12406, November 2015.
- [184] Urbach, A. R. and Ramalingam, V.: Molecular Recognition of Amino Acids, Peptides, and Proteins by Cucurbit[n]uril Receptors. *Isr. J. Chem.* 51(5-6): 664–678, May 2011.

- [185] Connors, K. A.: *Binding Constants*. New York, NY, John Wiley & Sons, 1987.
- [186] Masson, E., Ling, X., Joseph, R., Kyeremeh-Mensah, L., and Lu, X.: Cucurbituril chemistry: A tale of supramolecular success. *RSC Adv.* 2(4): 1213–1247, 2012.
- [187] Márquez, C., Hudgins, R. R., and Nau, W. M.: Mechanism of Host-Guest Complexation by Cucurbituril. *J. Am. Chem. Soc.* 126(18): 5806–5816, May 2004.
- [188] Biedermann, F., Nau, W. M., and Schneider, H.-J.: The Hydrophobic Effect Revisited—Studies with Supramolecular Complexes Imply High-Energy Water as a Noncovalent Driving Force. *Angew. Chem. Int. Ed.* 53(42): 11158–11171, October 2014.
- [189] 'il Saleh, N., Koner, A., and Nau, W.: Activation and Stabilization of Drugs by Supramolecular pKa Shifts: Drug-Delivery Applications Tailored for Cucurbiturils. *Angewandte Chemie.* 120(29): 5478–5481, July 2008.
- [190] Nau, W. M., Florea, M., and Assaf, K. I.: Deep Inside Cucurbiturils: Physical Properties and Volumes of their Inner Cavity Determine the Hydrophobic Driving Force for Host–Guest Complexation. *Isr. J. Chem.* 51(5-6): 559–577, May 2011.
- [191] Ghosh, I. and Nau, W. M.: The strategic use of supramolecular pKa shifts to enhance the bioavailability of drugs. *Advanced Drug Delivery Reviews.* 64(9): 764–783, June 2012.
- [192] Gibb, C. L. D. and Gibb, B. C.: Binding of cyclic carboxylates to octa-acid deep-cavity cavitand. *J Comput Aided Mol Des.* 28(4): 319–325, November 2013.
- [193] Sullivan, M. R., Sokkalingam, P., Nguyen, T., Donahue, J. P., and Gibb, B. C.: Binding of carboxylate and trimethylammonium salts to octa-acid and TEMOA deep-cavity cavitands. *J Comput Aided Mol Des.* pp 1–8, July 2016.
- [194] Carnegie, R. S., Gibb, C. L. D., and Gibb, B. C.: Anion Complexation and The Hofmeister Effect. *Angew. Chem.* 126(43): 11682–11684, October 2014.
- [195] Lin, Y.-L., Meng, Y., Jiang, W., and Roux, B.: Explaining why Gleevec is a specific and potent inhibitor of Abl kinase. *Proc. Natl. Acad. Sci.* 110(5): 1664–1669, January 2013.
- [196] Shan, Y., Seeliger, M. A., Eastwood, M. P., Frank, F., Xu, H., Jensen, M. O., Dror, R. O., Kuriyan, J., and Shaw, D. E.: A conserved protonation-dependent switch controls drug binding in the Abl kinase. *PNAS.* 106(1): 139–144, June 2009.
- [197] Szakács, Z., Béni, S., Varga, Z., Örfi, L., Kéri, G., and Noszál, B.: Acid-Base Profiling of Imatinib (Gleevec) and Its Fragments. *Journal of Medicinal Chemistry.* 48(1): 249–255, January 2005.
- [198] Grante, I., Actins, A., and Orola, L.: Protonation effects on the UV/Vis absorption spectra of imatinib: A theoretical and experimental study. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.* 129: 326–332, August 2014.
- [199] Hall, M. L., Jorgensen, W. L., and Whitehead, L.: Automated Ligand- and Structure-Based Protocol for *in Silico* Prediction of Human Serum Albumin Binding. *Journal of Chemical Information and Modeling.* 53(4): 907–922, April 2013.
- [200] Epps, D. E., Raub, T. J., Caiolfa, V., Chiari, A., and Zamai, M.: Determination of the Affinity of Drugs toward Serum Albumin by Measurement of the Quenching of the Intrinsic Tryptophan Fluorescence of the Protein. *Journal of Pharmacy and Pharmacology.* 51(1): 41–48, January 1999.
- [201] Bou-Abdallah, F., Sprague, S. E., Smith, B. M., and Giffune, T. R.: Binding thermodynamics of Diclofenac and Naproxen with human and bovine serum albumins: A calorimetric and spectroscopic study. *The Journal of Chemical Thermodynamics.* 103: 299–309, December 2016.
- [202] Merski, M., Fischer, M., Balius, T. E., Eidam, O., and Shoichet, B. K.: Homologous ligands accommodated by discrete conformations of a buried cavity. *PNAS.* 112(16): 5039–5044, April 2015.
- [203] Onufriev, A. V. and Alexov, E.: Protonation and pK changes in protein–ligand binding. *Quarterly Reviews of Biophysics.* 46(02): 181–209, May 2013.

- [204] Newman, J., Dolezal, O., Fazio, V., Caradoc-Davies, T., and Peat, T. S.: The DINGO dataset: A comprehensive set of data for the SAMPL challenge. *J Comput Aided Mol Des.* 26(5): 497–503, December 2011.
- [205] Rocklin, G. J., Mobley, D. L., Dill, K. A., and Hünenberger, P. H.: Calculating the binding free energies of charged species based on explicit-solvent simulations employing lattice-sum methods: An accurate correction scheme for electrostatic finite-size effects. *The Journal of Chemical Physics.* 139(18): 184103, 2013.
- [206] Lin, Y.-L., Aleksandrov, A., Simonson, T., and Roux, B.: An Overview of Electrostatic Free Energy Computations for Solutions and Proteins. *J. Chem. Theory Comput.* 10(7): 2690–2709, July 2014.
- [207] Reif, M. M. and Oostenbrink, C.: Net charge changes in the calculation of relative ligand-binding free energies via classical atomistic molecular dynamics simulation. *Journal of Computational Chemistry.* 35(3): 227–243, January 2014.
- [208] Fasano, M., Curry, S., Terreno, E., Galliano, M., Fanali, G., Narciso, P., Notari, S., and Ascenzi, P.: The extraordinary ligand binding properties of human serum albumin. *IUBMB Life (International Union of Biochemistry and Molecular Biology: Life).* 57(12): 787–796, December 2005.
- [209] Elinder, M., Geitmann, M., Gossas, T., Kallblad, P., Winquist, J., Nordstrom, H., Hamalainen, M., and Danielson, U. H.: Experimental Validation of a Fragment Library for Lead Discovery Using SPR Biosensor Technology. *Journal of Biomolecular Screening.* 16(1): 15–25, January 2011.
- [210] Gilson, M., Given, J., Bush, B., and McCammon, J.: The statistical-thermodynamic basis for computation of binding affinities: A critical review. *Biophysical Journal.* 72(3): 1047–1069, March 1997.
- [211] Lexa, K. W., Dolghih, E., and Jacobson, M. P.: A Structure-Based Model for Predicting Serum Albumin Binding. *PLoS ONE.* 9(4): e93323, April 2014.
- [212] Evoli, S., Mobley, D., Guzzi, R., and Rizzuti, B.: Multiple binding modes of ibuprofen in human serum albumin identified by absolute binding free energy calculations. *bioRxiv.* 068502 pp, August 2016.
- [213] Martin, Y. C.: Let's not forget tautomers. *Journal of Computer-Aided Molecular Design.* 23(10): 693–704, October 2009.
- [214] Song, Y., Mao, J., and Gunner, M. R.: MCCE2: Improving protein pKa calculations with extensive side chain rotamer sampling. *Journal of Computational Chemistry.* pp NA–NA, 2009.
- [215] Latta, M., Knapp, M., Sarmientos, P., Bréfort, G., Becquart, J., Guerrier, L., Jung, G., and Mayaux, J.-F.: Synthesis and Purification of Mature Human Serum Albumin from *E. Coli*. *Bio/Technology.* 5(12): 1309–1314, December 1987.
- [216] Lang, B. E. and Cole, K. D.: Unfolding properties of recombinant human serum albumin products are due to bioprocessing steps. *Biotechnology Progress.* 31(1): 62–69, January 2015.
- [217] Reinhard, L., Mayerhofer, H., Geerlof, A., Mueller-Dieckmann, J., and Weiss, M. S.: Optimization of protein buffer cocktails using Thermofluor. *Acta Crystallographica Section F Structural Biology and Crystallization Communications.* 69(2): 209–214, February 2013.
- [218] Shirts, M. R., Klein, C., Swails, J. M., Yin, J., Gilson, M. K., Mobley, D. L., Case, D. A., and Shirts, M. R.: Lessons learned from comparing molecular dynamics englines on the SAMPL5 dataset. *J Comput Aided Mol Des.* 2016.
- [219] Monroe, J. I. and Shirts, M. R.: Converging free energies of binding in cucurbit[7]uril and octa-acid host–guest systems from SAMPL4 using expanded ensemble simulations. *J Comput Aided Mol Des.* 28(4): 401–415, March 2014.
- [220] Bosisio, S., Mey, A. S. J. S., and Michel, J.: Blinded predictions of host-guest standard free energies of binding in the SAMPL5 challenge. *J Comput Aided Mol Des.* 2016.
- [221] Mobley, D. L. and Guthrie, J. P.: FreeSolv: A database of experimental and calculated hydration free energies, with input files. *J Comput Aided Mol Des.* 28(7): 711–720, PMC4113415, June 2014.

- [222] Liu, T., Lin, Y., Wen, X., Jorissen, R. N., and Gilson, M. K.: BindingDB: A web-accessible database of experimentally determined protein–ligand binding affinities. *Nucl. Acids Res.* 35(suppl 1): D198–D201, January 2007.

## UC, IRVINE

### FACILITIES AND OTHER RESOURCES

For conducting the proposed work, my main requirement is computers, in the form of both workstations for researchers to work at, and supercomputing or cluster facilities on which to run the calculations. We have ample resources on this front. I own a portion of the GreenPlanet shared cluster at the University of California, Irvine. We have ~1100 AMD processor cores along with another 200 Intel Xeon cores. We also recently added (with Tom Poulos) three GPU nodes from Exxact running NVIDIA Titan X cards (each node has 8 GPUs which have fast communication between blocks of 4). We also have close to 100 TB of storage for the group. On the GreenPlanet cluster we also have access to other processor cores contributed by other groups when on a reduced priority basis. Additionally, we have access to the HPC Cluster at UC Irvine, another shared computing facility, where we can use a reasonable portion of the several thousand nodes available depending on the usage of other groups, without cost. We also typically have supercomputing resources such as through NSF XSEDE. In addition to these facilities for running the simulations, we have ample resources in the lab in terms of workstations, with a number of desktop Macs and laptops on hand (more than enough for all lab personnel). Additionally, we recently purchased four more Exxact GPU nodes (identical to the above which are now housed in a shared GPU facility at UCSD with several other groups doing related research; this gives us access to another 32 GPUs plus spill-over access to ~100 more).

In addition to computational resources, my group has licenses to the software we need already. We use OpenEye software for helping to prepare our systems for simulations, and we have a license for that. Additionally, we have licenses for AMBER, MCCE, Modeller, Dock, PyMol, Desmond, the Schrödinger toolkits, and other common molecular modeling packages, and the majority of our simulations are done using GROMACS. So we are well equipped for performing the calculations proposed here.

#### Impact of the scientific environment on the probability of success

The scientific environment at UCI is excellent and will substantially impact the probability of success. We have regular molecular simulations meetings together with other groups at UCI (including the groups of Ray Luo, Ioan Andricioaei, and Doug Tobias, among others), and we can benefit from their expertise. We also have collaborations (and are building others) with experimentalists at UCI, including Larry Overman, Tom Poulos, and Chris Vanderwal. I am also receiving both formal and informal mentoring from more senior faculty at UCI – formally from Tom Poulos in the Department of Pharmaceutical Sciences, and informally from other computational experts noted above.

UCI has invested substantially in the success of the Mobley lab. In addition to receiving roughly 20 nodes in the GreenPlanet cluster and various disk storage, furniture, etc., we received substantial financial resources to help expand the cluster, purchase additional software licenses, and support laboratory personnel.

#### SUBAWARDS:

#### SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH - CHODERA LABORATORY

**Computer:** All lab members are equipped with laptop computers with integrated graphics processors (GPUs), and have access to high-performance development machines containing a range of modern GPU accelerators. The group has priority access to a high-performance computing cluster with 1920 total hyperthreads and 120 NVIDIA GTX-680, GTX-TITAN, GTX-TITAN-X, or GTX-1080 GPUs. Project storage is provided by a high-performance shared 1.5PB GPFS storage system. Dedicated servers provide access to Folding@Home, which currently provides ~31 PFLOP/s aggregate computational power in over 350,000 actively computing cores---{bf equivalent computing facilities would cost tens of millions of dollars}. Network connections are at least 1 Gbit/s throughout MSKCC, with HPC systems connected at 10 Gbit/s.

**Laboratory:** The Chodera wetlab occupies ~340 square feet of space. The central feature of the wetlab is an integrated platform for fully automated biophysical experiments instrumented for remote monitoring and operation. This system includes a Thermo BenchTrak Orbitor, a Tecan EVO200 with three dispensing technologies (including an HP D300), four Inheco incubators, a BioNex HiG4 centrifuge, Tecan Infinite M1000PRO plate reader (capable of absorbance, fluorescence and FP, luminescence, and AlphaScreen

measurements, with injectors installed for kinetics measurements), Caliper GXII microfluidic electrophoresis platform, Roche LC480 qPCR machine, Agilent VCode barcode printer and PlateLoc plate sealer, Thermo MultiDrop Combi reagent dispenser, and Thermo automated Cytomat Hotel. This platform automates cloning, site-directed mutagenesis, recombinant bacterial protein expression and purification, cell-free transcription and translation, microfluidic gel electrophoresis, Thermofluor protein stability assays, and fluorescence measurements of binding affinities. It can also automate preparation of ITC and SPR experiments that can be conducted at the Rockefeller HTSRC across the street. There is bench space for one group member to work manually using standard molecular biology tools. A Mettler-Toledo Quantos automated gravimetric solution preparation system ensures compound concentrations are always accurately and traceably prepared. A LabMinds Revo is available to automatically prepare large quantities of buffers for biophysical assays reliably, reproducible, and traceably. An electronic lab notebook tracks all materials and measurements in the laboratory using barcodes. Shared equipment space, standard laboratory refrigerators and freezers, and common shared equipment (centrifuges, incubators, etc.) is also provided. Both experimental and computational spaces are located in Memorial Sloan-Kettering's new Zuckerman Research Center (ZRC).

**Animal:** N/A

**Office:** All lab members have desks in a modern open-plan computational biology working space where the Chodera lab currently occupies ~400 sq ft. Group members are equipped with monitors, backup storage, and other standard workstation accessories. Additional office space includes Dr. Chodera's office, office space for a shared administrative assistant, shared conference rooms, and meeting and library space. A shared departmental Jura Impressa XS90 high-performance espresso machine provides ready access to coffee, which we have found to be essential to high productivity in computational science.

**Clinical:** N/A

**Other Resources:** The **Rockefeller high-throughput screening resource center (HTSRC)** is located across the street at the Rockefeller University. The HTSRC provides a number of high-throughput binding and biophysical measurement facilities at a minimal cost to us, most notably (1) a GE/MicroCal Auto-iTC200 automated isothermal titration calorimeter capable of processing up to 384 samples unattended, and (2) a Proteon XPR36 SPR instrument (capable of processing 96 samples), among others. The **MSKCC Organic Synthesis Core** under the direction of Dr. Ouathek Ouerfelli is a fully-staffed 12-person facility providing organic synthesis and consultation services to MSKCC laboratories. The **MSKCC Analytical NMR Core** under the direction of Dr. George Sukenik allows for the unattended 1H-NMR characterization of compounds using an automated sample workflow. Numerous additional MSKCC core facilities are available, including proteomics and mass spectroscopy, NMR, X-ray crystallography, high-throughput screening, analytical chemistry, DNA sequencing, and bioinformatics consulting. Many of these core facilities are highly automated.

## FACILITIES AND OTHER RESOURCES (GIBB, DEPARTMENT OF CHEMISTRY, TULANE UNIVERSITY)

**Laboratory:** The group has two laboratories in Percival Stern Hall (each 900 sq. ft. and furnished with 4 fume hoods) located adjacent to the Gibb's office. In addition, Gibb has a laboratory in the new Donna and Paul Flower Hall for Research and Innovation adjacent to Stern Hall. This laboratory is approximately 1200 sq. ft. and is equipped with four fume hoods. All of these spaces are new (2012+), contemporary space for organic synthesis and physical organic studies. Major/specialized equipment for these laboratories include: two Isothermal Titration Calorimeters, Dynamic Light Scattering/Zeta-Sizer, a micro-well plate reader (UV-Vis/Fluorescence), UV-visible spectrometer, an HPLC, and an osmometer. Minor/general equipment for the laboratories include: automated flash chromatographic system for organic mobile phases, refrigerators, drying ovens, rotary evaporators, balances, ultrasound baths, vacuum manifolds, glassware (for reactions and chromatography), and hot plates.

**Computer:** In his office Gibb has one portable MacBook Pro laptop with 15" Retina display (2.6 GHz Intel Core i7, with 16 GB RAM, and Mac OSX version 10.10.5 operating system) and related peripherals for: viewing (27 inch Apple LCD monitor), printing (color, HP Laserjet Pro), scanning and data backup. The computer has the requisite software installed (such as Microsoft Office (Word, Excel, PowerPoint), Key Note, ChemDraw, Adobe Acrobat Professional, Adobe Photoshop, and Adobe Illustrator. In addition to the five laboratory computers

dedicated to instruments, the labs are also equipped with three high-end (Apple) desktop computers. The group uses an Electronic Laboratory Notebook (ELN) system (iLabber from Biovia) for data storage, and a DropBox folder for rapid movement of documents and files within the group. Gibb and Department of Chemistry pays for licenses for software (e.g., Mnova from Mestrelab Research). Additionally, the Department maintains a computer coordinator who assists with all information technology-related needs.

**Office:** The research space in Percival Stern Hall includes two offices (160 sq. ft. each), group conference room (350 sq. ft.), and a student workroom (140 sq. ft.) directly adjacent to the laboratories.

**General:** The general support structure of the Department of Chemistry includes an electronic shop, machine shop, as well as electronic and NMR technicians. Comprehensive secretarial services are also available. A comprehensive library is available for the group, the facility of which includes on-line access to SciFinder and other science search engines.

**Equipment:** Major/specialized equipment for the laboratory includes: two Isothermal Titration Calorimeters, a Dynamic Light Scattering/Zeta-Sizer, a micro-well plate reader (UV/Vis/Fluorescence), UV-visible spectrometer, an HPLC, and an osmometer. Minor/general equipment for the laboratories include: an automated flash chromatography system (organic mobile phase), refrigerators, a lyophilizer, drying ovens, rotary evaporators, balances, ultrasound baths, vacuum manifolds, glassware (for reactions and chromatography), and hot plates.

**Department Equipment:** The group has access to Departmental equipment including: NMR spectrometers (400, 300 MHz, and 300 MHz solid-state), mass spectrometers (MALDI-TOF-MS, MicroTOF ESI-MS and high res. MALDI-TOF), GC-MS (2), X-ray diffractometers (2), HPLCs (3), gas chromatogram (semi-preparative), UV-vis spectrophotometers (3), spectrofluorometers (2), IR spectrometers (3, including 1 FT Raman), and inert atmosphere equipment (3 glove boxes).

**Coordinated Instrument Center of Tulane University:** The group also has access to the Tulane Coordinated Instrumentation Facility (CIF). Instruments at the CIF pertinent to this proposal include: NMR spectrometer (500 MHz), elemental analyzer, Inductively Coupled Plasma MS, and Gas Chromatography MS.

## UNIVERSITY OF MARYLAND (ISAACS)

### FACILITIES & OTHER RESOURCES

**Laboratory:** The Isaacs group laboratories ( $\approx$  1400 sq. ft.) are housed in the newest wing of the chemistry building and comprise bench and hood space for 8 students. This space is fully equipped for the synthetic (e.g. vacuum lines and pumps, rotary evaporators, centrifuge, hotplate stirrers, microwave synthesizer, freezers, lyophilizer, common glassware, etc.) and analytical (Isothermal Titration Microcalorimetry, UV/Vis spectrometer, fluorescence spectrometer, HPLC, thermomixer, capillary electrophoresis) aspects of the proposed research. Adjacent to the synthetic laboratories are two instrument rooms ( $\approx$  600 sq. ft.) for group use.

**Clinical:** Not applicable.

**Animal:** Not applicable.

**Computer:** The Isaacs group computer resources include an iMac and HP Laserjet for PI use. For student use we have an iMac, a MacBook, and an HP printer. The labs are outfitted with wireless internet. These computers run standard word processing, scientific data analysis, graphics creation, and molecular modeling software packages.

**Office:** Dr. Isaacs' office space is located across the hall from the synthetic labs and instrumentation rooms. Students have desk space adjacent to their respective benches and fume hoods.

**Other:** Dr. Isaacs research group has access to all of the shared instrumentation facilities within the Department of Chemistry and Biochemistry at the University of Maryland. Most relevant to the work proposed

herein are the NMR (800, 3 x 600, 500, 4 x 400 MHz, directed by Dr. Fu Chen), x-ray (single crystal and powder diffraction capability, directed by Dr. Peter Zavalij), and mass spectrometry (ESI, MALDI, FAB, EI, high resolution, directed by Dr. Yue Li) facilities which are directed by Ph.D. level staff members.

## EQUIPMENT - CHODERA LABORATORY

### Computational

*Local GPU cluster:* The Chodera laboratory has priority access to a new high-performance computing cluster with 480 Intel Xeon E5-2665 hyperthreaded cores (960 effective hyperthreads) and 120 NVIDIA GTX-680 or Titan graphics processor-based accelerators (GPUs). Project storage is provided by a high-performance shared 1.4PB GPFS storage system connected to the computing cluster. Network connections are at least 1 Gbit/s throughout MSKCC facilities, and cluster, GPU, and storage systems are connected with 10 Gbit/s links.

*Software development resources:* All Chodera laboratory members are equipped with laptop computers with GPUs capable of GPU-accelerated software development. All members also have access to a pool of powerful GPU development machines containing an assortment of most available GPUs for software development and automated build testing/benchmarking.

*Folding@home:* The Chodera laboratory is a member of the Folding@home Consortium. Folding@home is a distributed computing infrastructure run by Vijay Pande at Stanford University with over 500,000 actively computing codes, making it the most powerful supercluster in the world in terms of aggregate performance, with \$sim\$15 PFLOP/s of aggregate computational power available for use at any time. The free availability of large quantities of computer time through this network---which would cost tens of millions of dollars in hardware and power---leverages funding provided for this proposal enormously. Access to the Folding@home network is provided via two dedicated servers at MSKCC connected to 180TB of usable storage housed in a high-availability datacenter.

### Experimental

*Integrated automation platform for accurate liquid handling and biophysical measurement:* The experimental laboratory is equipped with an integrated automated system capable of carrying out a number of high-throughput automated plate-based biophysical assays (in 96- and 384-well plate formats) with a focus on measurement accuracy. The automated system integrates the following systems via a Thermo Fisher BenchTrak Orbitor plate-handling robot on a 3.2-meter track: a Tecan EVO200 liquid-handling robot with both liquid-displacement and high-precision air-displacement pipetting arms and stations for vacuum filtration, Peltier cooling/heating, heating/shaking, and septum piercing; an HP-D300 Digital Titration dispensing unit capable of accurately dispensing compounds in DMSO from picoliter to microliter volumes; four Inheco deep-well incubator/shaker stations for high-throughput bacterial culture; a Bionex HiG4 plate centrifuge capable of 4000g; a Tecan Infinite M1000PRO multifunction plate reader capable of absorbance, fluorescence, fluorescence polarization, and alpha-screen measurements with injectors for time-dependent measurements; a Roche LightCycler 480 qPCR machine also capable of ThermoFluor melts for protein quality control; an Agilent PlateLoc plate sealer; barcode tracking capabilities for all laboratory materials; a LabChip Caliper GXII microfluidic electrophoresis device for proteins and nucleic acids; a Thermo Fisher MultiDrop Combi reagent dispense; and a high-capacity automated plate carousel. A uPrint SE Plus 3D printer is available for fabricating custom SBS-format reagent or labware holders out of ABS plastic.

*Gravimetric solution preparation:* Biophysical measurements of protein-ligand binding affinities are fundamentally limited by the accuracy with which compound concentrations are known. High accuracies in affinity measurements are absolutely essential to validating and improving computational methodologies for probing and predicting binding affinities, so it is essential that these concentrations be well-determined. Methods to measure concentrations are generally costly, inaccurate, time-consuming, and often not universally applicable. Precise preparation of initial compound solutions remains the best way to ensure accuracy. Our laboratory is therefore equipped with a high-precision Mettler-Toledo Quantos balance for automated gravimetric solution preparation. Powder dosing heads dispense compound directly into vials on the analytical balance, while liquid dosing heads dispense solvent under argon (to prevent water uptake by hygroscopic solvents such as DMSO), ensuring accurate concentrations of compound solutions. Provenance, masses, concentrations, and uncertainties are tracked via barcodes and electronically within our ELN.

*Additional biophysical characterization:* Our laboratory also has access to instruments necessary to conduct automated isothermal titration calorimetry (ITC) experiments using a GE/MicroCal Auto-iTC200 and multiplexed surface plasmon resonance (SPR) experiments with a BioRad Proteon XPR36, both located in the adjacent Rockefeller HTSRC facility and available for our use at low cost. Both instruments accommodate sealed 96-well plates for fully automated measurement. Our laboratory automation platform allows numerous experiments to be set up automatically---including dilution, pipetting, plate sealing, and notification of laboratory members that the materials are ready to walk across the street to the HTSRC facility.

*Electronic laboratory notebook:* An electronic laboratory notebook (ELN) system manages all samples and data. 1D and 2D barcodes are used to track all materials received or generated within the laboratory.

*Standard molecular biology equipment:* The wet laboratory is also equipped with standard molecular biology equipment, including a wide array of multichannel and repeating pipettes for manually piloting robotic assays.

## RESEARCH & RELATED Senior/Key Person Profile (Expanded)

<b>PROFILE - Project Director/Principal Investigator</b>				
Prefix:	First Name*: DAVID	Middle Name	Last Name*: MOBLEY	Suffix:
Position/Title*:	Assistant Professor			
Organization Name*:	The Regents of the University of California, Irvine			
Department:	PHARMACEUTICAL SCIENCE			
Division:	DEPARTMENT OF PHARMACEUTICAL S			
Street1*:	3134B Natural Sciences 1			
Street2:				
City*:	Irvine			
County:	Orange			
State*:	CA: California			
Province:				
Country*:	USA: UNITED STATES			
Zip / Postal Code*:	92697-7600			
Phone Number*: (949) 824-6383	Fax Number: (949) 824-2949	E-Mail*: dmobley@uci.edu		
Credential, e.g., agency login: dlmobley				
Project Role*: PD/PI	Other Project Role Category:			
Degree Type: Ph.D.	Degree Year: 2004			
Attach Biographical Sketch*:	File Name Biosketch_Mobley1005646862.pdf			
Attach Current & Pending Support:				

<b>PROFILE - Senior/Key Person</b>				
Prefix:	First Name*: John	Middle Name	Last Name*: Chodera	Suffix:
Position/Title*:				
Organization Name*:	Memorial Sloan Kettering Cancer Center			
Department:				
Division:				
Street1*:	1275 York Ave			
Street2:				
City*:	New York			
County:				
State*:	NY: New York			
Province:				
Country*:	USA: UNITED STATES			
Zip / Postal Code*:	10065-6007			
Phone Number*: (646) 227-2952	Fax Number:	E-Mail*: john.chodera@choderlab.org		
Credential, e.g., agency login: JCHODERA				
Project Role*: Co-Investigator	Other Project Role Category:			
Degree Type: Ph.D.	Degree Year: 2006			
Attach Biographical Sketch*:	File Name Biosketch_Chodera_R11005723797.pdf			
Attach Current & Pending Support:				

<b>PROFILE - Senior/Key Person</b>				
Prefix:	First Name*: Bruce	Middle Name	Last Name*: Gibb	Suffix:

Position/Title*:	Professor			
Organization Name*:	The Administrators of the Tulane Educational Fund			
Department:	Chemistry			
Division:				
Street1*:	6823 St Charles			
Street2:				
City*:	New Orleans			
County:				
State*:	LA: Louisiana			
Province:				
Country*:	USA: UNITED STATES			
Zip / Postal Code*:	70118-5665			
Phone Number*:	504-314-7841	Fax Number:	E-Mail*:	bgibb@tulane.edu
Credential, e.g., agency login: bcgibb				
Project Role*:	Co-Investigator	Other Project Role Category:		
Degree Type:	Ph.D.	Degree Year: 1992		
File Name				
Attach Biographical Sketch*:	4_1_Gibb___Biosketch1005647048.pdf			
Attach Current & Pending Support:				

#### PROFILE - Senior/Key Person

Prefix: Prof.	First Name*:	Lyle	Middle Name D.	Last Name*:	Isaacs	Suffix: PhD	
Position/Title*:							
Organization Name*:	University of Maryland College Park						
Department:							
Division:							
Street1*:	3341 Chemistry Bldg						
Street2:	8051 Regents Dr						
City*:	College Park						
County:							
State*:	MD: Maryland						
Province:							
Country*:	USA: UNITED STATES						
Zip / Postal Code*:	20742-2021						
Phone Number*:	(301)	Fax Number:	E-Mail*:				lisaacs@umd.edu
405-8111							
Credential, e.g., agency login: ISAACS							
Project Role*:	Other (Specify)					Other Project Role Category:	Co-investigator
Degree Type:	Ph.D.					Degree Year:	1995
File Name							
Attach Biographical Sketch*:						2_1_Biosketch_Isaacs1005723791.pdf	
Attach Current & Pending Support:							

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: David L. Mobley

ERA COMMONS USER NAME (credential, e.g., agency login): dlmobley

POSITION TITLE: Associate Professor, Departments of Pharmaceutical Sciences and Chemistry

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of California, Davis	B.S.	06/2000	Physics
University of California, Davis	M.S.	06/2002	Physics
University of California, Davis	Ph.D.	06/2004	Physics
University of California, San Francisco	Postdoctoral	2004-2008	Comp. chem./modeling

**A. PERSONAL STATEMENT**

My research focuses specifically on using molecular simulations to understand and predict molecular interactions, solvation, solubility, and other properties relating to molecular design. A major goal is enabling molecular design for applications in drug discovery, bioengineering and other areas. I also have major interests – and an extensive background – in using blind prediction challenges to drive progress in my own work and in the field. The present project focuses on developing model systems of varying complexity to span between physical modeling exercises which are tractable with today's methods and pharmaceutical applications which are, in some cases, far too complex; generating experimental data; and running blind challenges to use this data to advance predictive modeling.

My group is particularly well suited to this task, given our extensive experience with predictive modeling and blind challenges and long history with the SAMPL challenge itself. In my postdoctoral work with Ken Dill, I participated in informal blind predictive challenges with experimentalists in the Shoichet lab, where I predicted binding free energies and the Shoichet lab separated measured the same. This led me to early see the value of blind tests for method development, as they involve much more careful planning and analysis of protocols than do retrospective tests, and a great deal more is typically learned. This early involvement in blind challenges led to my participation in an OpenEye CUP blind prediction challenge on hydration free energies which we now refer to as SAMPL0, and subsequently I participated in every SAMPL challenge through SAMPL3 (where I also oversaw the hydration free energy component of the challenger), when SAMPL transitioned out of being run by OpenEye. At that point, I took over running SAMPL, running SAMPL4 largely within my group with help on host-guest systems from Michael Gilson (see support letter). Subsequently, I worked with John Chodera to coordinate experimental work at Genentech for log D data for SAMPL5, and with Mike Gilson to bring in host-guest measurements by Bruce Gibb and Lyle Isaacs. So my role in SAMPL0-3 was as a participant and partial organizer, and in SAMPL4-5 I've been the primary organizer with help from others.

In addition to my work on SAMPL, I have extensive experience applying free energy calculations and physical methods both to predicting binding and to prediction of physical properties, driving my group's role in performing reference calculations (Aim 4) for the challenges proposed in this work. My group consists of a postdoctoral researcher, eight graduate students, and several undergraduates, and we are actively involved in methodology and application of free energy calculations to biomolecular binding, drug discovery, and prediction of solvation and solubility. We also have a major force field effort underway, currently in its early stages, which will have overlap with the science covered in this proposal.

The four publications below highlight our specific expertise for this project and focus on our role in, and the community's lessons learned from, the past two SAMPL challenges, of which I was an organizer:

a. Rustenburg, A.S, Dancer, J., Lin, B., Feng, J.A., Ortwine, D.F., **Mobley, D.L.**, and Chodera, J.D.

Measuring experimental cyclohexane-water distribution coefficients for the SAMPL5 challenge. *Journal of Computer Aided Molecular Design*, in press.

b. **D. L. Mobley**, S. Liu, N. M. Lim, K. L. Wymer, A. L. Perryman, S. Forli, N. Deng, J. Su, K. Branson, and A. J. Olson, "Blind prediction of HIV integrase binding from the SAMPL4 challenge", *J. Comput. Aided Mol. Design* 28(4):327-345 (2014). PMCID PMC4331050.

c. H. S. Muddana, A. T. Fenley, **D. L. Mobley**, and M. K. Gilson, "The SAMPL4 host-guest blind prediction challenge: an overview", *J. Comput. Aided Mol. Design* 28(4):305-317 (2014). PMCID PMC4053502

d. **D. L. Mobley**, K. L. Wymer, and N. M. Lim, "Blind prediction of solvation free energies from the SAMPL4 challenge", *J. Comput. Aided Mol. Design* 28:135-150 (2014). PMCID PMC4006301

## B. POSITIONS AND HONORS

### Positions and Employment

06/2004 – 12/2007	Postdoctoral researcher, Dept. of Pharm. Chem., University of California, San Francisco
12/2007 – 06/2008	Chief Science Officer, Simprota Corporation, San Francisco, CA
06/2008 – 08/2008	Postdoctoral researcher, Dept. of Pharm. Chem., University of California, San Francisco
08/2008 – 06/2012	Assistant Professor, Department of Chemistry, University of New Orleans, LA
07/2012 – present	Adjunct Professor, Department of Chemistry, University of New Orleans, LA
07/2012 – 06/2014	Assistant Professor, Department of Pharmaceutical Sciences, Univ. of California, Irvine
12/2012 – 06/2014	Assistant Professor (joint), Department of Chemistry, Univ. of California, Irvine
07/2014 – present	Associate Professor, Department of Pharmaceutical Sciences, Univ. of California, Irvine
07/2014 – present	Associate Professor (joint), Department of Chemistry, Univ. of California, Irvine
06/2013 – present	Scientific Advisory Board, Schrödinger Software, New York, NY

### Honors and Awards

2014	National Science Foundation CAREER Award
2009	Hewlett Packard Outstanding Junior Faculty Award, American Chemical Society
2003	Graduate Fellowship, Kavli Institute for Theoretical Physics, UC Santa Barbara
2001-2003	National Science Foundation NEAT-IGERT Fellowship, UC Davis
2000-2001	UC Davis Physics Department Award
2000	Saxon-Patten Prize, UC Davis
2000	Departmental Citation in Physics, Physics Department, UC Davis
2000	Howard Hughes Medical Institute Science Teaching Internship

### Other Experience and Professional Memberships

American Chemical Society

Biophysical Society

## C. CONTRIBUTIONS TO SCIENCE

To date, I have published more than 50 articles in peer-reviewed journals, which have collectively received over 3800 citations in the literature. My current h-index is 30, and my i10-index is 43.

**1. Predictive absolute binding free energy calculations:** Alchemical binding free energy calculations initially showed considerable promise for helping to guide early stage pharmaceutical drug discovery by predicting protein-ligand interactions in advance of the synthesis of new ligands. However, by the time I began my postdoctoral work early enthusiasm had waned and applications of these techniques were relatively rare, largely because of challenges relating to automation (addressed more below) and technical and conceptual issues relating to the calculation of absolute binding free energies. However, publications in 1997 and 2003 removed the major challenges hampering application of absolute techniques and paved the way for new success with free energy calculations. My work in this area was the first to apply absolute binding free energy calculations prospectively, to make (experimentally verified) blind predictions in a series of three different

binding sites. We also demonstrated the thermodynamic importance of key aspects of binding such as ligand orientational sampling and protein conformational changes. This work made absolute binding calculations practical for the first time, and helped spark a resurgence of interest in these techniques. My role in this work was to design, oversee, and in some cases conduct the research (the work began when I was a postdoc, and I actually conducted it, but then as I started my own group I oversaw the work of students on these projects).

a. D. L. Mobley, A. P. Graves, J. D. Chodera, A. C. McReynolds, B. K. Shoichet and K. A. Dill, "Predicting absolute ligand binding free energies to a simple model site," *J. Mol. Biol.* **371**(4): 1118-1134 (2007).

b. S. E. Boyce, D. L. Mobley, G. Rocklin, A. P. Graves, K. A. Dill, B. K. Shoichet. "Predicting ligand binding affinity with alchemical free energy methods in a polar model binding site", *J. Mol. Biol.* **394**: 747-763 (2009).

c. G. J. Rocklin, S. E. Boyce, M. Fisher, I. Fish, D. L. Mobley, B. K. Shoichet\*, and K. A. Dill\*. "Blind prediction of charged ligand binding affinities in a model binding site", *J. Mol. Biol.* **425**(22):4569-4583 (2013).

**2. Automation of relative free energy calculations.** Relative free energy techniques were more established than absolute calculations, but applications were small in scale and limited due to the difficulty of setting up and conducting these calculations. We developed an automated approach for planning and setting up relative free energy calculations, and also improved automation of analysis. This allowed these calculations to be applied on a large scale, including in drug discovery applications, for the first time. I planned and oversaw the work on automated planning, with collaborators inside and outside my group, and then collaborated with colleagues in industry who implemented the approach in their software for industrial applications.

a. S. Liu, Y. Wu, T. Lin, R. Abel, J. Redmann, C. M. Summa, V. R. Jaber, N. M. Lim, and D. L. Mobley, "Lead Optimization Mapper: Automating free energy calculations for lead optimization", *J. Comput. Aided Mol. Design* **27**(9):755-770 (2013).

b. L. Wang, Y. Wu, Y. Deng, B. Kim, L. Pierce, G. Krilov, D. Lupyan, S. Robinson, M. K. Dahlgren, J. Greenwood, D. L. Romero, C. Masse, J. L. Knight, T. Steinbrecher, T. Beuming, W. Damm, E. Harder, W. Sherman, M. Brewer, R. Wester, M. Murcko, L. Frye, R. Farid, T. Lin, D. L. Mobley, W. L. Jorgensen, B. J. Berne, R. A. Friesner, and R. Abel. "Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field", *J. Am. Chem. Soc.* **137**(7):2695-2703 (2015).

c. P. V. Klimovich, M. R. Shirts and D. L. Mobley, "Guidelines for the analysis of free energy calculations", *J. Comput. Aided Mol. Design.* **29**(5):397-411 (2015).

**3. Testing force fields using solvation free energies.** The accuracy of computed binding free energies depends crucially on the accuracy of the underlying force fields. We realized this and began using solvation free energies as a way to test and identify systematic errors in our force fields, with benefits for binding free energy calculations. We also used our work comparing to experiment in this area to develop a database of calculated and experimental hydration free energies that is widely used in a variety of contexts to help test and improve models. I planned, oversaw, and in some cases conducted this work, which took place in my group (after the initial study, which I did as a postdoc) with help from outside collaborators.

a. D. L. Mobley, C. I. Bayly, M. D. Cooper, M. R. Shirts, and K. A. Dill. "Small molecule hydration free energies in explicit solvent: An extensive test of fixed-charge force fields", *J. Chem. Theory Comput.* **5**: 350-358 (2009).

b. P. V. Klimovich and D. L. Mobley, "Predicting hydration free energies using all-atom molecular dynamics simulations and multiple starting conformations", *J. Computer-Aided Molecular Design* **24**: 307-316 (2010).

c. D. L. Mobley, S. Liu, D. Cerutti, W. C. Swope, and J. Rice, "Alchemical prediction of hydration free energies for SAMPL", special issue, *J. Comput. Aided Mol. Design* **26**(5):551-562 (2012).

d. C. J. Fennell, K. L. Wymer, and D. L. Mobley, "A fixed-charge model for alcohol polarization in the condensed phase, and its role in small molecule hydration", *J. Phys. Chem. B* **118**(24):6438-6446 (2014). Invited article.

e. D. L. Mobley and J. P. Guthrie, "FreeSolv: A database of experimental and calculated hydration free energies, with input files," *J. Comput. Aided Mol. Design* **28**:711-720 (2014).

**4. Participating in and organizing blind SAMPL challenges:** As noted above, SAMPL blind predictive challenges have played a key role in our work since our first entrance into blind challenges in #1 above. In 2014, I actually transitioned to running the SAMPL challenge, soliciting predictions of a variety of properties from the computational community all over the world. This challenge provides, and will continue to provide, a

valuable opportunity for testing and comparing different methods. In addition to the work noted under A, the following important publications have resulted from our work in SAMPL:

- a. C. C. Bannan, K. H. Burley, M. Chiu, M. R. Shirts, M. K. Gilson, and D. L. Mobley, "Blind prediction of cyclohexane-water distribution coefficients from the SAMPL5 challenge", *J. Comput. Aided Mol. Design*, in press.
  - b. T. S. Peat, O. Dolezal, J. Newman, D. L. Mobley, J. J. Deadman, "Interrogating HIV integrase for compounds that bind – a SAMPL4 challenge", *J. Comput. Aided Mol. Design* **28**:347-362 (2014).
  - c. **D. L. Mobley**, S. Liu, D. Cerutti, W. C. Swope, and J. Rice, "Alchemical prediction of hydration free energies for SAMPL", special issue, *J. Comput. Aided Mol. Design* **26**(5):551-562 (2012).
  - d. P. V. Klimovich and **D. L. Mobley**, "Predicting hydration free energies using all-atom molecular dynamics simulations and multiple starting conformations", *J. Computer-Aided Molecular Design* **24**: 307-316 (2010).

Full list of published work available at MyNCBI:

<https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/43376427/?sort=date&direction=ascending>

#### **D. RESEARCH SUPPORT**

### **Ongoing Research Support**

1R01GM108889-01 (NIH)      Mobley (PI)      9/1/2014-8/31/2019

9/1/2014-8/31/2019

Alchemical free energy methods for efficient drug lead optimization

This study focuses on automating planning of protein simulation-based relative free energy calculations for drug lead discovery, on improving methods for sampling ligand and protein motions in molecular simulations, and on applying these techniques to several drug discovery projects.

Role: PI

CHE-1352608 (NSF)      Mobley (PI)      07/15/2014-07/14/2019

07/15/2014-07/14/2019

CAREER: Computing accurate free energies for solubility, solvation and transfer

This study focuses on developing and applying molecular-simulation-based techniques for prediction of solvation free energies, transfer free energies and transfer properties, and solubilities.

Role: PI

## ***Completed Research Support***

1R15GM096257-01A1 (NIH)      Mobley (PI)      3/1/2012-2/28/2015

3/1/2012-2/28/2015

(At the University of New Orleans)

## Improving alchemical methods for predicting protein-ligand binding

The goal of this study is to test alchemical binding free energy techniques on three different binding sites, incorporating sampling enhancements relating to binding mode and sidechain sampling as needed.

Role: PI

1450865 (NSF) Mobley (PI) 02/15/2015-01/31/2016

02/15/2015-01/31/2016

## Accelerating our Understanding of Supramolecular Chemistry in Aqueous Solutions: A Workshop Proposal

This provided funds for a workshop in Arlington, VA in June, 2015 bringing together physical and

This provided funds for a workshop in Arlington, VA in June, 2013 bringing together physical and supramolecular chemists to plan how to move the field forward and facilitate knowledge transfer between the physical and supramolecular chemistry communities.

Physical &  
Role: co-PI

**BIOGRAPHICAL SKETCH**

---

NAME: **John D. Chodera**

---

eRA COMMONS USER NAME: **JCHODERA**

---

POSITION TITLE: **Assistant Member**, Computational Biology Program

---

**EDUCATION/TRAINING**

INSTITUTION AND LOCATION	DEGREE	Completion Date	FIELD OF STUDY
California Institute of Technology	BS	06/1999	Biology
University of California, San Francisco	PhD	12/2006	Biophysics
Stanford University	Postdoc	2007-2008	Chemistry
QB3 Fellow, University of California, Berkeley	Postdoc	2008-2012	Quantitative Biosciences

---

**A. PERSONAL STATEMENT**

My research focuses on the use of rigorous statistical mechanics and physical modeling to develop predictive, quantitative computational models to enable rapid rational engineering of small molecule ligands for use as tool compounds for computational biology or potential therapeutics. This project focuses on developing model systems of complexity intermediate between trivial physical modeling exercises and complex pharmaceutical drug targets that focus on specific challenges to predictive physical modeling; generating datasets for these model systems with particular attention to experimental error and concordance between experimental and modeled systems; running blind challenges that focus the community in ways that significantly advance predictive modeling; and curating and disseminating this data and the results of these competitions.

My laboratory is particularly well suited to developing model protein:ligand systems of intermediate complexity. We have significant expertise in the structural and chemical bioinformatics necessary to mine public databases for potential model systems; we have developed an automated cloning and bacterial expression pipeline to screen for bacterial expression; we develop and employ high-quality automated biophysical assays and Bayesian experimental analysis techniques to measure binding affinities; and we both extensively utilize alchemical free energy calculations and co-organize the primary meetings for this field (Alchemical Free Energy Calculations in Drug Discovery) so are intimately aware of which model systems will provide maximal value to the community for blind challenges and high-quality datasets. In addition, we have experience in coordinating the measurement of physical property datasets by sending students to work with pharma collaborators, analyzing and curating this data, and releasing his data for blind challenges.

At the Sloan Kettering Institute, my laboratory consists of twelve theorists and experimentalists that combine theory, advanced simulation algorithms, high performance computing, and automated biophysical measurements to develop quantitative models for predicting and understanding how small molecules (such as drugs) modulate cellular pathways, how mutations lead to drug resistance, and how this resistance can be circumvented or suppressed. My laboratory has extensive experience in the use of alchemical free energy calculations for the computation of protein-small molecule binding affinities, and is actively engaged in efforts to scale our methodologies to aid in the design of high-affinity ligands that bind selectively to desired members of protein families. My laboratory makes heavy use of large-scale computational resources, including the Folding@Home distributed computing platform, national supercomputing resources, and high-performance GPU computing resources at MSKCC. I am also actively involved in developing new high-throughput protocols for high-quality, high dynamic range binding affinity and physical property measurements; laboratory automation techniques; experimental design guided by Bayesian inference and information theoretic principles; and the use of Bayesian inference and bootstrap simulation for accurate assessment of measurement error.

The four publications highlighting our specific expertise for this proposal demonstrate (a) our grasp of the challenges facing predictive modeling using modern free energy methods in drug discovery, (b) our early recognition of the value in iterative blinded challenges to drive improvements in quantitative predictive modeling, (c) our ability to collect useful blind challenge experimental datasets in collaboration with pharma, and (d) our focus on the thorough characterization of all sources of experimental error in affinity measurement.

- a. **Chodera, J.D.**, Mobley, D.L., Shirts, M.R., Dixon, R.W., Branson, K.M., and Pande, V.S. Free energy methods in drug discovery and design: Progress and challenges. *Current Opinion in Structural Biology*, 21:150-160, 2011. PMCID: PMC3085996
- b. Mobley, D.L., Graves, A.P., **Chodera, J.D.**, McReynolds, A.C., Shoichet, B.K., and Dill, K.A. Predicting absolute ligand binding free energies to a simple model site. *Journal of Molecular Biology*, 371:1118-1134, 2007. PMCID: PMC2104542
- c. Rustenburg, A.S., Dancer, J., Lin, B., Feng, J.A., Ortwine, D.F., Mobley, D.L., and **Chodera, J.D.**. Measuring experimental cyclohexane-water distribution coefficients for the SAMPL5 challenge. *Journal of Computer Aided Molecular Design*, in press.
- d. Hanson, S.M., Ekins, S., and **Chodera, J.D.**. Modeling error in experimental assays using the bootstrap principle: understanding discrepancies between assays using different dispensing technologies. *Journal of Computer Aided Molecular Design* 29:1073, 2015. PMCID: PMC4696763.

## B. Positions and Honors

### **POSITIONS AND EMPLOYMENT (current positions in bold)**

- 2005 IBM Almaden Research summer internship, Blue Gene project, under William C. Swope  
2007-2008 Postdoctoral Fellow, Department of Chemistry, Stanford University  
2008-2012 QB3 Distinguished Postdoctoral Fellow, University of California, Berkeley, Berkeley, CA  
2012-present **Assistant Member** and Laboratory Head, Computational Biology Program,  
Sloan Kettering Institute for Cancer Research, MSKCC (primary appointment)  
2013-present **Assistant Professor**, Program in Physiology, Biophysics, and Systems Biology,  
Weill Cornell Graduate School of Medical Sciences  
2013-present **Faculty Member**, Tri-Institutional PhD Program in Chemical Biology  
2013-present **Faculty Member**, Tri-Institutional PhD Program in Computational Biology and Medicine  
2015-present **Faculty Member**, Gerstner Sloan Kettering Graduate School of Medical Sciences, MSKCC

### **HONORS AND AWARDS**

- 2000-2005 Howard Hughes Medical Institute Predoctoral Fellowship  
2005 Frank M. Goyan Award for outstanding work in Physical Chemistry, UCSF  
2005-2006 IBM Predoctoral Fellowship  
2008-2012 QB3-Berkeley Distinguished Postdoctoral Fellowship  
2013-2106 Louis V. Gerstner Young Investigator Award

### **OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS**

- 2000-present Member, American Chemical Society  
2014-present Scientific Advisory Board, Schrödinger

## C. CONTRIBUTIONS TO SCIENCE

To date, I have published more than 50 articles in peer-reviewed journals, which have collectively received over 4950 citations in the literature. My current h-index is 30, and my i10-index is 46.

**1. Accurate alchemical free energy calculations of ligand binding affinities.** With the aim of enabling true computer-guided design of small molecules as potential therapeutics and chemical probes, I have spent the better part of a decade developing alchemical free energy methodologies into a quantitative, predictive tool for

accurate computation of small molecule binding affinities to biomolecular targets. Work I have led or contributed to has benchmarked and improved the accuracies of free energy calculations, fixed deficiencies in methodologies, helped establish best practices, developed new efficient simulation algorithms, and exploited high-performance graphics computing hardware (GPUs) to greatly advance our progress toward this goal. We have made effective use of model systems and blind tests as a means of identifying systematic improvements in methodologies. Key papers demonstrate the capability of GPU-based free energy calculations to discover and compute affinities to new binding sites, review challenges facing the deployment of these techniques in drug discovery, address the problem of multiple kinetically-trapped conformational states contributing to binding, and demonstrate the power of cycles of experiment and computation to drive improvements.

- a. Wang, K., **Chodera, J.D.**, Yang, Y., and Shirts, M.R. Identifying ligand binding sites and poses using GPU-accelerated Hamiltonian replica exchange molecular dynamics. *Journal of Computer-Aided Molecular Design* 27:989, 2013. PMCID: PMC4154199
- b. **Chodera, J.D.**, Mobley, D.L., Shirts, M.R., Dixon, R.W., Branson, K.M., and Pande, V.S. Free energy methods in drug discovery and design: Progress and challenges. *Current Opinion in Structural Biology*, 21:150-160, 2011. PMCID: PMC3085996
- c. Mobley, D.L., **Chodera, J.D.**, and Dill, K.A. Confine-and-release method: Obtaining correct binding free energies in the presence of protein conformational change. *Journal of Chemical Theory and Computation*, 3:1231-1235, 2007. PMCID: PMC2562444
- d. Mobley, D.L., Graves, A.P., **Chodera, J.D.**, McReynolds, A.C., Shoichet, B.K., and Dill, K.A. Predicting absolute ligand binding free energies to a simple model site. *Journal of Molecular Biology*, 371:1118-1134, 2007. PMCID: PMC2104542

**2. Quantitative experimental biophysics.** I have been involved in the development of new techniques for the analysis of a variety of biophysical measurements. In the field of single-molecule force spectroscopy, I developed new techniques for the analysis of both nonequilibrium and equilibrium experiments. Working with force spectroscopists at UC Berkeley, I developed data analysis techniques crucial to demonstrating that nascent polypeptide chains translated by the ribosome have their folding properties modulated by electrostatic interactions with the ribosome (a), mechanical characterization of the molten globule state of a protein (b), and limitations of constant-force-feedback experiments (c). I have also worked extensively with biophysical techniques for the measurement of protein-ligand binding affinities, focusing on highly accurate quantitative measurements using techniques such as isothermal titration calorimetry (d).

- a. Kaiser, C., Goldman, D.H., **Chodera, J.D.**, Tinoco, I. Jr., and Bustamante, C. (2011) The ribosome modulates nascent protein folding. *Science* 334:1723. PMCID: PMC4172366
- b. Elms, P.J., **Chodera, J.D.**, Bustamante, C., Marqsee, S. (2012) The molten globule state is unusually deformable under mechanical force. *Proceedings of the National Academy of Sciences USA* 109:3796. PMCID: PMC3309780.
- c. Elms, P.J., **Chodera, J.D.**, Bustamante, C.J., Marqsee, S. (2012) Limitations of constant-force-feedback experiments. *Biophysical Journal*, 103, 1490, 2012. PMCID: PMC3471466
- d. Tellinghuisen, J., and **Chodera, J.D.** Systematic errors in isothermal titration calorimetry: Concentrations and baselines. *Analytical Biochemistry* 414:297, 2011.

**3. Biomolecular conformational dynamics and structural biology.** Biological macromolecules are not static entities, but populate a variety of kinetically metastable conformational states critical to binding and function. The long lifetimes of these metastable states present a challenge for molecular simulation, which are generally limited in length to a few microseconds. Together with collaborators at Stanford, the IBM Almaden Research Center, and the Freie Universität Berlin, I developed an approach to use *Markov state models* (MSMs) to build stochastic models of the long-time dynamics of biomolecules from many short atomistically-detailed molecular simulations. This technique allows for the characterization of thermally accessible metastable conformational states, along with their associated interconversion kinetics and equilibrium free energies, and is now utilized by many laboratories around the world.

- a. **Chodera, J.D.**, Sighal, N., Pande, V.S., Dill, K.A., and Swope, W.C. (2007). Automatic discovery of metastable states for the construction of Markov models of macromolecular conformational dynamics. *Journal of Chemical Physics* 126, 155101. PMID: 174616665
- b. Pitera, J.W. and **Chodera, J.D.** On the use of experimental observations to bias simulated observables. *Journal of Chemical Theory and Computation* 8:3445, 2012.

- c. Noé, F., Doose, S., Daidone, I., Löllmann, M., Sauer, M., **Chodera, J.D.**, and Smith, J.C. (2011). Dynamical fingerprints: A theoretical framework for understanding biomolecular processes by combination of simulation and kinetic experiments. *Proceedings of the National Academy of Sciences USA* 108:4822, 2011. PMCID: PMC3064371
- d. Prinz, J.H., Wu, H., Sarich, M., Keller, B., Fischbach, M., Held, M., **Chodera, J.D.**, Schütte, C., and Noé, F. (2011). Markov models of molecular kinetics: Generation and validation. *Journal of Chemical Physics* 134:174105. PMID: 21548671

**4. Advances in molecular simulation algorithms and methodologies.** Throughout my career, I have been active in the development of new algorithms to increase the efficiency of molecular simulations, establish best practices, benchmark and improve molecular mechanics forcefields, and exploit novel computing paradigms. Key advances include recognizing replica exchange simulations can be considered a form of Gibbs sampling (a), new estimators for combining simulation data from a variety of temperatures (b), the development of a new GPU-accelerated molecular simulation framework (c), and a simple solution to the longstanding problem of detecting when a simulation has sufficiently equilibrated (d).

- a. **Chodera, J.D.**, and Shirts, M.R. Replica exchange and expanded ensemble simulations as Gibbs sampling: Simple improvements for enhanced mixing. *Journal of Chemical Physics* 135:194110, 2011. PMID: 22112069
- b. Prinz, J.H, **Chodera, J.D.**, Pande, V.S., Swope, W.C., Smith, J.C., Noé, F. (2011) Optimal use of data in parallel tempering simulations for the construction of discrete-state Markov models of biomolecular dynamics. *Journal of Chemical Physics* 134, 244108. PMCID: PMC3139503
- c. Eastman, P., Friedrichs, M., **Chodera, J.D.**, Radmer, R., Bruns, C., Ku, J., Beauchamp, K., Lane, T.J., Wang, L.P., Shukla, D., Tye, T., Houston, M., Stinch, T., Klein, C., Shirts, M.R., and Pande, V.S. OpenMM 4: A reusable, extensible, hardware independent library for high performance molecular simulation. *Journal of Chemical Theory and Computation* 9:461, 2012. PMCID: PMC3539733
- d. **Chodera, J.D.** A simple method for automated equilibration detection in molecular simulations. *Journal of Chemical Theory and Computation*, in press. Submitted to PMC.

**5. Nonequilibrium statistical mechanics.** The discovery of the Jarzynski equality (JE) in 1997 and the Crooks fluctuation theorem (CFT) in 1999 touched off a revolution in the field of statistical mechanics, providing for the first time exact relationships between the behavior of systems driven out of equilibrium and their equilibrium counterparts. I have been heavily involved in efforts to produce robust, reliable, and useful statistical estimators from these theorems, enabling the analysis of both nonequilibrium molecular simulations and real nonequilibrium biophysical experimental data to produce optimal estimates of physical properties like free energies and equilibrium expectations, along with good estimates of error (a and b). Together with Gavin Crooks and David Min, I developed a new efficient simulation methodology that exploits nonequilibrium driving--nonequilibrium candidate Monte Carlo (NCMC)---which can increase the acceptance probability of Monte Carlo in complex systems moves by orders of magnitude (c). More recently, we have shown how nonequilibrium theorems and estimators can yield new insight into the errors made in simulating physical systems by discretizing dynamical equations of motion for computer simulation (d).

- a. Minh, D.D.L and **Chodera, J.D.** Optimal estimators and asymptotic variances for nonequilibrium path-ensemble averages. *Journal of Chemical Physics* 131, 134110, 2009. PMCID: PMC2771048
- b. Minh, D.D.L. and **Chodera, J.D.** Estimating equilibrium ensemble averages using multiple time slices from driven nonequilibrium processes: Theory and application to free energies, moments, and thermodynamic length in single-molecule pulling experiments. *Journal of Chemical Physics* 134, 024111, 2011. PMID 21241084.
- c. Nilmeier, J.P., Crooks, G.E., Minh, D.D.L., and **Chodera, J.D.** Nonequilibrium candidate Monte Carlo is an efficient tool for equilibrium simulation. *Proceedings of the National Academy of Sciences USA* 108, E1009, 2011. PMCID: PMC3215031
- d. Sivak, D.A., **Chodera, J.D.**, and Crooks, G.E. Using nonequilibrium fluctuation theorems to understand and correct errors in equilibrium and nonequilibrium simulations of discrete Langevin dynamics. *Physical Review X*, 011007, 2013.

Complete list of published work available at MyNCBI Collections:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/john.chodera.1/bibliography/43349161/public>

## D. RESEARCH SUPPORT

### Ongoing Research Support

**I8-A8-058** (PI: Luo) 1/1/2015 – 12/31/2016

Starr Cancer Consortium

Designing Sinefungin Scaffolds as Specific Protein Methyltransferase Inhibitors

Our long-term goal is to develop PMT inhibitors for epigenetic cancer therapy, with the current objective to establish a drug-discovery pipeline with sinefungin analogues.

Role: Co-Investigator

**SK2015-0252** (PI: Chodera) 7/1/2015 – 10/31/2016

AstraZeneca

Evaluating the potential for Markov state models of conformational dynamics

Our goal is to evaluate the potential for Markov state models of conformational dynamics to describe the mechanism of slow off-rate inhibition in the human kinases CK2 and SYK.

Role: Investigator

**SK2016-0731** (PI: Chodera) 8/29/2016 – 8/28/2018

Merck KG

Benchmarking absolute alchemical free energy calculations with YANK

The objective of this project is to perform a large-scale benchmark of alchemical free energy calculations using the GPU-accelerated open source code YANK.

Role: Investigator

### Completed Research Support

None

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Bruce C Gibb

ERA COMMONS USER NAME (credential, e.g., agency login): bkgibb

POSITION TITLE: Professor of Chemistry

**EDUCATION/TRAINING**

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Robert Gordon's University, Aberdeen, UK	B.Sc.	06/1987	Physical Sciences
Robert Gordon's University, Aberdeen, UK	Ph.D.	06/1992	Organic Chemistry
University of British Columbia, Vancouver	Postdoc	10/1994	Supramolecular Chem.
New York University, New York	Postdoc	07/1996	Bioorganic Chemistry

**A. Personal Statement**

The current application builds on our five-year collaboration with Profs. David Mobley (UC Irvine) and Michael Gilson (UC San Diego), which in turn stems from my 20 years of independent research on aqueous supramolecular chemistry. Our work with Mobley and Gilson has centered round the Statistical Assessment of the Modeling of Proteins and Ligands (SAMPL) exercise (OpenEye Scientific).<sup>1,2</sup> In this collaboration our group synthesizes host and guest molecules and then utilizes Isothermal Titration Calorimetry (ITC) to determine the thermodynamics of host-guest complexation. Our data is sealed until the group of computational chemists marshaled by Mobley and Gilson has, *a priori*, calculated the thermodynamics of the different binding events. Whilst this exercise has proven to be invaluable for computational chemists to test the predictive powers of their different approaches, the scrutiny our results receives also ensures exceedingly high standards of data collection within my own group; a fact that I consider essential to student training as research scientists.

The SAMPL exercise dove-tails with our ongoing research into a family of hosts we use<sup>3</sup> to probe the complex relationship between the Hydrophobic effect and solute shape,<sup>4</sup> and how salts influence aqueous solutions, i.e., the Hofmeister effect. Additionally, as is described below, we use our understanding of these phenomena to study molecular compartmentalization within yocto liter spaces, and how this can be used to bring about novel purification protocols and unusual chemical reactions.

1. Sullivan M. R., Sokkalingam P., Nguyen T., Donahue J. P., Gibb B. C. Binding of carboxylate and trimethylammonium salts to octa-acid and TEMOA deep-cavity cavitands. *J. Comput. Aided Mol. Des.*, 2016, SAMPL5 Special Issue. doi: 10.1007/s10822-016-9925-0. PubMed PMID: 27432339.
2. Gibb C. L. D., Gibb B. C. *Binding of cyclic carboxylates to octa-acid deep-cavity cavitand*. *J. Comput. Aided Mol. Des.*, 2014, 28(4), 319-25. doi: 10.1007/s10822-013-9690-2. PubMed PMID: 24218290; PubMed Central PMCID: PMC4018434.
3. Jordan J. H., Gibb B. C. *Molecular containers assembled through the hydrophobic effect*. *Chem Soc Rev*, 2015, 44(2), 547-85. doi: 10.1039/c4cs00191e. PubMed PMID: 25088697.
4. Hillyer M. B., Gibb B. C. *Molecular Shape and the Hydrophobic Effect*. *Annu. Rev. Phys. Chem.*, 2016, 67, 307-29. doi: 10.1146/annurev-physchem-040215-112316. PubMed PMID: 27215816.

## B. Positions and Honors

### Positions:

- 1996-2002 Assistant Professor, Department of Chemistry, Univ. of New Orleans (UNO)  
2002-2005 Associate Professor, Department of Chemistry, UNO, LA  
2005-2008 Professor of Chemistry, Department of Chemistry, UNO, LA  
2008-2011 University Research Professor of Chemistry, Department of Chemistry, UNO, LA  
2012- Professor of Chemistry, Tulane University, LA

### Other experiences and professional memberships:

- 1996- Member, American Chemical Society, American Association for the Advancement of Science, Royal Society of Chemistry  
1998-2005 Co-organizer, placement program for (30+) students from the IUT system in France  
2003- Co-chair of the 7th International Conference on Calixarenes, Vancouver, B.C., Canada, 08/03  
2004- Ad hoc Reviewer, NIH General Medicine ZRG1 BCMB-M (10) B study section  
2004- Invited participant, NSF Young Investigator Supramolecular Chemistry Workshop  
2006- Ad hoc Reviewer, NIH, Synthetic and Biological Chemistry: A (SBC-A) Study Section  
2007- Invited participant, NSF Workshop on Complexity and Emergent Phenomena in Chemistry  
2007- Member for the NIH, Synthetic and Biological Chemistry: A (SBC-A) Study Section (2007-2011)  
2009-2012 Associate Chair, Department of Chemistry, UNO, LA  
2009- Columnist, Nature Chemistry  
2010- Organizer, Supramolecular Chemistry Symposium, Joint SE/SW Regional ACS meeting, New Orleans  
2011- Member, International Advisory Committee, International Conference on Calixarenes  
2013- Co-Editor-in-Chief, *Supramolecular Chemistry* (Taylor and Francis Group)  
2013- Organizer and co-founder of the C. David Gutsche Award, a biennial \$5000 award for senior researchers who have made a significant impact in the field of calixarene chemistry  
2014- Chair: Mardi Gras Symposium, Tulane University; a one-day symposium with 7 international speakers and 105 attendees (2014)  
2015- Visiting Professor, Wuhan University of Science and Technology as a Chair Professor of the Chutian Scholars Program (2015-2017)  
2015- Member, International Scientific Committee for the International Symposium on Macrocyclic and Supramolecular Chemistry (ISMSC) series  
2015- PI, NSF Workshop; "Accelerating our Understanding of Supramolecular Chemistry in Aqueous Solutions"  
2015- Consultant, Statistical Assessment of the Modeling of Proteins and Ligands (SAMPL), OpenEye Scientific

### Honors and Awards:

- 1996 UNO Scholar Award  
1998 Research Corporation, Research Innovation Award  
1999 UNO Scholar Award  
2001 UNO Science Research Development Award  
2008-2011 UNO University Research Professor

## C. Contributions to Science

**The Hofmeister Effect.** In large part because of improved molecular dynamics simulations and new surface-specific spectroscopic techniques, the last decade or so has seen a revival in the age-old problem of understanding the Hofmeister effect, i.e., the ubiquitous phenomenon whereby, irrespective of the physicochemical technique, ranges of salts are seen to influence the properties of water or aqueous solutions in predictable ways. As outlined in this application, our recent research with deep-cavity cavitands has affected science's understanding of the Hofmeister effect by unequivocally demonstrating that even under unfavorable conditions, anions have a measurable and significant affinity for hydrophobic surfaces.<sup>1-4</sup> Furthermore, we have shown that anion binding influences the thermodynamics of (hydrophobic) guest binding to hosts in a manner that parallels the Hofmeister series.

From a personal perspective, understanding the Hofmeister effect is a large component of aqueous supramolecular chemistry. Yet the two groups of scientists who respectively study the Hofmeister effect and supramolecular chemistry in water have essentially remained separate. It is for this reason that our work has not only involved fundamental research at the boundary between these two fields, but has also involved efforts to bring these two fields together. This application – involving collaboration between a supramolecular chemist (the PI), a leader in molecular simulations and statistical thermodynamic theory of aqueous solutions (Ashbaugh), and an expert in hydration-shell vibration spectroscopic methods, densitometry, and theory (Ben-Amotz) – is one such local example of bringing these fields together. On a larger scale, the PI recently led a NSF supported workshop entitled, “*Accelerating our Understanding of Supramolecular Chemistry in Aqueous Solutions*”. Held last May in Washington DC, this meeting brought together sixteen water scientists (physical chemists, computationalists, instrumentalists, physicists and biophysicists) and sixteen supramolecular chemists (physical-(in)organic chemists) to discuss each side’s approach to solving mutual/related problems in the field. One metric of the success of this meeting was that an exit survey suggested twenty-four new collaborations between pairs of attendees in the two fields. Further such endeavors are ongoing.

- 1) Sokkalingam P., Shrberg J., Rick S. W., Gibb B. C. Binding Hydrated Anions with Hydrophobic Pockets. *J. Am. Chem. Soc.*, **2016**, 138(1), 48-51.
- 2) Gibb C. L. D., Oertling E. E., Velaga S., Gibb B. C. *Thermodynamic Profiles of Salt Effects on a Host-Guest System: New Insight into the Hofmeister Effect*. *Journal of Physical Chemistry B*, **2015**, 119(17), 5624-38
- 3) Carnegie R., Gibb C. L. D., Gibb B. C. *Anion Complexation and The Hofmeister Effect*. *Angew. Chem. Int. Ed.*, **2014**, 53(43), 11498-500
- 4) Gibb C. L. D., Gibb B. C. *Anion binding to hydrophobic concavity is central to the salting-in effects of Hofmeister chaotropes*. *J. Am. Chem. Soc.*, **2011**, 133(19), 7344-7

**Assemblies driven by the Hydrophobic Effect.** With the exception of cyclodextrin chemistry, which had mostly peeled away from supramolecular chemistry and moved decidedly into a more applied realm, when I began my independent career, supramolecular chemistry was primarily studied in organic solvents. State-of-the-art in regards to self-assembled hosts/supramolecular containers were the (hydrogen bonded) Rebek “jelly doughnut” and (metal coordinated)  $L_4M_6$  cages from the Fujita lab. My goal was to work in water, and I wanted to avoid these two common strategies for assembly – hydrogen-bonding and metal coordination – and use the Hydrophobic effect to drive the formation of structurally specific, mono-dispersed supramolecular containers large enough to encapsulate sizable guests. We first designed and synthesized more straightforward hosts soluble in organic solvents, before devising the first host that relied solely on the Hydrophobic effect to drive assembly.<sup>1</sup> This deep-cavity cavitand, as well as related hosts we have synthesized, define a dry, yocto-liter sized environment by dimerizing around guest molecules. Their ease of synthesis, combined with their encapsulation properties, is reflected in the fact that at least six laboratories around the world have independently worked with these types of hosts.<sup>1</sup> Since that time, others have entered this new field with their own self-assembling systems; most notably Mitsuhiro Shionoya (U. Tokyo) and Michito Yoshizawa (Tokyo Institute of Technology). Our research has now expanded to include the formation of tetrameric and hexameric assemblies that represent the largest such structures devised to date.<sup>2,3</sup> *En masse*, these supramolecular containers have provided valuable information about the structural requirements for controlled assembly using the Hydrophobic effect, and in conjunction with the concomitantly developing cucurbiturils, are shedding light on how the Hydrophobic effect can be orchestrated to control supramolecular properties.<sup>4</sup>

- 1) Jordan, J. H., Gibb, B. C., Molecular containers assembled through the hydrophobic effect, *Chem. Soc. Rev.*, **2015**, 44 (2), 547-85
- 2) Gan H., Benjamin C. J., Gibb B. C. *Non-monotonic Assembly of a Deep-Cavity Cavitand*. *J. Am. Chem. Soc.*, **2011**, 133, 4770-3
- 3) Gan H., Gibb B. C. *Guest-Mediated Switching of the Assembly State of a Water-Soluble Deep-Cavity Cavitand* *Chemical Communications*, **2012**, 49, 1395-7.
- 4) Hillyer M. B., Gibb B. C. *Molecular Shape and the Hydrophobic Effect*. *Annu. Rev. Phys. Chem.*, **2016**, 67, 307-29.

**Controlling Photochemistry and Photophysics.** In collaboration with V. Ramamurthy (U. Miami) we have advanced the ability to control photochemical and photophysical processes in aqueous solutions.<sup>1-4</sup> Our self-assembling containers have opened up the range of processes that can be studied in water, and brought a new level of control in regards to not only cage-effects, but also to the regioselectivity and stereoselectivity of these processes. In short, we have demonstrated that the hydrophobic effect can be orchestrated to bring about selective complexation and assembly so as to force photochemical and photophysical processes down

pathways that do not exist in free solution (or even in structurally defined media such as zeolites). Furthermore, our work demonstrated for the first time cross-talk between supramolecular complexes that mimic chemical signaling between enzymes.<sup>3</sup>

- 1) Kaanumalle L. S., Gibb C. L. D., Gibb B. C., Ramamurthy V. *Controlling Photochemistry with Distinct Hydrophobic Nano-Environments*. *J. Am. Chem. Soc.*, **2004**, 126, 14366-7
- 2) Kaanumalle L. S., Gibb C. L. D., Gibb B. C., Ramamurthy V. *A Hydrophobic Nano-Capsule Controls the Photophysics of Aromatic Molecules by Suppressing their Favored Solution Pathways*. *J. Am. Chem. Soc.*, **2005**, 127, 3674-5.
- 3) Natarajan A., Kaanumalle L. S., Jockusch S., Gibb C. L. D., Gibb B. C., Turro N. J., et al. *Controlling Photoreactions with Restricted Spaces and Weak Intermolecular Forces: Remarkable Product Selectivity during Oxidation of Olefins by Singlet Oxygen*. *J. Am. Chem. Soc.*, **2007**, 129, 4132-3. See also commentary: Greer A. *Molecular Cross-Talk*. *Nature*, **2007**, 447, 273-4.
- 4) Gibb, C. L. D.; Sundaresan, A. K.; Ramamurthy, V.; Gibb, B. C., Temptation of the Excited-State chemistry of  $\alpha$ -(n-Alkyl) Dibenzyl Ketones: How guest packing with a nano-scale supramolecular capsule influences photochemistry. *J. Am. Chem. Soc.* **2008**, 130, 4069-4080

**Molecular Protections and Separations.** The supramolecular systems devised in the group have many unusual and unique properties resulting from their ability to engender compartmentalization. One area that we have helped pioneer, and an area that is very much ongoing in our lab, is to use these nano-containers as a means to bring about molecular separations. Although these processes can be made more complex by the binding of two different guests within a container,<sup>1</sup> we have reported on a number of different approaches. One example is the physical separation/purification of hydrocarbon gases using aqueous solutions.<sup>2</sup> Thus, when a mixture of, for example, propane and butane is added to the head space above a solution of one of our water-soluble hosts, it is observed that only butane is pulled into solution (to form the corresponding 2:2 host-guest complex), leaving behind an enriched/pure sample of propane in the gas-phase. Such purifications are beyond the state-of-the-art of semi-permeable membrane technology. We have also demonstrated how molecular containers can be used to bring about chemical separations of normally difficult-to-separate mixtures.<sup>3</sup> One example of such kinetic resolutions is to add a mixture of two guests to a hydrolytic solution containing a host. The guest that binds preferentially is protected within the nano-container, whilst the less complementary guest is exposed to the reactive solution and hydrolyzed. This type of kinetic resolution via molecular protection represents a new strategy for separating complex mixtures.

- 1) Sullivan M. R., Gibb B. C. *Differentiation of small alkane and alkyl halide constitutional isomers via encapsulation*. Special issue on aqueous supramolecular chemistry, *Org. Biomol. Chem.*, **2015**, 13(6), 1869-77
- 2) Gibb C. L. D., Gibb B. C. *Templated Assembly of Water-Soluble Nano-Capsules: Inter-Phase Sequestration, Storage, and Separation of Hydrocarbon Gases*. *J. Am. Chem. Soc.*, **2006**, 128(51), 16498-9
- 3) Liu, S.; Gan, H.; Hermann, A. T.; Rick, S. W.; Gibb, B. C., Kinetic Resolution of Constitutional Isomers Controlled by Selective Protection inside a Supramolecular Nanocapsule. *Nature Chemistry* **2010**, 2 (10), 847-852

**Editorship.** As co-editor in chief of *Supramolecular Chemistry* (along with Philip Gale, U. of Southampton) I am fortunate to be in a position to help shape the future of the field. Although relatively specialized, the journal provides a valuable forum for countless authors from both developed nations and newly industrialized countries such as China and India. Moreover, the journal works closely with a number of international conferences including: the International Symposium on Macrocyclic and Supramolecular Chemistry, the International Conference on Molecular Sensors and Molecular Logic Gates, the International Conference on Calixarenes, and the International Conference on Cucurbiturils. Through these collaborations the journal helps support these meetings and produces special issues dedicated to each conference. Relatedly, the journal also publishes thematic special editions on a range of subjects, as well as those dedicated to honoring leaders in the field. In addition, we also publish invited “big picture” essays from world leaders on their opinions of the state-of-the-art and future of the field. In combination, these different activities mean that *Supramolecular Chemistry* is not only a key forum for everything supramolecular, but that it also helps glue, shape and direct the field.

Complete list of Published Work: <http://www.gibbggroup.org/blog/wp-content/uploads/2013/08/Gibb-CV.pdf>

#### D. Research Support

NIH R01 GM098141      Gibb (PI)      06/01/12-02/28/17  
*Using Deep-Cavity Cavitands to Study Supramolecular Chemistry in Water*  
The goal of this study is to contribute to our understanding of the Hofmeister Effect by probing how anions influence binding events driven by the Hydrophobic effect.  
Role: PI

NSF CHE 1450865      Gibb (PI)      02/15/15-01/31/17  
*Accelerating our Understanding of Supramolecular Chemistry in Aqueous Solutions: A Workshop Proposal*  
The goal of this study was to organize a workshop to bring together two separate groups of scientists: water and aqueous solutions scientists, and supramolecular chemists.  
Role: PI

NSF CHE 1507344      Gibb (PI)      08/15/15-08/14/18  
*Nano-Containers for Novel Separations and Reactions*  
The goal of this study is to investigate self-assembled dimeric nano-capsules as yocto-liter reaction flasks and as containers for the separation of complex mixtures of small (< C20) molecules.  
Role: PI

NSF CBET 1403167      Ashbaugh (PI)      07/01/14-06/30/17  
*Capacious Deep-Cavity Cavitand/Hydrophobic Guest Assemblies with Tunable Interior Volumes*  
The goal of this grant is to understand how hydrophobe shape influences the Hydrophobic effect and how this in turns influences the formation of self-assembled supramolecular containers.  
Role: co-PI

NSF 143280      Khonsari (PI)      08/01/14-07/31/17  
*The Smart MATerial Design, Analysis, and Processing (SMATDAP) consortium: Building next-generation polymers and the tools to accelerate cost-effective commercial production*  
The goals of this award are to develop new, real-time and multi-channel analysis of polymerization processes, particularly in regard to the development of supramolecular polymers.  
Role: co-PI

**Completed Research Support**  
NIH 1S10OD020117-01      Jayawickramarajah (PI)      03/09/15-03/08/16  
*Acquisition of a Surface Plasmon Resonance Biosensor: Enhancing Biomedical (Bio)Molecular Recognition Projects*  
This was an equipment award for the purchase of a new Surface Plasmon Resonance.  
Role: co-PI

Louisiana Board of Regents (LEQSF(2015-16)-ENH-TR-39      Grayson (PI)      03/09/15-03/08/16  
*Nano-materials Separation and Characterization Equipment*  
This was an award for the purchase of new GPC equipment.  
Role: co-PI

NSF CHE 1244024      Gibb (PI)      05/31/12-07/31/15  
*Studies of Deep Cavity Cavitands*  
The goals of this award were to: devise multi-(supra)molecule systems possessing unusual relationships between the components, the environment and the net overall state of the system, and study encapsulation approaches to the separation of constitutional isomers.  
Role: PI

NSF CHE 1228232      Mague (PI)      09/01/12-08/31/15  
*MRI: Acquisition of a Single-Crystal, Micro-Source Diffractometer*  
This was an award for the purchase of new diffractometer.  
Role: co-PI

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Isaacs, Lyle

ERA COMMONS USER NAME (credential, e.g., agency login): ISAACS

POSITION TITLE: Professor of Chemistry

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of Chicago	B.S.	06/1991	Chemistry
University of California, Los Angeles	M.S.	06/1992	Organic Chemistry
Swiss Federal Institute of Technology, Zurich	Ph.D.	08/1995	Organic Chemistry
Harvard University	Postdoc	06/1998	Supramolecular Chem.

**A. Personal Statement**

For his independent work at the University of Maryland, Lyle Isaacs is recognized as a world leader in the area of cucurbit[n]uril (CB[n]) molecular containers. The focus of this work has been manifold: 1) developing a thorough mechanistic understanding of the CB[n] forming reaction, 2) using this mechanistic understanding to create new members of the CB[n] family of molecular containers with exciting new structures, and 3) investigating their unique molecular recognition properties. For example, we have discovered the ultra tight affinity binding of CB[n] toward its best guests and used CB[n]-type receptors to regulate the enzymatic activity of bovine carbonic anhydrase, to perform homotropic allosteric binding, and to trigger the decloaking of cytotoxic nanoparticles in the cell. In more recent work, Isaacs and collaborators (Briken and Eikermann) have explored the use of acyclic CB[n] type molecular containers as: 1) a solubilizing excipient for insoluble drugs, and 2) as an *in vivo* reversal agent for neuromuscular block induced by rocuronium, vecuronium, and cis-atracurium. Acyclic CB[n] compounds (a.k.a. Calabadiols) do not display toxicity in both *in vitro* and *in vivo* assays which sets the stage for their further development as reversal agents for diverse biomedical applications. Over the past five years, the Isaacs group has provided blind challenge data for SAMPL3, SAMPL4, and SAMPL5 by synthesizing cyclic and acyclic CB[n]-type receptors and measuring their binding properties toward appropriate guest molecules. We have found the SAMPL challenges to be scientifically stimulating, and our participation has led our work in new directions. Accordingly, Dr. Isaacs has both the scientific expertise and a high level of enthusiasm to serve as a co-investigator on this project.

**B. Positions and Honors****Positions and Employment**

10/95 – 6/98	Harvard University, NIH postdoctoral fellow (with George M. Whitesides)
6/98 – 8/04	University of Maryland, Assistant Professor, Department of Chemistry and Biochemistry
8/04 – 8/08	University of Maryland, Associate Professor, Department of Chemistry and Biochemistry
8/08 – present	University of Maryland, Professor, Department of Chemistry and Biochemistry
7/10 – 6/13	University of Maryland, Director, Chemistry Graduate Program

8/12 – present Director, UMD Chemistry Graduate Assistance in Areas of National Needs (GAANN) Program

### **Other Experience and Professional Memberships**

1991 – present	Member, American Chemical Society
2001 – present	Member, American Academy of Arts and Sciences
2005 – present	Member, Maryland Nanocenter
2007	Organizer of the NSF Workshop on Cucurbit[n]uril Molecular Containers
2009 – present	Member, International Advisory Board of the International Conference on Cucurbiturils
2009 – present	Member of the Editorial Board of the Journal of Systems Chemistry
2010 – 2016	Member, International Advisory Board of the International Symposium on Macrocyclic and Supramolecular Chemistry
2013	Organizer of the International Symposium on Macrocyclic and Supramolecular Chemistry
2015	Local Co-Organizer, American Chemical Society, National Organic Symposium
2015	Co-organizer of the “Molecular Containers” symposium at Pacifichem 2015

### **Honors & Awards**

- U.S. Department of Defense Graduate Fellow (1991)  
Silver Medallion Dissertation Award (ETH Zürich, 1996)  
National Institutes of Health Postdoctoral Fellow (1996 – 1998)  
National Science Foundation Career Award (2000 – 2004, declined)  
Cottrell Scholar, Research Corporation (2001 – 2006)  
Junior Faculty Award, College of Life Sciences, University of Maryland (2001)  
Outstanding Invention of 2010 “*Molecular Container to Enhance Solubility of Drugs*” University of Maryland, Office of Technology Commercialization.  
Elected Fellow, American Association for the Advancement of Science (2013)

### **C. Contribution to Science**

Dr. Isaacs has made internationally recognized and highly cited contributions to science at all stages of his career development. Dr. Isaacs has published a total of 134 articles in peer reviewed journals. These publications have received over 8000 citations in the literature. Dr. Isaacs has an h-index of 47.

1. *Cucurbit[n]uril molecular container chemistry and recognition properties.* The Isaacs group is a world-leader in the area of cucurbit[n]uril molecular containers. Specifically, we are renowned for: 1) our investigation of the mechanism of CB[n] formation that allowed the creation of numerous new CB[n]-type receptors (e.g. chiral CB[n], acyclic CB[n], double cavity CB[n], chromophoric CB[n], monofunctionalized CB[n]), 2) our discovery of the remarkable affinity of CB[n] toward their guests in water (e.g.  $K_a$  up to  $10^{17} \text{ M}^{-1}$ ), 3) the use of the recognition properties of CB[n] in diverse applications (e.g. homotropic allosteric, chiral recognition, non-natural folding, chemical sensing, supramolecular polymers, drug delivery), and 4) our landmark review article that launched >100 groups to join the CB[n] field.

Lagona, J.; Mukhopadhyay, P.; Chakrabarti, S.; Isaacs, L. The Cucurbit[n]uril Family. *Angew. Chem. Int. Ed.* **2005**, *44*, 4844-4870. (review article; cited 1158 times)

Rekharsky, M. V.; Mori, T.; Yang, C.; Ko, Y. H.; Selvapalam, N.; Kim, H.; Sobransingh, D.; Kaifer, A. E.; Liu, S.; Isaacs, L.; Chen, W.; Gilson, M. K.; Kim, K.; Inoue, Y. A synthetic host-guest system achieves avidin-biotin affinity by overcoming enthalpy-entropy compensation. *Proc. Natl. Acad. Sci.* **2007**, *104*, 20737-20742. (cited 248 times)

Huang, W.-H.; Zavalij, P. Y.; Isaacs, L. Cucurbit[n]uril Formation Proceeds by Step-Growth Cyclo-Oligomerization. *J. Am. Chem. Soc.* **2008**, *130*, 8446-8454. (cited 53 times)

Cao, L.; Hettiarachichi, G.; Briken, V.; Isaacs, L. Cucurbit[7]uril Containers for Targeted Delivery of Oxaliplatin to Cancer Cells. *Angew. Chem. Int. Ed.* **2013**, *52*, 12033-12037. (cited 20 times)

**2. Biomedical Applications of Acyclic CB[n] Containers.** Dr. Isaacs research group used our mechanistic knowledge of CB[n] formation to create acyclic CB[n] containers that function well in two important biomedical application areas. First, a major problem facing the pharmaceutical industry is that many of their most promising drugs and drug candidates are so insoluble that they cannot be formulated on their own. Isaacs and Briken created acyclic CB[n] compounds that act as containers that solubilize and thereby formulate these drugs for in vitro and in vivo testing. Second, a major issue facing anesthesiologists is that residual neuromuscular block at the end of surgery results in patients having difficulty breathing which increases healthcare costs and mortality. Isaacs and Eikermann demonstrated that certain acyclic CB[n] compounds are able to sequester the neuromuscular blocking agent rocuronium from the bloodstream of rats and thereby allow them to regain their neuromuscular function rapidly. Acyclic CB[n] are under active development toward real world application.

Ma, D.; Hettiarachchi, G.; Nguyen, D.; Zhang, B.; Wittenberg, J. B.; Zavalij, P. Y.; Briken, V.; Isaacs, L. Acyclic Cucurbit[n]uril Molecular Containers Enhance the Solubility and Bioactivity of Poorly Soluble Pharmaceuticals. *Nat. Chem.* **2012**, 4, 503-510. (cited 82 times)

Ma, D.; Zhang, B.; Hoffmann, U.; Grosse Sundrup, M.; Eikermann, M.; Isaacs, L. Acyclic Cucurbit[n]uril Type Molecular Containers Bind Neuromuscular Blocking Agents in Vitro and Reverse Neuromuscular Block In Vivo. *Angew. Chem. Int. Ed.* **2012**, 51, 11358-11362. (cited 31 times)

Hoffmann, U.; Grosse-Sundrup, M.; Eikermann-Haerter, K.; Ayata, C.; Zhang, B.; Ma, D.; Isaacs, L.; Eikermann, M. Calabadion, a new broad spectrum agent to reverse the effects of benzylisoquinoline and steroid neuromuscular blocking agents. *Anesthesiology* **2013**, 119, 317-325. (cited 3 times)

Zhang, B.; Isaacs, L. Acyclic Cucurbit[n]uril-Type Molecular Containers: Influence of Aromatic Walls on their Function as Solubilizing Excipients for Insoluble Drugs. *J. Med. Chem.* **2014**, 57, 9554-9563. (cited 1 time)

**3. The conceptualization and demonstration of multi-component self sorting systems.** Researchers in the field of supramolecular chemistry take inspiration from Nature to create non-natural receptors that perform useful recognition, transport, or catalytic function. However, a widespread misconception was that supramolecular chemists synthetic systems were not as selective as natural systems and would be incapable of functioning in complex multicomponent mixtures. The Isaacs group shifted the viewpoint of the field in a series of papers that showed that mixtures of supramolecular receptors performed their functions faithfully even withing complex mixtures. The work has been highly cited and has launched numerous research groups worldwide to start research programs on self-sorting systems.

Wu, A.; Isaacs, L. Self-Sorting: The Exception or the Rule? *J. Am. Chem. Soc.* **2003**, 125, 4831-4835. (cited 196 times)

Mukhopadhyay, P.; Wu, A.; Isaacs, L. Social Self-Sorting in Aqueous Solution. *J. Org. Chem.* **2004**, 69, 6157-6164. (cited 114 times)

Liu, S.-M.; Ruspic, C.; Mukhopadhyay, P.; Chakrabarti, S.; Zavalij, P.; Isaacs, L. The CB[n] Family: Prime Components for Self-Sorting Systems. *J. Am. Chem. Soc.* **2005**, 127, 15959-15967. (cited 358 times)

Mukhopadhyay, P.; Zavalij, P. Y.; Isaacs, L. High Fidelity Kinetic Self-Sorting in Multi-Component Systems Based on Guests with Multiple Binding Epitopes. *J. Am. Chem. Soc.* **2006**, 128, 14093-14102. (cited 111 times)

**4. Development of the tether directed remote functionalization approach to regioselectively multiply functionalize buckminsterfullerene ( $C_{60}$ ).** My PhD dissertation with Prof. Francois Diederich focused on the functionalization of  $C_{60}$  as a means to tune the properties of this important class of compounds for specific applications. In the early 1990s, a major challenges to the field was that  $C_{60}$  features 30 reactive C=C double bonds and therefore numerous regioisomers can result when two or more groups are added to the carbon sphere. My research introduced the concept of tether directed remote functionalization to create bis, tris,

tetrakis, pentakis, and hexakis adducts of C<sub>60</sub>. The work stimulated significant follow up research in numerous labs worldwide.

Isaacs, L.; Haldimann, R. F.; Diederich, F. Tether-Directed Remote Functionalization of Buckminsterfullerene: Regiospecific Hexaadduct Formation. *Angew. Chem. Int. Ed. Engl.* **1994**, 33, 2339-2342. (cited 140 times)

Isaacs, L.; Seiler, P.; Diederich, F. Solubilized Derivatives of C<sub>195</sub> and C<sub>260</sub>: The First Members of a New Class of Carbon Allotropes C<sub>n(60+5)</sub>. *Angew. Chem. Int. Ed. Engl.* **1995**, 34, 1466-1469. (cited 76 times)

#### Complete List of Published Work in MyBibliography:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/lyle.isaacs.1/bibliography/45414278/public/?sort=date&direction=asc>  
[ending](#)

#### D. Research Support

##### Ongoing Research Support

CHE-1404911 National Science Foundation “Synthesis and Application of Cucurbituril Type Receptors” This project explores the preparation of cucurbituril-type receptors and exploitation of their molecular recognition properties including ultratight host-guest binding, peptide and protein recognition, and the use of immobilized cucurbituril type receptors in bioanalytical assays. Role: PI. Dr. Isaacs is responsible for the conception of the projects, supervision of their execution, and their dissemination in the scientific literature.	Isaacs (PI)	09/01/14 – 08/31/18
1R01 CA168365-01A1 National Institutes of Health “Acyclic Cucurbit[n]uril Molecular Containers for Drug Solubilization and Delivery” Role: Isaacs (PI), Briken (co-PI). Dr. Isaacs is responsible for overseeing the design of new acyclic CB[n]-type receptors and investigation of their solubilization ability toward insoluble drugs as well as the administrative reporting and dissemination of the results in the literature.	Isaacs (PI)	04/01/2013 – 03/31/2018
P200A150033 Department of Education “UMD Chemistry GAANN” This grant provides funding to the Department of Chemistry and Biochemistry to support five students from the Chemistry graduate program as GAANN fellows each year. Role: PI, Jeffery Davis and Herman Sintim (Co-PIs).	Isaacs (PI)	09/01/2015 – 08/31/2018

# RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 1

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2017

\* End Date: 06-30-2018

Budget Period: 1

## A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal.	Acad.	Sum.	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
							Months	Months	Months			
1.	DAVID		MOBLEY		PD/PI	0.00		1		11,843.00	4,856.00	16,699.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:			<b>Total Senior/Key Person</b>			<b>16,699.00</b>

## B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
1	<b>Total Number Other Personnel</b>						
						<b>Total Other Personnel</b>	<b>23,052.00</b>
						<b>Total Salary, Wages and Fringe Benefits (A+B)</b>	<b>39,751.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 1

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2017

\* End Date: 06-30-2018

Budget Period: 1

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item	* Funds Requested (\$)
Total funds requested for all equipment listed in the attached file	
Total Equipment	

Additional Equipment:

File Name:

Mime Type:

### D. Travel

	Funds Requested (\$)
1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)	10,000.00
2. Foreign Travel Costs	
Total Travel Cost	10,000.00

### E. Participant/Trainee Support Costs

- 1. Tuition/Fees/Health Insurance
- 2. Stipends
- 3. Travel
- 4. Subsistence
- 5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 1

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2017

\* End Date: 06-30-2018

Budget Period: 1

F. Other Direct Costs	Funds Requested (\$)
1. Materials and Supplies	
2. Publication Costs	
3. Consultant Services	
4. ADP/Computer Services	
5. Subawards/Consortium/Contractual Costs	247,338.00
6. Equipment or Facility Rental/User Fees	
7. Alterations and Renovations	
8. Graduate Student Tuition Remission	12,002.00
9. SAMPL/D3R workshop	10,000.00
<b>Total Other Direct Costs</b>	<b>269,340.00</b>

G. Direct Costs	Funds Requested (\$)
<b>Total Direct Costs (A thru F)</b>	<b>319,091.00</b>

H. Indirect Costs	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. Organized Research_On Campus		54.5	134,751.00	73,439.00
<b>Total Indirect Costs</b>				<b>73,439.00</b>
<b>Cognizant Federal Agency</b>	DHHS, Robert W. Lee, (415) 437-7820			
(Agency Name, POC Name, and POC Phone Number)				

I. Total Direct and Indirect Costs	Funds Requested (\$)
<b>Total Direct and Indirect Institutional Costs (G + H)</b>	<b>392,530.00</b>

J. Fee	Funds Requested (\$)

K. * Budget Justification	File Name: Budget_Justification_Combined_r11005647039.pdf (Only attach one file.)	Mime Type: application/pdf
---------------------------	---	----------------------------

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 2

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2018

\* End Date: 06-30-2019

Budget Period: 2

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal.	Acad.	Sum.	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
							Months	Months	Months			
1.	DAVID		MOBLEY		PD/PI	0.00	1	0		12,684.00	5,454.00	18,138.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:			<b>Total Senior/Key Person</b>			<b>18,138.00</b>

### B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
1	<b>Total Number Other Personnel</b>						
		6	3		22,950.00	558.00	23,508.00
						<b>Total Other Personnel</b>	<b>23,508.00</b>
						<b>Total Salary, Wages and Fringe Benefits (A+B)</b>	<b>41,646.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 2

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2018

\* End Date: 06-30-2019

Budget Period: 2

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item	* Funds Requested (\$)
Total funds requested for all equipment listed in the attached file	
Total Equipment	

Additional Equipment:

File Name:

Mime Type:

### D. Travel

	Funds Requested (\$)
1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)	20,600.00
2. Foreign Travel Costs	
Total Travel Cost	20,600.00

### E. Participant/Trainee Support Costs

- 1. Tuition/Fees/Health Insurance
- 2. Stipends
- 3. Travel
- 4. Subsistence
- 5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 2

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2018

\* End Date: 06-30-2019

Budget Period: 2

F. Other Direct Costs	Funds Requested (\$)
1. Materials and Supplies	
2. Publication Costs	
3. Consultant Services	
4. ADP/Computer Services	
5. Subawards/Consortium/Contractual Costs	252,243.00
6. Equipment or Facility Rental/User Fees	
7. Alterations and Renovations	
8. Graduate Student Tuition Remission	12,723.00
	<b>Total Other Direct Costs</b>
	<b>264,966.00</b>

G. Direct Costs	Funds Requested (\$)
	<b>Total Direct Costs (A thru F)</b>
	<b>327,212.00</b>

H. Indirect Costs	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. Organized Research_On Campus		54.5	62,246.00	33,924.00
<b>Total Indirect Costs</b>				<b>33,924.00</b>
<b>Cognizant Federal Agency</b>	DHHS, Robert W. Lee, (415) 437-7820			
(Agency Name, POC Name, and POC Phone Number)				

I. Total Direct and Indirect Costs	Funds Requested (\$)
	<b>Total Direct and Indirect Institutional Costs (G + H)</b>
	<b>361,136.00</b>

J. Fee	Funds Requested (\$)

K. * Budget Justification	File Name: Budget_Justification_Combined_r11005647039.pdf (Only attach one file.)	Mime Type: application/pdf
---------------------------	---	----------------------------

RESEARCH & RELATED Budget {F-K} (Funds Requested)

# RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 3

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2019

\* End Date: 06-30-2020

Budget Period: 3

## A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal.	Acad.	Sum.	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
							Months	Months	Months			
1.	DAVID		MOBLEY		PD/PI	25,876.00	1	1	25,876.00	7,465.00		33,341.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:			Total Senior/Key Person			33,341.00

## B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
1	<b>Total Number Other Personnel</b>						
						<b>Total Other Personnel</b>	<b>23,978.00</b>
						<b>Total Salary, Wages and Fringe Benefits (A+B)</b>	<b>57,319.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 3

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2019

\* End Date: 06-30-2020

Budget Period: 3

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item	* Funds Requested (\$)
Total funds requested for all equipment listed in the attached file	
Total Equipment	

Additional Equipment:

File Name:

Mime Type:

### D. Travel

	Funds Requested (\$)
1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)	10,609.00
2. Foreign Travel Costs	
Total Travel Cost	10,609.00

### E. Participant/Trainee Support Costs

- 1. Tuition/Fees/Health Insurance
- 2. Stipends
- 3. Travel
- 4. Subsistence
- 5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 3

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2019

\* End Date: 06-30-2020

Budget Period: 3

F. Other Direct Costs	Funds Requested (\$)
1. Materials and Supplies	
2. Publication Costs	
3. Consultant Services	
4. ADP/Computer Services	
5. Subawards/Consortium/Contractual Costs	257,261.00
6. Equipment or Facility Rental/User Fees	
7. Alterations and Renovations	
8. Graduate Student Tuition Remission	13,486.00
9. SAMPL/D3R	10,609.00
<b>Total Other Direct Costs</b>	<b>281,356.00</b>

G. Direct Costs	Funds Requested (\$)
<b>Total Direct Costs (A thru F)</b>	<b>349,284.00</b>

H. Indirect Costs	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. Organized Research_On Campus		54.5	78,537.00	42,803.00
<b>Cognizant Federal Agency</b>	DHHS, Robert W. Lee, (415) 437-7820			
(Agency Name, POC Name, and POC Phone Number)				
<b>Total Indirect Costs</b>	<b>42,803.00</b>			

I. Total Direct and Indirect Costs	Funds Requested (\$)
<b>Total Direct and Indirect Institutional Costs (G + H)</b>	<b>392,087.00</b>

J. Fee	Funds Requested (\$)

K. * Budget Justification	File Name: Budget_Justification_Combined_r11005647039.pdf (Only attach one file.)	Mime Type: application/pdf
---------------------------	---	----------------------------

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 4

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2020

\* End Date: 06-30-2021

Budget Period: 4

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal.	Acad.	Sum.	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
							Months	Months	Months			
1.	DAVID		MOBLEY		PD/PI	1.00		1	1	27,714.00	8,273.00	35,987.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:			<b>Total Senior/Key Person</b>			<b>35,987.00</b>

### B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
1	<b>Total Number Other Personnel</b>						
						<b>Total Other Personnel</b>	<b>24,458.00</b>
						<b>Total Salary, Wages and Fringe Benefits (A+B)</b>	<b>60,445.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 4

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2020

\* End Date: 06-30-2021

Budget Period: 4

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

21,854.00

Total Travel Cost

21,854.00

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 4

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2020

\* End Date: 06-30-2021

Budget Period: 4

F. Other Direct Costs	Funds Requested (\$)
1. Materials and Supplies	
2. Publication Costs	
3. Consultant Services	
4. ADP/Computer Services	
5. Subawards/Consortium/Contractual Costs	262,137.00
6. Equipment or Facility Rental/User Fees	
7. Alterations and Renovations	
8. Graduate Student Tuition Remission	14,295.00
<b>Total Other Direct Costs</b>	<b>276,432.00</b>

G. Direct Costs	Funds Requested (\$)
<b>Total Direct Costs (A thru F)</b>	<b>358,731.00</b>

H. Indirect Costs	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)		
1. Organized Research_On Campus		54.5	82,299.00	44,853.00		
<b>Cognizant Federal Agency</b>		<b>Total Indirect Costs</b>		<b>44,853.00</b>		
DHHS, Robert W. Lee, (415) 437-7820						
(Agency Name, POC Name, and POC Phone Number)						

I. Total Direct and Indirect Costs	Funds Requested (\$)
<b>Total Direct and Indirect Institutional Costs (G + H)</b>	<b>403,584.00</b>

J. Fee	Funds Requested (\$)

K. * Budget Justification	File Name: Budget_Justification_Combined_r11005647039.pdf (Only attach one file.)	Mime Type: application/pdf
---------------------------	---	----------------------------

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 5

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2021

\* End Date: 06-30-2022

Budget Period: 5

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal.	Acad.	Sum.	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
							Months	Months	Months			
1.	DAVID		MOBLEY		PD/PI	0.00	1	1	28,268.00	8,721.00		36,989.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:			<b>Total Senior/Key Person</b>			<b>36,989.00</b>

### B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
1	<b>Total Number Other Personnel</b>						
						<b>Total Other Personnel</b>	<b>24,947.00</b>
						<b>Total Salary, Wages and Fringe Benefits (A+B)</b>	<b>61,936.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 5

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2021

\* End Date: 06-30-2022

Budget Period: 5

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item	* Funds Requested (\$)
Total funds requested for all equipment listed in the attached file	
Total Equipment	

Additional Equipment:

File Name:

Mime Type:

### D. Travel

	Funds Requested (\$)
1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)	11,255.00
2. Foreign Travel Costs	
Total Travel Cost	11,255.00

### E. Participant/Trainee Support Costs

- 1. Tuition/Fees/Health Insurance
- 2. Stipends
- 3. Travel
- 4. Subsistence
- 5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 5

\* ORGANIZATIONAL DUNS: 046705849

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Regents of the University of California, Irvine

\* Start Date: 07-01-2021

\* End Date: 06-30-2022

Budget Period: 5

F. Other Direct Costs	Funds Requested (\$)
1. Materials and Supplies	
2. Publication Costs	
3. Consultant Services	
4. ADP/Computer Services	
5. Subawards/Consortium/Contractual Costs	267,899.00
6. Equipment or Facility Rental/User Fees	
7. Alterations and Renovations	
8. Graduate Student Tuition Remission	15,153.00
9. SAMPL/D3R	11,255.00
<b>Total Other Direct Costs</b>	<b>294,307.00</b>

G. Direct Costs	Funds Requested (\$)
<b>Total Direct Costs (A thru F)</b>	<b>367,498.00</b>

H. Indirect Costs	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. Organized Research_On Campus		54.5	84,446.00	46,023.00
<b>Cognizant Federal Agency</b>				<b>Total Indirect Costs</b> <b>46,023.00</b>
(Agency Name, POC Name, and POC Phone Number)				

I. Total Direct and Indirect Costs	Funds Requested (\$)
<b>Total Direct and Indirect Institutional Costs (G + H)</b>	<b>413,521.00</b>

J. Fee	Funds Requested (\$)

K. * Budget Justification	File Name: Budget_Justification_Combined_r11005647039.pdf (Only attach one file.)	Mime Type: application/pdf
---------------------------	---	----------------------------

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - Cumulative Budget

	<b>Totals (\$)</b>
<b>Section A, Senior/Key Person</b>	<b>141,154.00</b>
<b>Section B, Other Personnel</b>	<b>119,943.00</b>
Total Number Other Personnel	5
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>	<b>261,097.00</b>
<b>Section C, Equipment</b>	
<b>Section D, Travel</b>	<b>74,318.00</b>
1. Domestic	74,318.00
2. Foreign	
<b>Section E, Participant/Trainee Support Costs</b>	
1. Tuition/Fees/Health Insurance	
2. Stipends	
3. Travel	
4. Subsistence	
5. Other	
6. Number of Participants/Trainees	
<b>Section F, Other Direct Costs</b>	<b>1,386,401.00</b>
1. Materials and Supplies	
2. Publication Costs	
3. Consultant Services	
4. ADP/Computer Services	
5. Subawards/Consortium/Contractual Costs	1,286,878.00
6. Equipment or Facility Rental/User Fees	
7. Alterations and Renovations	
8. Other 1	67,659.00
9. Other 2	31,864.00
10. Other 3	
<b>Section G, Direct Costs (A thru F)</b>	<b>1,721,816.00</b>
<b>Section H, Indirect Costs</b>	<b>241,042.00</b>
<b>Section I, Total Direct and Indirect Costs (G + H)</b>	<b>1,962,858.00</b>
<b>Section J, Fee</b>	

**Budget Justification:****Senior Personnel:**

David Mobley, Ph.D. (PI): Years 1 – 2: 1 academic month. Year 3-5: 1 academic and 1 summer months salary  
Dr. Mobley, as the principal investigator, will supervise and coordinate the proposed research, coordinate internships/placements for students in the pharmaceutical industry for Aim 1, and help coordinate SAMPL challenges (Aim 4) along with overseeing experimental work in Aims 2-3. He will also maintain appropriate budget utilization, oversee the quality of the results and publications, and coordinate dissemination of data and results, and help coordinate SAMPL/D3R workshops.

**Other Personnel:**

1 Graduate Researcher (TBN): 6 academic months and 3 summer months.

Funding is requested for a graduate student researcher to be named, who will, under Dr. Mobley's oversight, have split duties consisting of (a) experimental work on measuring physical properties (log D, log P, protonation equilibria) in combination with industry partners (see support letters) under Aim 1, and (b) using this data to run SAMPL blind challenges and associated reference calculations and analyze the results of both the challenges and reference calculations, writing papers and helping to disseminate the computational and experimental results as well as the challenge results. The student will also play a role in coordination of SAMPL/D3R workshops and advertisement of the challenges themselves.

Consultant Costs: None

**General (all years):**

Salaries for all personnel are based upon current University of California academic and staff salary scales. All personnel budget calculations include salary range adjustments and merit increases as applicable for each year of support in accordance with published University guidelines.

According to University policy, graduate student researchers are permitted to maintain appointments of a maximum of 50% time during the academic year. However, of the available research time during the academic year, 100% will be devoted to this project.

Employee benefits were estimated using the composite rates agreed upon by the University of California Office of the President and the DHHS Audit Agency, the Cognizant Audit Agency for the University of California. Benefit rates used in this proposal are 41% of salary for academics, 12.7% for academic summer salary, and for students 1.3% during academic year and 3% during the summer and are projected to increase by 2% in each of the subsequent years.

Graduate student benefits include fee remission cost estimated using current fee rates. University policy requires the inclusion of fee remission for graduate student researchers employed during the academic year with an appointment of 25 percent time or more. Resident graduate student tuition is \$12,002 in Year 1. For years 2-5 this figure was escalated at 6% each year for tuition. Per University policy this increase reflects the average historical increase in fees over the last 5 years.

**Equipment**: None

**Supplies**: None

**Travel:**

Significant support is budgeted for domestic travel depending on the year, with years 2 and 4 requiring more travel on the part of the student participant while he or she spends additional time working with pharma partners collecting more extensive sets of experimental data. In years 2 and 4, \$20,600 and \$21,854 respectively is budgeted for travel. In years 1, 3, and 5, relatively less time will be spent with pharma partners so for years 1,2, and 5 travel is budgeted for \$10,000, \$10,609, and \$11,255 respectively. In addition to the travel to work with pharma partners, the budgeted travel expenses will also include travel to D3R/SAMPL

meetings for Dr. Mobley and the student. Travel costs were estimated based on historical costs for past trips. The cost of travel includes airfare on domestic U.S. flag carrier, ground transportation, lodging, meeting registration and Meal and Incidental Expenses (M&IE). Meal and Incidental Expenses (M&IE) is calculated using University of California at Irvine's established guidelines.

**Other:** SAMPL/D3R workshops are being run every two years (though challenges will take place more frequently on a rolling basis) and D3R's funds are insufficient to cover the entirety of a joint SAMPL/D3R workshop every two years – they will cover the D3R component, but SAMPL brings additional participants and expenses. Thus, we request in years 1, 3, and 5 funding of \$10,000, \$10,609, and \$11,255 respectively to pay for the SAMPL component of a SAMPL/D3R workshop. This will be used approximately as follows (cost estimates based on D3R tracking from the D3R/SAMPL4 workshop in 2016):

- Travel for invited speakers: 3 at \$500 each = \$1500
- Rooms for invited speakers: 3 at \$400 each = \$1200
- Defray participation costs for 30 participants at \$240 each (\$540 total cost each minus \$300 meeting registration) = \$7200
- Notebooks/pens/pencils/miscellaneous meeting supplies: \$100

Total: \$10,000

As noted under "Travel", these meeting costs are only in years 1, 3, and 5; in years 2 and 4, the funds are instead shifted to travel to allow collection of additional data.

#### **F&A Cost Rate:**

Facilities and Administrative costs are calculated in accordance with UCI's rate agreement which was approved by DHHS, the Federal Cognizant Agency for UCI on April 27, 2011. The on-campus rate was used. Calculations are made on a Modified Total Direct Cost base at the approved rate 54.5% for the period of 7/1/17 – 6/30/22.

#### **Subawards:**

#### **Tulane University - Bruce Gibb, Ph.D.**

#### **Senior/Key Personnel:**

Bruce Gibb, Ph.D., Co-Investigator (0.5 summer months effort) is a Professor of Chemistry at Tulane University. He is an expert in synthesis and experimental work on host-guest binding and supramolecular chemistry of molecular containers. Dr. Gibb will oversee all aspects of the proposed work relating to the synthesis of deep cavity cavitands and experimental measurements of binding on those cavitands. Funds are requested for 0.5 months of summer salary support for Dr. Gibb in Years 1 through 5 based on his current institutional salary. This budget item is increased 3% per year in years 2-5 to account of inflation/salary increases. Fringe benefits are included at the standard subcontract rate of 5.4%.

#### **Other Personnel:**

1 Graduate Student (TBN): One graduate student will actually conduct the work of synthesizing hosts and measuring binding of novel guests, as detailed in Aim 2, supervised by Dr. Gibb but also reporting to Drs. Mobley and Chodera. This student will work 25% time on the project at an annual salary of \$25,000 (with a 3% increase per year included in the budget). Fringe benefit is included at the standard subcontract rate of 6.1%.

**Materials and Supplies:** Supplies will include consumable goods such as starting materials, reagents, drug compounds, solvents, deuterated solvents, disposable glass items, ITC supplies, and other miscellaneous consumables (gases, etc.) for use by the graduate student conducting the measurements. These are budgeted at \$3,501 in year 1 and \$3,502 each for years 2 to 5.

**F&A Cost Rate:**

Indirect costs are requested based on modified total direct costs (Base \$92,949) at the Tulane University rate of 50.5%.

**University of Maryland – Lyle Isaacs, Ph.D****Senior/Key Personnel**

Lyle Isaacs, Ph.D., Co-Investigator (0.25 summer months effort) is a Professor of Chemistry and Biochemistry at the University of Maryland, Director of the Chemistry graduate program, and a member of the University of Maryland Nanocenter. Dr. Isaacs is expert in the synthesis of CB[n]-type receptors, the mechanism of CB[n] formation, and the supramolecular chemistry of the resulting molecular containers. Dr. Isaacs will oversee all aspects of the proposed work related to the synthesis of CB host compounds and the measurement of binding constants toward selected guest compounds. Funds are requested for 0.25 month summer salary support for Dr. Isaacs in Years 1 through 5 based on his current 9 month institutional salary of \$125,536.82. This budget item includes a request of 7.93% cover the costs of FICA (6.2%), Medicare (1.45%), and unemployment (0.28%) taxes. This budget item is increased 3% per year in years 2-5 to account for inflation / salary increases.

**Other Personnel:**

1 Post-Doctoral Fellow (TBN): Funds are requested to support a part-time postdoctoral fellow (5 months per year) to work on this project under the supervision of Dr. Isaacs for years 1 – 5. The postdoctoral fellow will also be responsible for the synthesis hosts and the measurement of binding of guests as detailed in Aim 2. This budget item includes a request for postdoctoral salary at \$47,476 per year in line with the Fair Labor Standard Act and projected NIH NRSA FY2017 stipend levels, 30% of salary for health benefits, 7.93% of salary for social security / medicare / unemployment, and 7.25% for retirement contributions. This budget item is increased 3% per year in years 2-5 to account for inflation / salary increases.

**General:** The University does not have a fringe benefit rate. Actual costs vary from person to person based on their individual benefits plan (helath, dental, prescription) choices. The University uses an average of 30% of salary for budgetary purposes for the benefits plan selections. Postdoctoral fellows also receive retirement contributions in the amount of 7.25% of salary. Finally, all employees incur social security / medicare / unemployment costs in the amount of 7.93 % of salary.

**Materials and Supplies:**

Isaacs Lab Supplies: Consumable goods (starting materials, reagents, drug compounds, solvents, deuterated solvents, silica gel, TLC plates, disposable glass items, ITC supplies (solvents, detergents and replacement parts) and miscellaneous consumables) are requested for the postdoctoral fellow at \$1527.33 per year. This budget item is increased 3% per year in years 2-5 to account for typical inflation for biomedical reseach supplies.

**Equipment / Facility User Fees**

Isaacs Lab Facility Charges: The postdoctoral fellows working on this project will make use of the departmental NMR, mass spectrometry, and X-ray crystallography facilities which are available for a fee. We estimate usage as follows:

NMR: 8 hours per month @ \$11/hr (8 x 5 months x \$11)	\$ 440
--	--------

MS: 1 samples per month @ \$60 / sample (1 x 5 months x \$60)	\$ 300
X-ray crystallography: 1 sample / year at @ \$250 / sample	\$ 250
<hr/>	
\$990 / year	

This budget item is increased 2% per year in anticipation of yearly increases to Equipment / facility user fees at the University of Maryland.

#### F&A Cost Rate:

Indirect costs are requested based on modified total direct costs (Base \$185,715.69) at the UMD institutional rate of 52.0 percent.

### **Memorial Sloan Kettering Cancer Center – John Chodera, Ph.D.**

#### **Senior/Key Personnel**

John D. Chodera, Ph.D., Co-Investigator (1.0 calendar months effort) will direct the protein-ligand model systems work for this project, support the execution of SAMPL blind challenge exercises, and co-supervise graduate student work in industry laboratories for the collection of data for blind challenges. He is an Assistant Member (Assistant Professor equivalent rank) at the Sloan Kettering Institute---the basic science arm of the Memorial Sloan Kettering Cancer Center---with extensive experience in biomolecular simulation, molecular simulation algorithm development, alchemical free energy calculations for ligand binding, and the use and interpretation of automated biophysical experiments. He has a publication track record spanning over 15 years of highly regarded work in these fields. He has a decade of experience with the Folding@home worldwide distributed computing project, wrote the GPU-accelerated alchemical free energy calculation code that will be used to compute small molecule binding affinities, has contributed to the development of the GPU-accelerated OpenMM simulation code that will be used for constant-pH simulations, and designed the automated biophysical wetlab in his laboratory at MSKCC that will be used for experimentally measuring binding affinities and other physical properties. He also has extensive experience with computing biophysical observables---including NMR data---from biomolecular simulations.

#### **Other Personnel**

Mehtap Isik, Graduate Student in the Tri-Institutional PhD Program in Chemical Biology (12.0 calendar months effort) BSc degrees in Chemistry and Molecular Biology & Genetics, ranked top of her graduating class from Bogazici University in Istanbul, Turkey. Ms. Isik will both develop the informatics platform for the identification of useful model systems for experimental development and will perform the experiments to collect new data in the Chodera laboratory at MSKCC. Ms. Isik is a third-year graduate student in the Chodera laboratory with extensive experience in biophysical experiments, computational biophysics, and structural and chemical bioinformatics.

### **OTHER DIRECT COSTS**

**Travel:** We ask for \$3,000/year in travel support to allow the PI and PhD student to attend the SAMPL blind challenge meetings and other conferences to present the results of this project.

**Publication fees:** We request \$2,500/year for publication fees.

**Materials and Supplies:** We request \$30,000/year for experimental laboratory supplies and instrument usage fees to cover the costs of cloning new protein constructs, engineering protein mutants, expressing proteins, performing binding assays, and other physical property measurements to develop data for blind challenges and subsequent public dataset release.

**F&A Cost Rate:** Indirect costs are requested based on modified total direct costs (Base \$504,494) at the MSKCC institutional rate of 71.4 percent.

## R&R SUBAWARD BUDGET ATTACHMENT(S) FORM

Period	Subaward Direct Costs	Subaward Indirect Costs	Subaward Costs	Subaward IDC Ceiling: 25,000 Allocated To IDC Base
<b>1. Sloan Kettering Institute</b>				
1	96,944	69,218	166,162	25,000
2	98,882	70,602	169,484	
3	100,860	72,014	172,874	
4	102,727	73,347	176,074	
5	105,081	75,028	180,109	
All	504,494	360,209	864,703	25,000
<b>2. Tulane University</b>				
1	18,589	9,387	27,976	25,000
2	18,590	9,388	27,978	
3	18,590	9,388	27,978	
4	18,590	9,388	27,978	
5	18,590	9,388	27,978	
All	92,949	46,939	139,888	25,000
<b>3. U of Maryland</b>				
1	35,000	18,200	53,200	25,000
2	36,040	18,741	54,781	0
3	37,111	19,298	56,409	0
4	38,214	19,871	58,085	0
5	39,350	20,462	59,812	0
All	185,715	96,572	282,287	25,000
<b>All Subawards</b>				
1	150,533	96,805	247,338	75,000
2	153,512	98,731	252,243	0
3	156,561	100,700	257,261	0
4	159,531	102,606	262,137	0
5	163,021	104,878	267,899	0
All	783,158	503,720	1,286,878	75,000

# RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 1

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2017

\* End Date: 06-30-2018

Budget Period: 1

## A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	John		Chodera		PD/PI		1			14,639.00	5,007.00	19,646.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:		Mime Type:					<b>Total Senior/Key Person</b>		<b>19,646.00</b>

## B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
<b>1</b>	<b>Total Number Other Personnel</b>					<b>Total Other Personnel</b>	<b>36,798.00</b>
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>							<b>56,444.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 1

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2017

\* End Date: 06-30-2018

Budget Period: 1

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

3,000.00

Total Travel Cost

3,000.00

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 1

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2017

\* End Date: 06-30-2018

Budget Period: 1

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		35,000.00
2. Publication Costs		2,500.00
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	Total Other Direct Costs	37,500.00

G. Direct Costs		Funds Requested (\$)
Total Direct Costs (A thru F)		96,944.00

H. Indirect Costs				
Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)	
1. Modified Total Direct Costs	71.4	96,944.00	69,218.00	
Total Indirect Costs				69,218.00
Cognizant Federal Agency (Agency Name, POC Name, and POC Phone Number)				

I. Total Direct and Indirect Costs		Funds Requested (\$)
Total Direct and Indirect Institutional Costs (G + H)		166,162.00

J. Fee		Funds Requested (\$)

K. * Budget Justification	File Name: 8__Budget_Justification__Chodera1005647046.pdf (Only attach one file.)	Mime Type: application/pdf
---------------------------	---	----------------------------

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 2

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2018

\* End Date: 06-30-2019

Budget Period: 2

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	John		Chodera		PD/PI		1			14,932.00	5,107.00	20,039.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:		Mime Type:					<b>Total Senior/Key Person</b>		<b>20,039.00</b>

### B. Other Personnel

* Number of Personnel	* Project Role	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits	* Funds Requested (\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
1	<b>Total Number Other Personnel</b>	12			37,533.00	0.00	37,533.00
					<b>Total Other Personnel</b>		<b>37,533.00</b>
					<b>Total Salary, Wages and Fringe Benefits (A+B)</b>		<b>57,572.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 2

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2018

\* End Date: 06-30-2019

Budget Period: 2

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

3,060.00

Total Travel Cost

3,060.00

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 2

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2018

\* End Date: 06-30-2019

Budget Period: 2

<b>F. Other Direct Costs</b>		<b>Funds Requested (\$)</b>
1. Materials and Supplies		35,700.00
2. Publication Costs		2,550.00
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	<b>Total Other Direct Costs</b>	<b>38,250.00</b>

<b>G. Direct Costs</b>		<b>Funds Requested (\$)</b>
	<b>Total Direct Costs (A thru F)</b>	<b>98,882.00</b>

<b>H. Indirect Costs</b>				
<b>Indirect Cost Type</b>	<b>Indirect Cost Rate (%)</b>	<b>Indirect Cost Base (\$)</b>	<b>* Funds Requested (\$)</b>	
1. Modified Total Direct Costs	71.4	98,882.00	70,602.00	
		<b>Total Indirect Costs</b>	<b>70,602.00</b>	

**Cognizant Federal Agency**  
(Agency Name, POC Name, and POC Phone Number)

<b>I. Total Direct and Indirect Costs</b>		<b>Funds Requested (\$)</b>
	<b>Total Direct and Indirect Institutional Costs (G + H)</b>	<b>169,484.00</b>

<b>J. Fee</b>		<b>Funds Requested (\$)</b>

<b>K. * Budget Justification</b>	File Name:	Mime Type: application/pdf
	8__Budget_Justification__Chodera1005647046.pdf	
(Only attach one file.)		

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 3

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2019

\* End Date: 06-30-2020

Budget Period: 3

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	John		Chodera		PD/PI		1			15,231.00	5,209.00	20,440.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:			<b>Total Senior/Key Person</b>			<b>20,440.00</b>

### B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
<b>1</b>	<b>Total Number Other Personnel</b>						
		12			38,284.00	0.00	38,284.00
					<b>Total Other Personnel</b>		<b>38,284.00</b>
					<b>Total Salary, Wages and Fringe Benefits (A+B)</b>		<b>58,724.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 3

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2019

\* End Date: 06-30-2020

Budget Period: 3

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

3,121.00

Total Travel Cost

3,121.00

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 3

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2019

\* End Date: 06-30-2020

Budget Period: 3

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		36,414.00
2. Publication Costs		2,601.00
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	Total Other Direct Costs	39,015.00

G. Direct Costs		Funds Requested (\$)
	Total Direct Costs (A thru F)	100,860.00

H. Indirect Costs				
Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)	
1. Modified Total Direct Costs	71.4	100,860.00	72,014.00	
		Total Indirect Costs	72,014.00	
Cognizant Federal Agency				
(Agency Name, POC Name, and POC Phone Number)				

I. Total Direct and Indirect Costs		Funds Requested (\$)
	Total Direct and Indirect Institutional Costs (G + H)	172,874.00

J. Fee		Funds Requested (\$)

K. * Budget Justification	File Name:	Mime Type: application/pdf
	8__Budget_Justification__Chodera1005647046.pdf	
(Only attach one file.)		

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 4

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2020

\* End Date: 06-30-2021

Budget Period: 4

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	John		Chodera		PD/PI		1			15,425.00	5,275.00	20,700.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:					Total Senior/Key Person	20,700.00

### B. Other Personnel

* Number of Personnel	* Project Role	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits	* Funds Requested (\$)
1	Post Doctoral Associates Graduate Students Undergraduate Students Secretarial/Clerical		12		39,049.00	0.00	39,049.00
1	<b>Total Number Other Personnel</b>				<b>Total Other Personnel</b>		<b>39,049.00</b>
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>							<b>59,749.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 4

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2020

\* End Date: 06-30-2021

Budget Period: 4

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

3,183.00

Total Travel Cost

3,183.00

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 4

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2020

\* End Date: 06-30-2021

Budget Period: 4

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		37,142.00
2. Publication Costs		2,653.00
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	Total Other Direct Costs	39,795.00

G. Direct Costs		Funds Requested (\$)
	Total Direct Costs (A thru F)	102,727.00

H. Indirect Costs				
Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)	
1. Modified Total Direct Costs	71.4	102,727.00	73,347.00	
				Total Indirect Costs
				73,347.00

**Cognizant Federal Agency**  
(Agency Name, POC Name, and POC Phone Number)

I. Total Direct and Indirect Costs		Funds Requested (\$)
	Total Direct and Indirect Institutional Costs (G + H)	176,074.00

J. Fee		Funds Requested (\$)

K. * Budget Justification	File Name:	Mime Type: application/pdf
	8__Budget_Justification__Chodera1005647046.pdf	
(Only attach one file.)		

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 5

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2021

\* End Date: 06-30-2022

Budget Period: 5

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	John		Chodera		PD/PI		1			15,425.00	5,275.00	20,700.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:			<b>Total Senior/Key Person</b>			<b>20,700.00</b>

### B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
<b>1</b>	<b>Total Number Other Personnel</b>					<b>Total Other Personnel</b>	<b>39,830.00</b>
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>							<b>60,530.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 5

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2021

\* End Date: 06-30-2022

Budget Period: 5

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

3,247.00

Total Travel Cost

3,247.00

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 5

\* ORGANIZATIONAL DUNS: 0649318840000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: Memorial Sloan Kettering Cancer Center

\* Start Date: 07-01-2021

\* End Date: 06-30-2022

Budget Period: 5

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		38,598.00
2. Publication Costs		2,706.00
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	Total Other Direct Costs	41,304.00

G. Direct Costs		Funds Requested (\$)
	Total Direct Costs (A thru F)	105,081.00

H. Indirect Costs				
Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)	
1. Modified Total Direct Costs	71.4	105,081.00	75,028.00	
		Total Indirect Costs	75,028.00	
Cognizant Federal Agency				
(Agency Name, POC Name, and POC Phone Number)				

I. Total Direct and Indirect Costs		Funds Requested (\$)
	Total Direct and Indirect Institutional Costs (G + H)	180,109.00

J. Fee		Funds Requested (\$)

K. * Budget Justification	File Name:	Mime Type: application/pdf
	8__Budget_Justification__Chodera1005647046.pdf	
(Only attach one file.)		

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - Cumulative Budget

	<b>Totals (\$)</b>
<b>Section A, Senior/Key Person</b>	<b>101,525.00</b>
<b>Section B, Other Personnel</b>	<b>191,494.00</b>
Total Number Other Personnel	5
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>	<b>293,019.00</b>
<b>Section C, Equipment</b>	
<b>Section D, Travel</b>	<b>15,611.00</b>
1. Domestic	15,611.00
2. Foreign	
<b>Section E, Participant/Trainee Support Costs</b>	
1. Tuition/Fees/Health Insurance	
2. Stipends	
3. Travel	
4. Subsistence	
5. Other	
6. Number of Participants/Trainees	
<b>Section F, Other Direct Costs</b>	<b>195,864.00</b>
1. Materials and Supplies	182,854.00
2. Publication Costs	13,010.00
3. Consultant Services	
4. ADP/Computer Services	
5. Subawards/Consortium/Contractual Costs	
6. Equipment or Facility Rental/User Fees	
7. Alterations and Renovations	
8. Other 1	
9. Other 2	
10. Other 3	
<b>Section G, Direct Costs (A thru F)</b>	<b>504,494.00</b>
<b>Section H, Indirect Costs</b>	<b>360,209.00</b>
<b>Section I, Total Direct and Indirect Costs (G + H)</b>	<b>864,703.00</b>
<b>Section J, Fee</b>	

## BUDGET JUSTIFICATION – CHODERA LABORATORY

### Senior/Key Personnel

**John D. Chodera, Ph.D., Co-Investigator (1.0 calendar months effort)** will direct the protein-ligand model systems work for this project, support the execution of SAMPL blind challenge exercises, and co-supervise graduate student work in industry laboratories for the collection of data for blind challenges. He is an Assistant Member (Assistant Professor equivalent rank) at the Sloan Kettering Institute---the basic science arm of the Memorial Sloan Kettering Cancer Center---with extensive experience in biomolecular simulation, molecular simulation algorithm development, alchemical free energy calculations for ligand binding, and the use and interpretation of automated biophysical experiments. He has a publication track record spanning over 15 years of highly regarded work in these fields. He has a decade of experience with the Folding@home worldwide distributed computing project, wrote the GPU-accelerated alchemical free energy calculation code that will be used to compute small molecule binding affinities, has contributed to the development of the GPU-accelerated OpenMM simulation code that will be used for constant-pH simulations, and designed the automated biophysical wetlab in his laboratory at MSKCC that will be used for experimentally measuring binding affinities and other physical properties. He also has extensive experience with computing biophysical observables---including NMR data---from biomolecular simulations.

### Other Personnel

**Mehtap Isik, Graduate Student in the Tri-Institutional PhD Program in Chemical Biology (12.0 calendar months effort)** BSc degrees in Chemistry and Molecular Biology & Genetics, ranked top of her graduating class from Bogazici University in Istanbul, Turkey. Isik will both develop the informatics platform for the identification of useful model systems for experimental development and will perform the experiments to collect new data in the Chodera laboratory at MSKCC. Isik is a third-year graduate student in the Chodera laboratory with extensive experience in biophysical experiments, computational biophysics, and structural and chemical bioinformatics.

### OTHER DIRECT COSTS

**Travel:** We ask for \$3,000/year in travel support to allow the PI and PhD student to attend the SAMPL blind challenge meetings and other conferences to present the results of this project.

**Publication fees:** We request \$2,500/year to defer publication fees.

**Materials and Supplies:** We request \$35,000/year for experimental laboratory supplies and instrument usage fees to cover the costs of cloning new protein constructs, engineering protein mutants, expressing proteins, procuring compounds, and performing binding assays to create datasets for blind challenges and subsequent public dataset release.

All budgets include increases of 2%/year.

**F&A Cost Rate:** Indirect costs are requested based on modified total direct costs (Base \$504,494) at the MSKCC institutional rate of 71.4%.

# RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 1

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2017

\* End Date: 06-30-2018

Budget Period: 1

## A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	Bruce		Gibb		PD/PI				0.5	7,703.00	416.00	8,119.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:			Total Senior/Key Person			8,119.00

## B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
1	<b>Total Number Other Personnel</b>					<b>Total Other Personnel</b>	<b>6,969.00</b>
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>							<b>15,088.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 1

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2017

\* End Date: 06-30-2018

Budget Period: 1

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

Total Travel Cost

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 1

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2017 \* End Date: 06-30-2018 Budget Period: 1

<b>F. Other Direct Costs</b>		<b>Funds Requested (\$)</b>
1. Materials and Supplies		3,501.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	<b>Total Other Direct Costs</b>	<b>3,501.00</b>

<b>G. Direct Costs</b>		<b>Funds Requested (\$)</b>
	<b>Total Direct Costs (A thru F)</b>	<b>18,589.00</b>

<b>H. Indirect Costs</b>				
	<b>Indirect Cost Type</b>	<b>Indirect Cost Rate (%)</b>	<b>Indirect Cost Base (\$)</b>	<b>* Funds Requested (\$)</b>
1. MTDC		50.5	18,589.00	9,387.00
<b>Cognizant Federal Agency</b>				<b>Total Indirect Costs</b>
DHHS, Arif Karim, 214-767-3261 (Agency Name, POC Name, and POC Phone Number)				<b>9,387.00</b>

<b>I. Total Direct and Indirect Costs</b>		<b>Funds Requested (\$)</b>
<b>Total Direct and Indirect Institutional Costs (G + H)</b>		<b>27,976.00</b>

<b>J. Fee</b>		<b>Funds Requested (\$)</b>

<b>K. * Budget Justification</b>	File Name:	Mime Type: application/pdf
	Justification_Tulane_Gibbs1005647050.pdf	
	(Only attach one file.)	

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 2

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2018

\* End Date: 06-30-2019

Budget Period: 2

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	Bruce		Gibb		PD/PI				0.5	7,703.00	416.00	8,119.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:			Total Senior/Key Person			8,119.00

### B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
1	<b>Total Number Other Personnel</b>					<b>Total Other Personnel</b>	<b>6,969.00</b>
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>							<b>15,088.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 2

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2018

\* End Date: 06-30-2019

Budget Period: 2

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

Total Travel Cost

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 2

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2018

\* End Date: 06-30-2019

Budget Period: 2

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		3,502.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	Total Other Direct Costs	3,502.00

G. Direct Costs		Funds Requested (\$)
	Total Direct Costs (A thru F)	18,590.00

H. Indirect Costs				
	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. MTDC		50.5	18,590.00	9,388.00
<b>Cognizant Federal Agency</b>				<b>Total Indirect Costs</b>
DHHS, Arif Karim, 214-767-3261 (Agency Name, POC Name, and POC Phone Number)				<b>9,388.00</b>

I. Total Direct and Indirect Costs		Funds Requested (\$)
	Total Direct and Indirect Institutional Costs (G + H)	27,978.00

J. Fee		Funds Requested (\$)

K. * Budget Justification	File Name: Justification_Tulane_Gibbs1005647050.pdf (Only attach one file.)	Mime Type: application/pdf
---------------------------	---	----------------------------

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 3

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2019

\* End Date: 06-30-2020

Budget Period: 3

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	Bruce		Gibb		PD/PI				0.5	7,703.00	416.00	8,119.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:			Total Senior/Key Person			8,119.00

### B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
1	<b>Total Number Other Personnel</b>					<b>Total Other Personnel</b>	<b>6,969.00</b>
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>							<b>15,088.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 3

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2019

\* End Date: 06-30-2020

Budget Period: 3

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

Total Travel Cost

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 3

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2019

\* End Date: 06-30-2020

Budget Period: 3

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		3,502.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	Total Other Direct Costs	3,502.00

G. Direct Costs		Funds Requested (\$)
	Total Direct Costs (A thru F)	18,590.00

H. Indirect Costs				
	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. MTDC		50.5	18,590.00	9,388.00
<b>Cognizant Federal Agency</b>				<b>Total Indirect Costs</b>
DHHS, Arif Karim, 214-767-3261 (Agency Name, POC Name, and POC Phone Number)				<b>9,388.00</b>

I. Total Direct and Indirect Costs		Funds Requested (\$)
	Total Direct and Indirect Institutional Costs (G + H)	27,978.00

J. Fee		Funds Requested (\$)

K. * Budget Justification	File Name: Justification_Tulane_Gibbs1005647050.pdf (Only attach one file.)	Mime Type: application/pdf
---------------------------	---	----------------------------

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 4

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2020

\* End Date: 06-30-2021

Budget Period: 4

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	Bruce		Gibb		PD/PI				0.5	7,703.00	416.00	8,119.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:			Total Senior/Key Person			8,119.00

### B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
1	<b>Total Number Other Personnel</b>					<b>Total Other Personnel</b>	<b>6,969.00</b>
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>							<b>15,088.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 4

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2020

\* End Date: 06-30-2021

Budget Period: 4

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

Total Travel Cost

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 4

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2020

\* End Date: 06-30-2021

Budget Period: 4

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		3,502.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	Total Other Direct Costs	3,502.00

G. Direct Costs		Funds Requested (\$)
	Total Direct Costs (A thru F)	18,590.00

H. Indirect Costs				
	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. MTDC		50.5	18,590.00	9,388.00
<b>Cognizant Federal Agency</b>				<b>Total Indirect Costs</b>
DHHS, Arif Karim, 214-767-3261 (Agency Name, POC Name, and POC Phone Number)				<b>9,388.00</b>

I. Total Direct and Indirect Costs		Funds Requested (\$)
	Total Direct and Indirect Institutional Costs (G + H)	27,978.00

J. Fee		Funds Requested (\$)

K. * Budget Justification	File Name: Justification_Tulane_Gibbs1005647050.pdf (Only attach one file.)	Mime Type: application/pdf
---------------------------	---	----------------------------

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 5

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2021

\* End Date: 06-30-2022

Budget Period: 5

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	Bruce		Gibb		PD/PI				0.5	7,703.00	416.00	8,119.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:			Total Senior/Key Person			8,119.00

### B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\$)
1	Post Doctoral Associates						
1	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
1	<b>Total Number Other Personnel</b>					<b>Total Other Personnel</b>	<b>6,969.00</b>
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>							<b>15,088.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 5

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2021

\* End Date: 06-30-2022

Budget Period: 5

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

Total Travel Cost

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 5

\* ORGANIZATIONAL DUNS: 0537858120000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: The Administrators of the Tulane Educational Fund

\* Start Date: 07-01-2021

\* End Date: 06-30-2022

Budget Period: 5

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		3,502.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	Total Other Direct Costs	3,502.00

G. Direct Costs		Funds Requested (\$)
	Total Direct Costs (A thru F)	18,590.00

H. Indirect Costs				
	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. MTDC		50.5	18,590.00	9,388.00
<b>Cognizant Federal Agency</b>				<b>Total Indirect Costs</b>
DHHS, Arif Karim, 214-767-3261 (Agency Name, POC Name, and POC Phone Number)				<b>9,388.00</b>

I. Total Direct and Indirect Costs		Funds Requested (\$)
	Total Direct and Indirect Institutional Costs (G + H)	27,978.00

J. Fee		Funds Requested (\$)

K. * Budget Justification	File Name: Justification_Tulane_Gibbs1005647050.pdf (Only attach one file.)	Mime Type: application/pdf
---------------------------	---	----------------------------

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - Cumulative Budget

	<b>Totals (\$)</b>
<b>Section A, Senior/Key Person</b>	<b>40,595.00</b>
<b>Section B, Other Personnel</b>	<b>34,845.00</b>
Total Number Other Personnel	5
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>	<b>75,440.00</b>
<b>Section C, Equipment</b>	
<b>Section D, Travel</b>	
1. Domestic	
2. Foreign	
<b>Section E, Participant/Trainee Support Costs</b>	
1. Tuition/Fees/Health Insurance	
2. Stipends	
3. Travel	
4. Subsistence	
5. Other	
6. Number of Participants/Trainees	17,509.00
<b>Section F, Other Direct Costs</b>	<b>17,509.00</b>
1. Materials and Supplies	17,509.00
2. Publication Costs	
3. Consultant Services	
4. ADP/Computer Services	
5. Subawards/Consortium/Contractual Costs	
6. Equipment or Facility Rental/User Fees	
7. Alterations and Renovations	
8. Other 1	
9. Other 2	
10. Other 3	
<b>Section G, Direct Costs (A thru F)</b>	<b>92,949.00</b>
<b>Section H, Indirect Costs</b>	<b>46,939.00</b>
<b>Section I, Total Direct and Indirect Costs (G + H)</b>	<b>139,888.00</b>
<b>Section J, Fee</b>	

**Tulane University - Bruce Gibb, Ph.D.**

**Senior/Key Personnel:**

Bruce Gibb, Ph.D., Co-Investigator (0.5 summer months effort) is a Professor of Chemistry at Tulane University. He is an expert in synthesis and experimental work on host-guest binding and supramolecular chemistry of molecular containers. Dr. Gibb will oversee all aspects of the proposed work relating to the synthesis of deep cavity cavitands and experimental measurements of binding on those cavitands. Funds are requested for 0.5 months of summer salary support for Dr. Gibb in Years 1 through 5 based on his current institutional salary. This budget item is increased 3% per year in years 2-5 to account of inflation/salary increases. Fringe benefits are included at the standard subcontract rate of 5.4%.

**Other Personnel:**

1 Graduate Student (TBN): One graduate student will actually conduct the work of synthesizing hosts and measuring binding of novel guests, as detailed in Aim 2, supervised by Dr. Gibb but also reporting to Drs. Mobley and Chodera. This student will work 25% time on the project at an annual salary of \$25,000 (with a 3% increase per year included in the budget). Fringe benefit is included at the standard subcontract rate of 6.1%.

**Materials and Supplies:** Supplies will include consumable goods such as starting materials, reagents, drug compounds, solvents, deuterated solvents, disposable glass items, ITC supplies, and other miscellaneous consumables (gases, etc.) for use by the graduate student conducting the measurements. These are budgeted at \$3,501 in year 1 and \$3,502 for years 2 to 5.

**F&A Cost Rate:**

Indirect costs are requested based on modified total direct costs (Base \$92,949) at the Tulane University rate of 50.5%.

# RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 1

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2017

\* End Date: 06-30-2018

Budget Period: 1

## A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	Prof.	Lyle	D.	Isaacs	PhD	Co-investigator			0.25	3,487.00	277.00	3,764.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:					Total Senior/Key Person	3,764.00

## B. Other Personnel

* Number of Personnel	* Project Role	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits	* Funds Requested (\$)
1	Post Doctoral Associates Graduate Students Undergraduate Students Secretarial/Clerical			5	19,782.00	8,937.00	28,719.00
1	<b>Total Number Other Personnel</b>					<b>Total Other Personnel</b>	<b>28,719.00</b>
						<b>Total Salary, Wages and Fringe Benefits (A+B)</b>	<b>32,483.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 1

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2017

\* End Date: 06-30-2018

Budget Period: 1

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

Total Travel Cost

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 1

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2017

\* End Date: 06-30-2018

Budget Period: 1

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		1,527.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		990.00
7. Alterations and Renovations		
	Total Other Direct Costs	2,517.00

G. Direct Costs		Funds Requested (\$)
	Total Direct Costs (A thru F)	35,000.00

H. Indirect Costs				
Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)	
1. Modified Total Direct Cost	52	35,000.00	18,200.00	
<b>Total Indirect Costs</b>				<b>18,200.00</b>
<b>Cognizant Federal Agency</b>				DHHS, Steven Zuraf, 301-492-4855
(Agency Name, POC Name, and POC Phone Number)				

I. Total Direct and Indirect Costs		Funds Requested (\$)
	Total Direct and Indirect Institutional Costs (G + H)	53,200.00

J. Fee		Funds Requested (\$)

K. * Budget Justification	File Name:	Mime Type: application/pdf
	4__Sub_Budget_Justi_201609061005723789.pdf	
	(Only attach one file.)	

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 2

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2018

\* End Date: 06-30-2019

Budget Period: 2

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	Prof.	Lyle	D.	Isaacs	PhD	Co-investigator			0.25	3,592.00	285.00	3,877.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:					Total Senior/Key Person	3,877.00

### B. Other Personnel

* Number of Personnel	* Project Role	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits	* Funds Requested (\$)
1	Post Doctoral Associates Graduate Students Undergraduate Students Secretarial/Clerical			5	20,375.00	9,205.00	29,580.00
1	<b>Total Number Other Personnel</b>					<b>Total Other Personnel</b>	<b>29,580.00</b>
						<b>Total Salary, Wages and Fringe Benefits (A+B)</b>	<b>33,457.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 2

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2018

\* End Date: 06-30-2019

Budget Period: 2

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

Total Travel Cost

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 2

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2018

\* End Date: 06-30-2019

Budget Period: 2

<b>F. Other Direct Costs</b>		<b>Funds Requested (\$)</b>
1. Materials and Supplies		1,573.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		1,010.00
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	<b>Total Other Direct Costs</b>	<b>2,583.00</b>

<b>G. Direct Costs</b>		<b>Funds Requested (\$)</b>
	<b>Total Direct Costs (A thru F)</b>	<b>36,040.00</b>

<b>H. Indirect Costs</b>				
<b>Indirect Cost Type</b>	<b>Indirect Cost Rate (%)</b>	<b>Indirect Cost Base (\$)</b>	<b>* Funds Requested (\$)</b>	
1. Modified Total Direct Cost	52	36,040.00	18,741.00	
<b>Total Indirect Costs</b>				<b>18,741.00</b>
<b>Cognizant Federal Agency</b>				DHHS, Steven Zuraf, 301-492-4855
(Agency Name, POC Name, and POC Phone Number)				

<b>I. Total Direct and Indirect Costs</b>		<b>Funds Requested (\$)</b>
	<b>Total Direct and Indirect Institutional Costs (G + H)</b>	<b>54,781.00</b>

<b>J. Fee</b>		<b>Funds Requested (\$)</b>

<b>K. * Budget Justification</b>	File Name:	Mime Type: application/pdf
	4__Sub_Budget_Justi_201609061005723789.pdf	
(Only attach one file.)		

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 3

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2019

\* End Date: 06-30-2020

Budget Period: 3

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	Prof.	Lyle	D.	Isaacs	PhD	Co-investigator			0.25	3,700.00	293.00	3,993.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:					Total Senior/Key Person	3,993.00

### B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\$)
1	Post Doctoral Associates Graduate Students Undergraduate Students Secretarial/Clerical			5	20,986.00	9,482.00	30,468.00
1	<b>Total Number Other Personnel</b>					<b>Total Other Personnel</b>	<b>30,468.00</b>
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>						<b>34,461.00</b>	

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 3

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2019

\* End Date: 06-30-2020

Budget Period: 3

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

Total Travel Cost

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 3

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2019

\* End Date: 06-30-2020

Budget Period: 3

<b>F. Other Direct Costs</b>		<b>Funds Requested (\$)</b>
1. Materials and Supplies		1,620.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		1,030.00
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	<b>Total Other Direct Costs</b>	<b>2,650.00</b>

<b>G. Direct Costs</b>		<b>Funds Requested (\$)</b>
	<b>Total Direct Costs (A thru F)</b>	<b>37,111.00</b>

<b>H. Indirect Costs</b>				
<b>Indirect Cost Type</b>	<b>Indirect Cost Rate (%)</b>	<b>Indirect Cost Base (\$)</b>	<b>* Funds Requested (\$)</b>	
1. Modified Total Direct Cost	52	37,111.00	19,298.00	
<b>Total Indirect Costs</b>				<b>19,298.00</b>
<b>Cognizant Federal Agency</b>				DHHS, Steven Zuraf, 301-492-4855
(Agency Name, POC Name, and POC Phone Number)				

<b>I. Total Direct and Indirect Costs</b>		<b>Funds Requested (\$)</b>
	<b>Total Direct and Indirect Institutional Costs (G + H)</b>	<b>56,409.00</b>

<b>J. Fee</b>		<b>Funds Requested (\$)</b>

<b>K. * Budget Justification</b>	File Name:	Mime Type: application/pdf
	4__Sub_Budget_Justi_201609061005723789.pdf	
(Only attach one file.)		

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 4

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2020

\* End Date: 06-30-2021

Budget Period: 4

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	Prof.	Lyle	D.	Isaacs	PhD	Co-investigator			0.25	3,810.00	302.00	4,112.00
<b>Total Funds Requested for all Senior Key Persons in the attached file</b>												
Additional Senior Key Persons:			File Name:			Mime Type:					Total Senior/Key Person	4,112.00

### B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\$)
1	Post Doctoral Associates Graduate Students Undergraduate Students Secretarial/Clerical			5	21,616.00	9,766.00	31,382.00
1	<b>Total Number Other Personnel</b>					<b>Total Other Personnel</b>	<b>31,382.00</b>
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>							<b>35,494.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 4

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2020

\* End Date: 06-30-2021

Budget Period: 4

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

Total Travel Cost

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 4

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2020

\* End Date: 06-30-2021

Budget Period: 4

<b>F. Other Direct Costs</b>		<b>Funds Requested (\$)</b>
1. Materials and Supplies		1,669.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		1,051.00
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	<b>Total Other Direct Costs</b>	<b>2,720.00</b>

<b>G. Direct Costs</b>		<b>Funds Requested (\$)</b>
	<b>Total Direct Costs (A thru F)</b>	<b>38,214.00</b>

<b>H. Indirect Costs</b>				
<b>Indirect Cost Type</b>	<b>Indirect Cost Rate (%)</b>	<b>Indirect Cost Base (\$)</b>	<b>* Funds Requested (\$)</b>	
1. Modified Total Direct Cost	52	38,214.00	19,871.00	
<b>Total Indirect Costs</b>				<b>19,871.00</b>
<b>Cognizant Federal Agency</b>				DHHS, Steven Zuraf, 301-492-4855
(Agency Name, POC Name, and POC Phone Number)				

<b>I. Total Direct and Indirect Costs</b>		<b>Funds Requested (\$)</b>
	<b>Total Direct and Indirect Institutional Costs (G + H)</b>	<b>58,085.00</b>

<b>J. Fee</b>		<b>Funds Requested (\$)</b>

<b>K. * Budget Justification</b>	File Name:	Mime Type: application/pdf
	4__Sub_Budget_Justi_201609061005723789.pdf	
(Only attach one file.)		

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 5

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2021

\* End Date: 06-30-2022

Budget Period: 5

### A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requested Salary (\$)	* Fringe Benefits (\$)	* Funds Requested (\$)
1.	Prof.	Lyle	D.	Isaacs	PhD	Co-investigator			0.25	3,819.00	305.00	4,124.00

Total Funds Requested for all Senior Key Persons in the attached file

Additional Senior Key Persons:	File Name:	Mime Type:	Total Senior/Key Person	4,124.00
--------------------------------	------------	------------	-------------------------	----------

### B. Other Personnel

* Number of Personnel	* Project Role	Cal.	Acad.	Sum.	* Requested	* Fringe	* Funds Requested
		Months	Months	Months	Salary (\$)	Benefits	(\$)
1	Post Doctoral Associates						
	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
1	<b>Total Number Other Personnel</b>				22,264.00	10,059.00	32,323.00
<b>Total Other Personnel</b>							<b>32,323.00</b>
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>							<b>36,447.00</b>

RESEARCH & RELATED Budget {A-B} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 5

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2021

\* End Date: 06-30-2022

Budget Period: 5

### C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

\* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

### D. Travel

Funds Requested (\$)

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions)
2. Foreign Travel Costs

Total Travel Cost

### E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance
2. Stipends
3. Travel
4. Subsistence
5. Other:

Total Participant/Trainee Support Costs

RESEARCH & RELATED Budget {C-E} (Funds Requested)

## RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 5

\* ORGANIZATIONAL DUNS: 7909342850000

\* Budget Type:  Project  Subaward/Consortium

Enter name of Organization: University of Maryland College Park

\* Start Date: 07-01-2021

\* End Date: 06-30-2022

Budget Period: 5

<b>F. Other Direct Costs</b>		<b>Funds Requested (\$)</b>
1. Materials and Supplies		1,831.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		1,072.00
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
	<b>Total Other Direct Costs</b>	<b>2,903.00</b>

<b>G. Direct Costs</b>		<b>Funds Requested (\$)</b>
	<b>Total Direct Costs (A thru F)</b>	<b>39,350.00</b>

<b>H. Indirect Costs</b>				
<b>Indirect Cost Type</b>	<b>Indirect Cost Rate (%)</b>	<b>Indirect Cost Base (\$)</b>	<b>* Funds Requested (\$)</b>	
1. Modified Total Direct Cost	52	39,350.00	20,462.00	
<b>Total Indirect Costs</b>				<b>20,462.00</b>
<b>Cognizant Federal Agency</b>				DHHS, Steven Zuraf, 301-492-4855
(Agency Name, POC Name, and POC Phone Number)				

<b>I. Total Direct and Indirect Costs</b>		<b>Funds Requested (\$)</b>
	<b>Total Direct and Indirect Institutional Costs (G + H)</b>	<b>59,812.00</b>

<b>J. Fee</b>		<b>Funds Requested (\$)</b>

<b>K. * Budget Justification</b>	File Name:	Mime Type: application/pdf
	4__Sub_Budget_Justi_201609061005723789.pdf	
(Only attach one file.)		

RESEARCH & RELATED Budget {F-K} (Funds Requested)

## RESEARCH & RELATED BUDGET - Cumulative Budget

	<b>Totals (\$)</b>
<b>Section A, Senior/Key Person</b>	<b>19,870.00</b>
<b>Section B, Other Personnel</b>	<b>152,472.00</b>
Total Number Other Personnel	5
<b>Total Salary, Wages and Fringe Benefits (A+B)</b>	<b>172,342.00</b>
<b>Section C, Equipment</b>	
<b>Section D, Travel</b>	
1. Domestic	
2. Foreign	
<b>Section E, Participant/Trainee Support Costs</b>	
1. Tuition/Fees/Health Insurance	
2. Stipends	
3. Travel	
4. Subsistence	
5. Other	
6. Number of Participants/Trainees	
<b>Section F, Other Direct Costs</b>	<b>13,373.00</b>
1. Materials and Supplies	8,220.00
2. Publication Costs	
3. Consultant Services	
4. ADP/Computer Services	
5. Subawards/Consortium/Contractual Costs	
6. Equipment or Facility Rental/User Fees	5,153.00
7. Alterations and Renovations	
8. Other 1	
9. Other 2	
10. Other 3	
<b>Section G, Direct Costs (A thru F)</b>	<b>185,715.00</b>
<b>Section H, Indirect Costs</b>	<b>96,572.00</b>
<b>Section I, Total Direct and Indirect Costs (G + H)</b>	<b>282,287.00</b>
<b>Section J, Fee</b>	

**BUDGET JUSTIFICATION**  
**UNIVERSITY OF MARYLAND**

**Personnel**

**Key Personnel**

*Lyle Isaacs, Ph.D., Principal Investigator* is a Professor of Chemistry and Biochemistry at the University of Maryland, Director of the Chemistry graduate program, and a member of the University of Maryland Nanocenter. Dr. Isaacs is expert in the synthesis of CB[n]-type receptors, the mechanism of CB[n] formation, and the supramolecular chemistry of the resulting molecular containers. Dr. Isaacs will oversee all aspects of the proposed work related to the synthesis of host compounds and the measurement of binding constants toward selected guest compounds. Funds are requested for 0.25 month summer salary support for Dr. Isaacs in Years 1 through 5 based on his current 9 month institutional salary of \$125,536.82. This budget item includes a request of 7.93% cover the costs of FICA (6.2%), Medicare (1.45%), and unemployment (0.28%) taxes. This budget item is increased 3% per year in years 2-5 to account for inflation / salary increases.

**Other Personnel**

*TBD Post-Doctoral Fellow:* Funds are requested to support a part-time postdoctoral fellow (5 months per year) to work on this project under the supervision of Dr. Isaacs for years 1 – 5. The postdoctoral fellow will also be responsible for the synthesis of Calabadion 2 needed to support the efforts of the MGH team under Specific Aim 1. Finally, The postdoctoral fellow will also be in charge of developing and performing the assays to detect and quantify the presence of Calabadions in urine and plasma samples generated by the MGH team. This budget item includes a request for postdoctoral salary at \$47,476 per year in line with the Fair Labor Standard Act and projected NIH NRSA FY2017 stipend levels, 30% of salary for health benefits, 7.93% of salary for social security / medicare / unemployment, and 7.25% for retirement contributions. This budget item is increased 3% per year in years 2-5 to account for inflation / salary increases.

General: The University does not have a fringe benefit rate. Actual costs vary from person to person based on their individual benefits plan (health, dental, prescription) choices. The University uses an average of 30% of salary for budgetary purposes for the benefits plan selections. Postdoctoral fellows also receive retirement contributions in the amount of 7.25% of salary. Finally, all employees incur social security / medicare / unemployment costs in the amount of 7.93 % of salary.

**Materials and Supplies**

Isaacs Lab Supplies: Consumable goods (starting materials, reagents, drug compounds, solvents, deuterated solvents, silica gel, TLC plates, disposable glass items, ITC supplies (solvents, detergents and replacement parts) and miscellaneous consumables) are requested for the postdoctoral fellow at \$1527.33 per year. This budget item is increased 3% per year in years 2-5 to account for typical inflation for biomedical research supplies.

**Equipment / Facility User Fees**

Isaacs Lab Facility Charges: The postdoctoral fellows working on this project will make use of the departmental NMR, mass spectrometry, and X-ray crystallography facilities which are available for a fee. We estimate usage as follows:

NMR: 8 hours per month @ \$11/hr (8 x 5 months x \$11)	\$ 440
MS: 1 samples per month @ \$60 / sample (1 x 5 months x \$60)	\$ 300
X-ray crystallography: 1 sample / year at @ \$250 / sample	\$ 250
	_____
	\$990 / year

This budget item is increased 2% per year in anticipation of yearly increases to Equipment / facility user fees at the University of Maryland.

#### **Other Expenses**

Indirect costs are requested based on modified total direct costs (Base \$185,715.69) at the UMD institutional rate of 52.0 percent.

# PHS 398 Cover Page Supplement

## 1. Human Subjects Section

Clinical Trial?  Yes  No

\*Agency-Defined Phase III Clinical Trial?  Yes  No

## 2. Vertebrate Animals Section

Are vertebrate animals euthanized?  Yes  No

If "Yes" to euthanasia

Is method consistent with American Veterinary  
Medical Association (AVMA) guidelines?

Yes  No

If "No" to AVMA guidelines, describe method and  
provide scientific justification

## 3. \*Program Income Section

\*Is program income anticipated during the periods for which the grant support is requested?

Yes  No

If you checked "yes" above (indicating that program income is anticipated), then use the format below to reflect the amount and source(s). Otherwise, leave this section blank.

\*Budget Period    \*Anticipated Amount (\$)

\*Source(s)

# PHS 398 Cover Page Supplement

## 4. Human Embryonic Stem Cells Section

\*Does the proposed project involve human embryonic stem cells?  Yes  No

If the proposed project involves human embryonic stem cells, list below the registration number of the specific cell line(s) from the following list:  
<http://stemcells.nih.gov/research/registry/>. Or, if a specific stem cell line cannot be referenced at this time, please check the box indicating that one from the registry will be used:

**Cell Line(s):**  Specific stem cell line cannot be referenced at this time. One from the registry will be used.

## 5. Inventions and Patents Section (RENEWAL)

\*Inventions and Patents:  Yes  No

If the answer is "Yes" then please answer the following:

\*Previously reported:  Yes  No

## 6. Change of Investigator / Change of Institution Section

Change of Project Director / Principal Investigator

Name of former Project Director/Principal Investigator

Prefix:

\*First Name:

Middle Name:

\*Last Name:

Suffix:

Change of Grantee Institution

\*Name of former institution:

## **PHS 398 Research Plan**

OMB Number: 0925-0001

Expiration Date: 10/31/2018

<b>Introduction</b>	
1. Introduction to Application (Resubmission and Revision)	
<b>Research Plan Section</b>	
2. Specific Aims	Specific_Aims1005723862.pdf
3. Research Strategy*	Research_Strategy_R11005723864.pdf
4. Progress Report Publication List	
<b>Human Subjects Section</b>	
5. Protection of Human Subjects	
6. Data Safety Monitoring Plan	
7. Inclusion of Women and Minorities	
8. Inclusion of Children	
<b>Other Research Plan Section</b>	
9. Vertebrate Animals	
10. Select Agent Research	
11. Multiple PD/PI Leadership Plan	
12. Consortium/Contractual Arrangements	Commitment_combined_R21005724167.pdf
13. Letters of Support	SupportLetters_combined_R11005723847.pdf
14. Resource Sharing Plan(s)	Resource_Sharing1005646866.pdf
15. Authentication of Key Biological and/or Chemical Resources	Authentication_of_Key_Resources_Plan1005723793.pdf
<b>Appendix</b>	
16. Appendix	

## SPECIFIC AIMS

While computational techniques are currently widely used in pharmaceutical drug discovery, current generation technologies (such as docking) are unsuitable for true molecular design. Specifically, these techniques fail to predict small molecule binding affinities to target and antitarget biomolecules with sufficient accuracy for the variety of applications currently of interest. Computational screening techniques can do better than random selection of compounds, but they lack the accuracy to guide molecular design or optimization. A new generation of physical techniques, alchemical free energy calculations, are poised to fill this void by providing a quantitative, predictive tool that can be used in multiple stages of the drug discovery pipeline, including lead optimization to improve affinity and selectivity or the retention of potency as other physical properties are optimized.

Recent success of alchemical methods in predicting accurate affinities has sparked considerable enthusiasm, but the domain of applicability of these techniques is currently highly limited; broad application and routine use will require further evaluation, refinement, and development. There is a vast gulf between targets within the domain of applicability and those which are outside it. Bridging this gulf to expand the domain will require focused study of carefully selected systems of intermediate complexity. Without such a bridge, these techniques may encounter the same problems faced by docking and related techniques: routine failure without clear insights into why, and years to decades spent making small methodological modifications without dramatic improvements in predictive power.

We propose to collect targeted experimental datasets, use them to conduct blind prediction challenges, and release curated benchmark sets in a manner designed to drive expansion of the domain of applicability and improvements to physical modeling techniques. The data we generate will provide a spectrum of difficulty between systems tractable with current methodologies to the pharmaceutically-relevant drug targets featured in the NIH-funded D3R effort, which fields blind challenges using protein-ligand datasets from pharma. Our systematic set of challenges aims to rapidly advance free energy techniques to the point of standard application in drug design. At the same time, the data we collect will play a long lasting role in the community, going through a life cycle of collection, curation, blind challenges, and then public dissemination to serve as benchmark sets and standard reference data, and to drive construction of new and improved models. While our work here focuses primarily on generating new targeted data for a series of blind SAMPL (“Statistical Assessment of Modeling of Proteins and Ligands”) challenges and running those challenges, we also plan for subsequent data dissemination. Here, we will:

**Aim 1. Collect new physical property datasets to assess accuracy and spur improvements in force fields and modeling of protonation states and tautomers.**

We will develop new solution-phase datasets for druglike small molecules. These data can test critical aspects of small molecule modeling (including accounting for interactions and treatment of protonation/tautomeric state) and improve our ability to predict physical properties relevant to drug discovery in new regions of chemical space. We will initially focus on aqueous/nonpolar distribution coefficients and  $pK_a$  measurements, advancing to solubilities and membrane permeabilities, while using these data to drive improvements in the modeling of ligand interactions.

**Aim 2. Measure affinities of drug-like compounds in supramolecular hosts to challenge quantitative models of binding in systems not plagued by major receptor sampling issues.**

We will measure new host-guest binding free energies (using cucurbiturils and deep-cavity cavitands as hosts) to field binding challenges with varying complexity between physical property prediction and protein-ligand binding. Host guest systems are some of the simplest cases of molecular recognition, and thus these binding data will drive improvements in modeling of simple binding systems with techniques of relevance to drug discovery.

**Aim 3. Develop model protein-ligand systems that isolate specific modeling challenges of drug targets.**

We will identify suitable biological protein-ligand model systems that isolate individual modeling challenges (selected to push the limits of physical techniques) and develop these for blind challenges based on new protein-ligand affinity measurements. While the initial year will feature fragment binding to human serum albumin, subsequent challenge systems will be selected using a novel informatics platform to focus on timely modeling issues.

**Aim 4. Field community blind challenges to advance quantitative biomolecular design.**

The data collected in Aims 1–3 will drive annual SAMPL blind challenges, allowing the field to test the latest methods and force fields to assess progress, compare them against one another head-to-head, and perform sensitivity analysis to learn how much different factors (protonation state, tautomer selection, solvent model, force field, sampling method, etc.) affect predictive power. Results will then feed back into improved treatment of these factors for subsequent challenges, driving regular cycles of application, learning, and advancement.

Overall, the data generated here and the cycles of tests in SAMPL challenges will guide new innovations in physical methods for predicting binding and physical properties, providing a foundation for the next several generations of computational methods for pharmaceutical drug discovery.

## SIGNIFICANCE

**Physical modeling is poised to transform drug discovery and chemical biology by enabling true molecular design.** While modeling is used extensively in drug discovery, its main role at present is to aid with idea generation or filter large libraries of compounds for screening. Instead, we imagine using computational techniques extensively to guide the design process. Consider a medicinal chemist in the not-too-distant future who has just finished synthesizing several new derivatives of an existing inhibitor, and has obtained binding affinity or potency data against the desired biomolecular target. Before leaving work, she generates ideas for perhaps 100 new compounds which could be synthesized next, setting her computer to work overnight. By morning, the idea compounds have been prioritized based on reliable predictions of their affinity for the desired target, selectivity against antitargets, solubility, and membrane permeability. The chemist looks through the predicted properties for the top few compounds, selecting some for synthesis. If synthesizing and testing each compound takes several days, this workflow compresses roughly a year's work into a few days.

While this workflow is not yet a reality, significant strides have been made toward accurate binding affinities [97–104], solubilities [105–107], selectivity and drug resistance [108], and membrane permeability [109, 110]. A considerable amount of science and engineering still remains to make this vision a reality. Given recent progress, the question now seems more one of *when* rather than *whether*.

Widespread availability of inexpensive graphics processing units (GPUs) provides a 100-fold increase in price-to-performance ratio over CPUs, while advances in automation [111] and sampling protocols have helped simulation-based techniques reach the point where they now begin to be genuinely useful in guiding drug discovery for a limited *domain of applicability* [100–104, 112, 113]. Specifically, in some situations, free energy calculations appear to be capable of achieving RMS errors of 1–2 kcal/mol with current force fields, even in prospective applications, sufficient to drastically reduce the number of molecules that must be synthesized and assayed [114]. As a consequence, pharmaceutical companies are beginning to use these methods in active discovery projects.

**Despite progress, current physical modeling methodologies suffer from severe limitations hindering their widespread use in molecular design.** For example, even “small” protein conformational changes not gracefully handled by current methodologies can yield errors up to 5 kcal/mol in calculated binding free energies [115], force field limitations still pose major challenges [116], and the inability to treat important chemical effects like protonation and tautomer equilibria drastically limits the domain of applicability. **For many pharmaceutically relevant systems, the most important sources of error—and modeling challenges—are not yet clear.**

Progress on addressing these challenges has been frustratingly slow, hindered by a lack of high-quality data and community focus. **Neither retrospective tests nor prospective application in discovery projects provides the necessary impetus and data to rapidly overcome remaining barriers to widespread utility.** Large-scale retrospective tests can assess *retrospective* performance, but they do not provide accurate guidance on utility for prospective design, nor do they effectively identify the most important sources of error. Retrospective tests can also easily result in over-fitting, where researchers apply a variety of protocols until apparently significant results are obtained by chance [117]. In retrospective tests, performance may also not be indicative of expected performance in applications because even well-meaning researchers can take advantage of prior knowledge. For example, if the binding mode of a ligand is already known crystallographically, a researcher may use that binding mode in retrospective tests, whereas prospective or design work would require first selecting among candidate binding modes, introducing substantial uncertainty unaccounted for in the retrospective statistics [97, 118, 119]. This also means that in retrospective tests, researchers almost invariably try far fewer methods than in prospective tests, resulting in much less new insight. Prospective tests, in contrast, force researchers to anticipate a multitude of potential situations rather than only those observed in a known benchmark dataset. Prospective application in actual discovery projects, while important, also does not provide the necessary impetus, partly because often, the predicted compounds are in fact never tested [102] or the experimental data necessary to assess the quality of the predictions is absent—for example, because binding affinities are not measured or no crystallography is available.

**To accelerate progress in quantitative predictive physical modeling, we need a series of community blind prediction challenges focused on pushing the limits of predictive techniques, providing a bridge between challenging but tractable problems and pharmacologically relevant but currently intractable problems.** These challenges should be designed to have the necessary high quality experimental data, but also be prospective, predictive tests. While the Drug Design Data Resource (D3R [120], discussed further below) provides an existing community blind challenge on protein-ligand binding, it focuses on using pre-existing pharmaceutical datasets, rather than on measuring new data carefully selected maximize community learning [120]. D3R serves well to assess where we are now—but we need a carefully-designed effort focused on improving modeling.

**Physical modeling accuracy advances most rapidly when progress toward a complex goal can be decomposed into resolving a series of tractable problems, as revealed by carefully collected and curated data.** To make rapid progress, our field needs an effort which focuses on specific *component* problems of the overall problem of interest, collects and curates data that highlights these problems, and drives progress via prospective challenges. This process allows the entire community to learn from both methodological success and failure. The model we propose here has been proven to drive dramatic improvements in modeling, as evidenced by our **Statistical Assessment of Modeling of Proteins and Ligands (SAMPL)** series of challenges. SAMPL, born out of frustration with the lack of venues for comparing predictive accuracy on a level playing field, was initiated by Anthony Nicholls of OpenEye software in 2007/2008 [121], and has run challenges approximately every two years since then [122–129]. Governance transitioned to an unfunded academic collaboration during SAMPL3 in 2012; this collaboration ran subsequent challenges as SAMPL4 (2014) and SAMPL5 (2016). The PI of this proposal (Mobley) was a primary organizer of SAMPL4/5 (2014–2016). Much as unit testing is an indispensable tool for discovering where bugs in a program are hiding when complex integration tests fail, exercises like SAMPL are valuable in pinpointing and correcting modeling errors when the overall performance fails to live up to expectations for complex pharmacological targets. To accomplish this, SAMPL has historically focused on both simple challenges that attempt to isolate likely sources of modeling errors, such as physical properties of small molecules (hydration free energies, aqueous tautomer ratios, partition or distribution coefficients between aqueous and nonpolar phases) as well as small molecule binding to targets of reduced complexity (such as host-guest binding, and binding of fragments to trypsin and HIV integrase). **SAMPL has already been a tremendous community resource, resulting in nearly 100 publications which are typically cited 5–50 times or more each [1–96].**


Here, we **design a new series of SAMPL challenges specifically to guide the improvement of models**. Until now, this has been impossible, because SAMPL has been entirely unfunded; its very existence has required “donation” of data and time, giving us no ability to gather datasets tailored to our purpose. Our proposed new challenges bridge the gap between calculations of simple physical properties that isolate forcefield inaccuracies from sampling challenges, like hydration—which can already be calculated fairly accurately [126]—and the D3R Grand Challenges on protein-ligand binding, which are a major source of consternation for the community so far [120, 130–132]. Unless this gap is bridged, there is the very real possibility that modeling may simply continue to fall far short of expectations in pharmaceutical challenges like D3R for reasons which are unclear. Here, we design challenges to highlight major reasons for failure and drive progress towards resolving them.

**Our major goal is to rapidly advance predictive modeling to where it can guide biomolecular design, and extension of the SAMPL challenges will do exactly that.** This work will play a vital role in enhancing the work being done on *existing* data by D3R, helping prepare methods for application to the more challenging systems emerging from pharma in D3R’s challenges.

## INNOVATION


Blind predictive challenges—and SAMPL in particular—have already led to important new science on method development, evaluation, robustness, and force field improvements. However, they have not yet produced dramatic improvements in predictive molecular design, largely because the challenges posed have not been selected and staged for optimal impact. Indeed, SAMPL challenges to date have had to be opportunistic, making best use of measurements that contributing experimentalists were carrying out to advance other scientific goals. A central goal of this proposal, then, is to maximize the impact of future SAMPL exercises by crafting a series of challenges specifically designed to test and advance computational methods, and gathering the requisite experimental data.

Several historical examples serve to highlight how SAMPL can foster innovation (though far more examples are available in our SAMPL bibliography below; see also Figure 3). The first several SAMPL challenges on hydration free energies had rather hit-and-miss performance, highlighting pitfalls of existing methods and force fields which led to marked improvements in PB models [122, 133, 134], recognition of some limitations of fixed-charge force fields [135, 136], repair of some of these force field deficiencies via additional polarization or introduction of off-site charges [135–137], and helped motivate alternate implicit or hybrid solvent models [138–140]. Shifts in protonation



**Figure 1. SAMPL historical participation [126].** Historical participation in SAMPL host-guest + solvation/distribution challenges has climbed rapidly, and we expect this trend to continue. The number of participating groups is shown in blue, and the number of submissions in green. The inset shows the diversity of methods employed for the SAMPL4 hydration challenge, which is typical for SAMPL.

state and tautomer proved particularly important in the recent SAMPL5 log D challenge [128, 141]. This challenge provided a tractable opportunity to isolate and explore these specific physical effects, which are so important in protein-ligand binding, while avoiding the full complexity of pharmaceutical binding studies. Host-guest binding studies have also been particularly important [142], highlighting the importance of salt effects [129, 142, 143] and in some cases revealing more severe force field limitations than observed in hydration and distribution challenges [144, 145], pointing the way forward for improving predictive models of molecular interactions [142, 146].



**Figure 2. Timeline for our activities.** Activities covered by this grant include data collection and SAMPL challenges on our three major components (physical properties, host-guest binding, and protein-ligand binding), with each challenge cycle color-coded separately. Data collection within each Aim is shown by a colored bar indicating what is measured and curated. Data collection/curation is followed by a submission window for that challenge component, then all results and analysis are returned to participants and posted on the SAMPL website; this also will nucleate more detailed long-term discussion on the relevant Slack channel. At this point, we will also release the data to the public as a high quality benchmark. Each component will then wrap up with a virtual meeting focused on lessons learned and areas which need further exploration; these will be recorded and posted on our website to assist in rapid dissemination of new insights. Virtual meetings precede the submission window for the next SAMPL challenge, giving the opportunity to incorporate lessons learned for the next challenge. Submission windows and virtual meetings are staggered across categories so that participants can be involved in all three major areas without multiple simultaneous deadlines. In-person meetings are co-hosted with D3R and will occur every two years, supplemented by effort-wide virtual meetings in between. Special issues of JCAMPD will have deadlines shortly after the virtual meeting on the protein-ligand challenge for that year, and a 4-5 month timeline (based on historical experience) from the submission deadline until the special issue appears (with the first papers appearing online substantially sooner). Rapid dissemination of insights is critical for rapid progress, so we highly encourage the use of preprints and informal reports to supplement the special issue.

This work is also innovative because of the uniqueness of SAMPL. While there are other predictive challenges in the area of biomolecular modeling, such as D3R [120], the  $pK_a$  cooperative [147], CAPRI [148] and CASP [149], **no other blind challenge focuses specifically on data tailored and collected to drive quantitative protein-ligand modeling**. The SAMPL expansion we propose here is unique in its *specific design* to drive improvements in modeling accuracy rather than simply serving an evaluative role. SAMPL benefits the whole modeling community—for example, protein-ligand docking software has improved as a direct result of SAMPL hydration challenges [150], and commercial software vendors have introduced new features or scientific improvements based on participation in SAMPL challenges [141, 151]. In effect, **SAMPL serves as an engine to spur innovation by soliciting novel approaches to complex problems from the community and evaluating their success at predictions**.

This work also focuses on innovative experimental methods. Specifically, in Aim 3, we develop a new informatics platform to facilitate the rapid identification and study of particularly informative protein-ligand systems that are both experimentally tractable for high-throughput biophysical measurements and focus on specific challenges of interest. We employ a fully automated wetlab to screen potential model systems for expression, carry out high-accuracy biophysical measurements, and perform automated error analysis to carefully assess experimental uncertainty. **This work is at the forefront of innovation in high-throughput, automated biophysical experiments to produce high quality data with well-characterized uncertainties**. Not only will the data be of prime importance, but the techniques themselves will help future experiments.

In Aim 4, in addition to running SAMPL challenges, we will also perform reference calculations to test the accuracy of current state-of-the-art techniques. Both the Mobley and Chodera labs are experts in development of free energy methods for application to physical properties (e.g., [126, 152, 153] and binding (e.g., [115, 116, 154]), and **these reference calculations will drive innovation** as well, serving several key roles: (1) Benchmarking the latest method developments against current “best practices” methods (by doing calculations via both approaches); (2) Facilitating learning, allowing others to compare against our results to determine how a change in method or force field impacts results; (3) Focusing the field on key issues by doing sensitivity analysis to whether conditions such as ionic strength, protonation state, tautomer choice, etc., impact computed values.

Careful analysis of challenge predictions and results to identify why models fail and what specific problems need further attention is a critical and powerful aspect of SAMPL that spurs further innovation. Both organizers and participants play key roles in this; organizers identify global patterns and provide a venue for participants to explore these issues, while participants probe failure modes of individual methodologies in greater detail. When methods differ in performance, it is critical to understand whether the differences are statistically significant and important, and to provide an accurate accounting of the uncertainty in performance measures. Thus, careful and innovative analysis of challenge outcomes is particularly important in SAMPL [126, 128, 129], in some cases driving experimentation with new performance metrics [126].


## APPROACH

Our approach to systematically advancing modeling for biomolecular design involves collecting carefully targeted experimental datasets for challenges focusing on physical property prediction, host-guest binding, and protein-ligand binding. These datasets, spanning a spectrum of complexity, help isolate individual limitations in quantitative physical modeling to encourage and evaluate multiple solutions from the community. Aims 1–3 focus on tailoring and generating this experimental data, while Aim 4 focuses on fielding annual SAMPL challenges. Each annual challenge includes one or more components from each of the Aims. Aims 1–3 bring together multiple laboratories and both theorists and experimentalists: graduate students from the Mobley and Chodera laboratories are paired with well-equipped experimental groups in industry to collect physical property data (Aim 1); Gibb and Isaacs, leading experimentalists in supramolecular chemistry, work with theorist Mobley to perform host-guest affinity measurements (Aim 2); and the Chodera lab applies new automated approaches to identify suitable protein-ligand systems and measure binding (Aim 3). The annual SAMPL challenges organized by the Mobley and Chodera labs (Aim 4) will leverage the data of Aims 1–3 (Figure 2) and best practices reference calculations to drive progress.

### **Aim 1: Collect new physical property datasets to assess accuracy and spur improvements in force fields and modeling of protonation states and tautomers.**

Simple physical properties such as solvation, partitioning, and protonation equilibria can be calculated quite precisely (but not necessarily accurately) with physical methods, allowing quantitative comparison between calculations and experiment and revealing and isolating deficiencies in our models. These properties allow us to directly probe force field accuracy and chemical effects like protonation and tautomer handling in the absence of slow conformational changes and other effects which complicate assessment in protein-ligand systems.

**Rationale:** We will generate new solution-phase physical property measurements for drug-like molecules to motivate improvements in force fields and handling of protonation states and tautomers. This builds on our work on water-cyclohexane distribution coefficients for SAMPL5 (in partnership with Genentech), which revealed major issues with handling of protonation states and tautomers [128] as well as serious forcefield limitations [137] (Figure 3). Distribution coefficients give the equilibrium ratio of concentrations of a solute between aqueous and nonpolar phases, and thus relate to transfer free energies from aqueous to more protein- or membrane-like environments. Thus, they capture many of the characteristics of transfer of drugs from water into binding sites but absent challenges with receptor conformational sampling and specific ligand-receptor interactions. In SAMPL5,



**Figure 3. Lessons learned from SAMPL5 log D predictions.** Predictions of log D values for SAMPL5 provided a number of key lessons. (A) Methods which treated multiple protonation and tautomeric states in their predictions performed dramatically better than those which did not; here, red dots move to x symbols when these effects are treated, improving accuracy in every case [155]. (B) Re-parameterization of a force field to more accurately reproduce pure solvent dielectric constants resulted in dramatically better predictions (top) than the original force field (bottom) [137].

distribution coefficients were challenging enough that many methods performed poorly, with even the best methods having accuracies less than would be expected based on hydration free energies in water [128], yet failures were informative and the major sources of error were issues which will also plague prediction of ligand-receptor interactions. In some respects, distribution coefficients posed the ideal SAMPL challenge, hitting the sweet spot in terms of difficulty—difficult enough that clear failures were frequent, with ample room for improvement, but not so difficult that the reasons for failure were unclear in general. Still, many models consistently disagreed with experiment for some compounds [128, 137, 141, 156], revealing the impact that targeted follow-up experiments (such as those we will conduct here) could have on improving models.

**This new experimental data is critical to maximize impact on the modeling community.** While the community has already benefitted considerably from SAMPL, as indicated by the nearly 100 publications on SAMPL (see attached list), the citation count, and the growing participation (Figure 1), progress will be greatly accelerated by the proposed initiative. A funded, coordinated effort allows the targeted collection of datasets designed to focus on the most important problems. With multiple investigators and collaborators, we are poised to respond and adapt to new challenges and opportunities which emerge in a manner not previously possible. Additionally, we will be able to continue experimental work until the necessary data is collected rather than terminating it at a specific time point dictated by industry internships—allowing us to do things like ensure the full dynamic range of log D values is covered, unlike in SAMPL5 [128, 156]. This will improve our ability to learn from the data—for example, the lack of dynamic range for SAMPL5 meant that, when calculated values often spanned a larger dynamic range than the experimental values, it was unclear if this was an artifact of the data set itself, experimental limitations, or force field problems [128, 137, 141, 156]. With funding to extend the experimental set via follow-up experiments, we will be able to resolve similar issues, providing further impetus to improve models.

Below, we summarize plans for data collection for the SAMPL6-10 challenges of Aim 4 (see also Figure 2). These specific data sets were selected based on a desire to help the field resolve the problems encountered in SAMPL5 then progress to accurate estimation of new properties. Data sets will typically consist of at least 96 compounds for good statistics, though when possible, a much larger amount of data will be collected.

**SAMPL6: Cyclohexane/water and octanol/water distribution coefficients.** Building on the success of distribution coefficient measurements in SAMPL5 and their surprising ability to motivate rapid advances in physical modeling methodologies [128], we will measure cyclohexane-water distribution coefficients at pH 7.4 for a new batch of commercially-available drug- and fragment-like molecules. Given the routine nature of octanol-water distribution coefficient measurements and indications that their prediction may be computationally tractable [153, 157] despite the heterogeneous structure of the wet octanol phase [158], we will also measure octanol-water distribution coefficients for the same compounds. Because  $pK_a$  prediction was difficult but critical for SAMPL5, we will focus SAMPL6 on forcefields and tautomers by measuring  $pK_a$  values, revisiting  $pK_a$  prediction in SAMPL7 and 8.

**SAMPL7: pKa measurements for drug-like molecules.** While much less complex than protein-ligand affinities, distribution coefficient measurements still conflate the challenging issues of protonation state and tautomer prediction, as well as transfer into different environments which may contain small but important quantities of co-solvents. Thus, we will separate these issues and improve our handling of them one at a time. For SAMPL7, then, we will measure  $pK_a$  values for an extensive set of drug-like molecules in water which will serve as the focus of the challenge, paving the way for SAMPL8.

**SAMPL8: pKa measurements and distribution coefficients.** In the next challenge, we will jointly explore  $pK_a$  and transfer issues, measuring distribution coefficients and  $pK_a$  values for the same set of compounds, with participants predicting (a) log D; (b)  $pK_a$ ; and (c) log P. Unlike SAMPL6,  $pK_a$  values will not be provided.

**SAMPL9-10: Solubility prediction and membrane permeability.** With solubility predictions now becoming tractable [105–107] (with Schrödinger also working on amorphous solubility prediction), solubility measurements will be a valuable test for SAMPL9, combining the solvation aspects of SAMPL1-8 with a new solid phase component. New computational techniques are targeting membrane permeability [109, 110], and this is experimentally accessible (see support letters from Pfizer and Merck), leading to our interest in permeability for SAMPL10.


drug	features
memantine	adamantane; 1:1
saxagliptin	adamantane; 1:1
premarin	steroid
pancuronium	steroid
varenicline	1:1 vs 1:2
valsartan	$pK_a$ 4.37
omeprazole	$pK_a$ 4.77
ranolazine	$pK_a$ 7.17; epitopes
pradaxa	$pK_a$ 3.87; epitopes
nilotinib	epitopes; $pK_a$ 6.3
sensipar	epitopes; folding
vyvance	diamine; epitopes; folding
minocycline	tetracyclin; amino aniline

Table 1. Selected drugs whose binding to CB[n] hosts will be assayed for SAMPL6, 8, and 10 challenges (SA 2.1). These drugs bind to the cucurbituril-based host systems considered here, some at high affinity, so measuring their affinities provides a way to test methods for predicting binding interactions absent complexities present in protein-ligand systems.

**Experimental plan:** Experimental data will be collected in collaboration with our pharma partners (see support letters), roughly following the model used for SAMPL5, where Chodera lab student Bas Rustenburg went to Genentech to conduct cyclohexane-water log D measurements by adapting a Genentech high-throughput mass spectrometry workflow [156]. To collect this data, the Mobley and Chodera labs will send graduate students on visits or internships to industry collaborators to collect targeted datasets. Working with industry collaborators (see Letters of Collaboration from Genentech, Pfizer, and Merck) gives us substantial access to equipment and high-throughput measurement workflows—such as the Sirius T3 from Sirius Analytical (which can measure partition/distribution coefficients,  $pK_a$ s, and solubilities for molecules with titratable groups)—automation equipment, and compound libraries—for the purposes of rapidly collecting targeted datasets. Our previous experience demonstrates this model will work [156], and our partners see the value of this data and SAMPL to the modeling community.

Overall, Aim 1 extends prior SAMPL challenges via data focused on quantitative prediction of physical properties of tremendous relevance to accurately predicting biomolecular interactions, paving the way to applications in more complex systems addressed in Aims 2 and 3.

## Aim 2: Measure affinities of drug-like compounds in supramolecular hosts to challenge quantitative models of binding in systems not plagued by major receptor sampling issues.



**Figure 4. The best host-guest binding predictions of SAMPL3 [159] and SAMPL5 [144].** Binding free energy predictions have shown clear improvements from SAMPL3 to SAMPL5 as the major challenges become understood and are treated better by models, though a systematic offset remains in the best SAMPL5 predictions (yellow). Dashed lines denote errors of  $\pm 1.5$  kcal/mol.

importance of adequately sampling water rearrangements [127, 129, 142, 160].


This new attention has resulted in clear improvements as participants begin to treat the relevant effects more accurately (Figure 4). Host-guest binding proves remarkably difficult to model accurately [161], in part due to force field limitations (resulting in new force field work [146]).

Here, we design a series of SAMPL challenges focused on two classes of host-guest systems—cucurbiturils and analogs (SA 2.1) and Gibb's deep-cavity cavitands (GDCCs, SA 2.2)—both of which build on prior SAMPL challenges. These two sets of systems exhibit different challenges as recently reviewed [142], with the hosts of 2.1 bringing relatively modest co-solvent and ion effects but some receptor sampling problems for the acyclic hosts, and the GDCCs of 2.2 bringing profound ion and co-solvent effects as well as water sampling challenges. Methods which perform well on one class may not perform well on the other [142], since the distinct sets of challenges highlight different limitations. This diversity drives more innovation than would a focus on a single host class.

### Subaim 2.1: Cucurbituril-based receptors as model binding systems

**Cucurbituril derivatives for host-guest binding.** Building on previous success with cucurbit[ $n$ ]uril (abbreviated CB[ $n$ ]) experiments for SAMPL challenges [162–164], we will conduct a series of new experiments on these receptors for five new challenges, with experimental work conducted by co-investigator Isaacs, an expert on these systems who provided data for previous SAMPL challenges. CB[ $n$ ] receptors are particularly well suited to our

Aim 1 focuses on the behavior of small molecules and its environment-dependence, in the absence of receptors and the associated potential for slow sampling, strong specific interactions, and other challenges such as salt effects. Binding in host-guest systems retains many of the same challenges seen in Aim 1 and introduces strong specific interactions and other challenges like salt effects [142], while still avoiding many of the issues with slow sampling (of protein conformational changes, ions, and ligand binding modes) seen in protein-ligand interactions. That is, binding in host-guest systems introduces a wider variety of challenges relevant to biomolecular interactions, but without the full array of challenges seen in protein-ligand interactions, as reviewed recently [142]. Thus, new data for SAMPL challenges on host-guest binding is critical to provide challenges of intermediate complexity between those of physical properties and those in biomolecular binding. We believe that host-guest binding challenges provide a vital step towards accurately modeling biomolecular interactions, focusing the field on issues not commonly encountered in physical property challenges (such as the importance of accurately modeling ionic conditions) that are highly relevant for protein-ligand interactions. Already, over the past several SAMPL challenges, host-guest systems have provided key tests for modeling of binding interactions, resulting in new attention paid to how co-solvents and ions modulate binding (resulting in errors of up to 5 kcal/mol when these effects are neglected) and the




**Figure 5.** SAMPL6-10 host-guest challenges will feature cucurbituril hosts and analogs, including **Me<sub>4</sub>CB[8]**, glycoluril hexamer, and acyclic CB[n]-type receptors (SA 2.1). These receptors bind a variety of drug-like molecules, some with high affinity.

goals because they exhibit: (1) high binding affinities toward suitable guests in water comparable to protein-ligand affinities (routinely  $\mu$ M to nM; occasionally pM to fM) [165–171], (2) high selectivities between structurally related guests which translate into large  $\Delta\Delta G$  values [172], (3) low molecular weights (1–2 kDa) permitting high levels of theory to be used, and (4) highly restricted conformational degrees of freedom, reducing conformational sampling challenges often seen in protein-ligand binding. For SAMPL6-10, we will resynthesize a series of CB[n]-type receptors of increasing complexity, measure  $K_a$  values, and determine host-guest stoichiometry and geometry toward pharmaceutically relevant guests (selected drugs) in order to stringently test methods for predicting binding. Figure 5 shows the chemical structures of three hosts—Me<sub>4</sub>CB[8] [173], glycoluril hexamer [174], and acyclic CB[n]-type receptors [175–180] which span a range in terms of level of preorganization and formal charge.

**SAMPL6-10 cucurbituril challenges.** For SAMPL6, we will measure  $K_a$  and  $\Delta H$  values, stoichiometry, and geometry for the interaction of Me<sub>4</sub>CB[8] (a soluble CB[8] derivative) with 15 guests (selected top drugs, Table 1) by either direct or competition isothermal titration calorimetry (ITC), UV/Vis or fluorescence indicator displacement assay, or NMR competition experiments, as previously [164–166, 181]. Our selection of Me<sub>4</sub>CB[8] binding to top drugs allows us to modulate the computational complexity by: 1) changing host flexibility (e.g. Me<sub>4</sub>CB[8] can exhibit ellipsoidal deformation) [173], 2) allowing the possibility of binary or ternary (e.g. 1:1 and/or 1:2 host:guest) complexes [182–184], 3) using drugs with several potential binding epitopes or modes to induce sampling issues. Host:guest stoichiometry and geometry (e.g., which binding epitope is complexed) will be addressed by ITC  $n$  values, Job plots monitored by UV/Vis or NMR [185], and by <sup>1</sup>H NMR complexation induced changes in chemical shifts [186]. All studies will be conducted in phosphate buffered saline (pH 7.4 with physiological salt) which introduces its own complexities due to salt competition for binding [142, 187]. SAMPL7 will revisit the same host, but use 15 different guests be selected from commercial sources on the basis of reference calculations (on a larger set of guests) to ensure that they cover substantial dynamic range and/or exhibit affinities that depend substantially on the force field or water model, thus effectively testing our force fields and methods. For SAMPL8, we will focus on binding of the same 15 drugs (Table 1), but to glycoluril hexamer. This host introduces the complication of increased conformational dynamics, and influences the number and energy of solvating (and unusually coordinated) water molecules implicated in the high binding constants for CB[n]-guest complexes [171, 188]. The selected drugs include several with  $pK_a$  values in the 3.8 to 7.4 range; given that CB[n]-type receptors (like biomolecular receptors) can induce  $pK_a$  shifts in their guests of up to 4  $pK_a$  units [189–191], this will test how well models can predict these effects. Additionally, it will couple nicely with the focus on  $pK_a$  values in Aim 1. SAMPL9 will revisit glycouril hexamer with the same 15 guests from SAMPL7. SAMPL10 will shift to acyclic CB[n]-type receptors (e.g. M1C<sub>3</sub>, M1C<sub>0</sub>, and M1PC<sub>0</sub>) that contain anionic solubilizing groups attached via different linker lengths. As in SAMPL3 [159], these acyclic CB[n]-type receptors introduce conformational complexity, and water interactions play a key role. Moreover, the presence of 4 anionic groups near the cavity will likely impact the balance between ion-dipole interactions and solvation of the free host.

## Subaim 2.2. Gibb deep cavity cavitands for host-guest studies

**History of GDCC SAMPL challenges.** During SAMPL4 [192] and SAMPL5 [193] we focused on two specific GDCC hosts: the octa-acid 1 (R = H) and another octa-acid variant with four methyl groups at the portal of the binding pocket (1, R = Me). These studies used isothermal titration calorimetry (ITC) to measure the thermodynamics of (1) host 1 (R = H) binding a range of 9 carboxylate guests, and (2) the binding of 6 carboxylate



**Figure 6. Gibb deep cavity cavitands for the SAMPL6-10 datasets (SA 2.2).** These hosts bind a variety of carboxylate and trimethylammonium guests in a strongly salt-dependent manner, providing a stringent test of our ability to model salt-dependent binding.


and trimethylammonium guests to both hosts (**1**, R = H and Me; Figure 6). In both cases  $^1\text{H-NMR}$  titration was also used to confirm ITC-derived free energies of binding. As noted above, co-solvent effects and water rearrangements posed particular challenges for predicting binding in these hosts. SAMPL5 emphasized how differences in the shape of the hydrophobic pocket of the host can have a profound effect on affinity for some guests [129].

**Novel deep cavity hosts probe the effects of binding site charge constellations.** For future GDCC datasets, we will expand on the range of hosts by including **2** and **3** in our ITC studies (Figure 6). Like cavitand **1**, host **2** is an octa-acid derivative. However, the four benzoate groups are relocated from the extreme exterior in the case of **1**, to the rim of the binding pocket in **2**. We surmise that this will have a direct effect on the binding of charged guests as well as an indirect effect on guest complexation via changes to the solvation of the empty host. Octa-trimethylammonium cavitand (“positand” **3**) has the same overall architecture as host **1**, but inverts the charges on the water solubilizing exterior coat. While it is not yet clear if this switch in groups relatively remote from the pocket will directly affect guest complexation, results from related systems suggest it can (unpublished).

**SAMPL6-10 deep cavity cavitand datasets.** Data for SAMPL6 will focus on how well the effect of host carboxylate substituent location can be predicted, and will involve hosts **1** and **2** with a set of five previously uninvestigated guests. Guests will be selected from commercial sources on the basis of reference calculations in a similar manner to SAMPL7 in Subaim 2.1, specifically picking guests which have broad dynamic range and, here, have marked differences in affinities between hosts. SAMPL7 will provide a second iteration of this experiment to test algorithmic improvements in predictive modeling following SAMPL6 by comparing hosts **1** and **3** with a different set of guests. We anticipate that because of the relative remoteness of the charged groups in these two hosts, the effects of switching charges will be subtler than the differences between **1** and **2**. SAMPL8 will consider the effect of common biologically-relevant counterions/salts on guest binding, comparing the effects of NaCl and NaI on the complexation of five guests to **1**. We have previously shown that iodide has a weak affinity for the binding pocket of **1**, while sodium ions have an affinity for the outer carboxylates [194], requiring modeling to capture the differential affinities of these ions in addition to guest affinities to successfully model the observed affinities. SAMPL9 will follow up on this by examining the effects of these same two salts on the complexation of five guests to **3**, again giving the modeling community time to incorporate algorithmic improvements following SAMPL8. While we have not yet quantified salt affinities to host **3**, we expect the iodide to have affinity for both the pocket and the positively charged solubilizing groups. For SAMPL10 we will consider the effects of co-solvents on the binding of five guests to **1** and **2** to probe the effect of co-solvent competition for the binding site, as well as effects co-solvents may have in weakening the hydrophobic effect. While the number of guests considered in each challenge is relatively small, the total number of binding affinities measured is significant across the full family of hosts, meaning that the full data set will be of considerable value as a benchmark set [142].

### Aim 3: Develop model protein-ligand systems that isolate specific modeling challenges of drug targets.

We seek to drive advances in quantitative modeling of protein-ligand interactions. While D3R [120] benchmarks accuracy for targets of pharmaceutical interest, it does not provide a clear route to improving poor performance because the large number complexities exhibited by these targets make it difficult to identify clear points of failure [120, 130–132]. For example, while kinases are targets of great interest to drug discovery, blind challenges involving kinase targets conflate issues of slow protein conformational dynamics [195], protonation state effects of both protein [196] and ligand [197, 198], charged ligands, and the modeling of complex divalent salt environments and phosphorylation state effects along with the standard challenges of conformational sampling and forcefield accuracy. Thus D3R exercises serve the community well to understand current accuracy, but **blind challenges on complex pharmaceutical targets have limited ability to rapidly advance quantitative predictive modeling.**



**Figure 7. The SAMPL6/7 protein-ligand challenge focuses on soluble drug fragment binding to human serum albumin (HSA) (Aim 3).** (A) SAMPL6 will study binding of a library of 96 small soluble druglike fragments to recombinant HSA, with an engineered HSA mutant used for SAMPL7. (B) HSA has at least eight known binding sites, with two major well-characterized sites (green, Sudlow's Site I; purple, Site II) that bind a variety of drugs (figure from [199]). Two fluorescent probes—dansylamide and dansylglycine—bind with  $\sim\mu\text{M}$  affinity and high selectivity to Site I and Site II, respectively; both exhibit binding-enhanced fluorescence at 480 nm, and can be used to site-specifically probe ligand affinities by competition. (C, D) Binding affinities of soluble molecules can be measured by isothermal titration calorimetry (ITC); here, we show the (C) differential power and (D) integrated injection heats for the ITC titration of HSA by naproxen sodium collected using the Chodera lab automation pipeline; (E) HSA tryptophan fluorescence quenching can also be used to measure ligand binding affinity; here, HSA titration by diclofenac is shown, with the inset plot showing percent quenching at 346 nm [200, 201]. (F) Direct fluorescence binding assay of Dansylamide (fluorescent ligand) and HSA collected on the Chodera lab automation system. The binding curve can be constructed based on binding-induced fluorescence emission at 480 nm.

**We take the alternative approach of identifying and developing specific protein-ligand systems which isolate individual accuracy-limiting effects in a series of prospective challenges.** By developing *model binding systems*—real protein-ligand systems that may be of pharmacological interest, but comprised of single-domain proteins binding to a simple ligand series free of complex phenomena—we can study systems of complexity intermediate between completely artificial systems (such as the T4 lysozyme L99A system developed by Shoichet and Matthews [118, 142, 202]) and complex pharmaceutical targets where multiple modeling challenges make it difficult to learn from failure (Figure 8A). This process focuses the field on identifying and evaluating multiple solutions to selected accuracy-limiting effects (such as how to deal with ligand and protein protonation-state issues [203], slow protein conformational dynamics, etc.) while avoiding other complicating factors.

While model systems have had ample success in driving progress in individual research laboratories, community participation in blind challenges amplifies their power. For example, SAMPL3 featured the binding of small, rigid charged molecules to bovine trypsin [204], and rapidly focused the field on the deficiencies of current alchemical free energy methodologies in treating the binding of charged ligands. Within two years, multiple laboratories had developed practical solutions to effectively handle charged ligand binding [205–207].

**SAMPL6-10 model protein-ligand challenges.** We will introduce a new model protein-ligand system each year (revisiting the prior year's system if this becomes too difficult), with multiple challenges on each system (Figure 2) to allow iterative improvement and assessment. Our SAMPL6 data will focus on binding of small soluble drug fragments to one particular protein (below). However, maximizing gains in this area requires adapting subsequent challenges based on deficiencies identified by previous D3R/SAMPL challenges. Therefore, subsequent model systems will be rapidly identified and developed using our new informatics platform (below).

**SAMPL6: Assessing predictive modeling of binding to multiple weak sites via measuring fragment binding to human serum albumin (HSA).** HSA, the most abundant blood plasma protein, has a remarkable ability to bind a great variety of small molecule drugs in multiple binding sites (Figure 7B) [208]. As a result, HSA not only helps isolate the challenge of multiple weak ligands binding to a stable rigid protein, but it is also a pharmacologically relevant because of how it drastically modulates drug pharmacokinetics [199]. HSA has at least *eight* known binding sites, with numerous crystal structures available for drugs binding to two predominant sites (Site I and II) [199]. Small soluble molecules resembling drug fragments are highly likely to bind to HSA ( $\geq 90\%$  of such fragments, as detected by SPR [209]), providing an experimentally-tractable diverse set of ligands spanning several orders of magnitude in affinity [209]. As current advanced methodologies such as alchemical free energy calculations currently assume a single well-defined binding site with high affinity [210], this dataset will allow the


isolation of the effect of weak multiple binding from the majority of other confounding factors in protein-ligand binding. As HSA is relatively rigid, and computational methods already show some promise in computing binding affinities to HSA [199, 211, 212], this is an optimal model system for SAMPL6.

Recombinant HSA will be expressed in *E. coli* and purified via refolding from inclusion bodies [215], then defatted at low pH [216] to ensure the resulting protein is free of the glycosylation and bound fatty acids found in plasma-isolated HSA [216]. Recombinant expression will also allow a mutant form of HSA (engineered via single-primer mutagenesis) to be fielded for SAMPL7 (Figure 7). We will obtain a diverse library of 96 soluble drug-fragment-like molecules in pre-plated format as dry compound, and use our automated isothermal titration calorimetry (ITC) pipeline (Figure 7C,D) to characterize overall binding affinities to HSA. The same ligands pre-plated in DMSO format will be used to conduct a separate set of fluorescence titration assays (monitoring tryptophan fluorescence quenching, Figure 7D) and competition assays with site-specific fluorescent probes (Figure 7B) to resolve site-specific affinities to Sites I and II. We will field several levels of challenges, including challenges focused on affinities to Sites I and II, as well as challenges focused on predicting overall affinity and stoichiometry.

**SAMPL7-10: Rapid development of new tailored model systems using a novel informatics platform.** We are developing a novel informatics platform aimed at identifying protein targets that can be rapidly developed into experimentally- and computationally-tractable model systems focusing on individual challenges (Figure 8). This tool filters all known protein targets with structural data available in the PDB, first selecting for experimental tractability, then annotating experimentally tractable targets to determine which targets possess (or are likely to be free of) specific challenges for physical modeling. This will allow us to select systems which introduce only specific modeling challenges.

The Chodera lab has developed an automated wetlab to facilitate the development of such model protein-ligand systems using bacterial expression (see Equipment and Facilities). Potential targets matching desired challenge criteria will be screened for bacterial expression using high-throughput cloning, transformation, and expression testing, with purity and yield assessed by capillary electrophoresis on a Caliper GXII. Targets will be screened for stability in various buffers using ThermoFluor thermal shift assays [217]. Ligands identified via TargetExplorer as spanning a wide dynamic range of binding affinities will be purchased as dry powder stocks and prepared for assay by highly accurate gravimetric solution preparation techniques using a Quantos automated balance. Our lab has access to a wide variety of biophysical techniques for quantitative measurement of protein-ligand binding affinities, including fluorescence (if fluorescent probe ligands are available), absorption (e.g. Soret band shifts), automated isothermal titration calorimetry (provided ligands are sufficiently soluble), surface plasmon resonance, microscale thermophoresis (MST), luminescence, and alphascreen; all except MST are fully automated.

We take a twofold approach to developing challenge datasets: First, we will purchase and assay small molecules similar to known ligands, presuming that these molecules are likely to have measurable affinities. Second, using single-primer quick-change mutagenesis, we will introduce site-directed mutants to modulate the binding affinities of known ligands. This can be performed and screened for expression in 96-well format. Thus, datasets will consist of a matrix of protein mutants and ligands, providing opportunity to deeply explore the effects of interest.



**Figure 8. Mining model protein-ligand systems to focus on individual modeling challenges via a structural and chemical informatics platform (Aim 3).** We are developing a structural and chemical informatics system called TargetExplorer [<https://github.com/choderalab/targetexplorer>] that applies successive filters to all potential protein-ligand systems for which structural data is available. Suitable model systems should meet all experimental tractability criteria (green box) and possess only a few challenging properties, ideally only one (blue box). Tractability of experimental affinity measurements includes properties like known ligands with potentially fluorescent scaffolds (for fluorescence competition assays), highly soluble ligands (for ITC), or ligands above a minimal mass (for SPR or MST). Additional filters annotate experimentally tractable systems with their potential computational challenges, including charged ligands or potential ligand protonation state or tautomer effects [213] (deduced from predicted aqueous protonation/tautomer energies); potential protein protonation state effects (deduced from MCCE2 calculations [214]); protein conformational changes (deduced from variation in protein conformation or the presence of unresolved loops in protein-ligand crystal structures); the presence of post-translational modifications that may affect affinity (deduced from Uniprot annotations); coordinated metals (identified in crystal structures); and ordered waters (present in multiple crystal structures).

**Aim 4: Field community blind challenges to advance quantitative biomolecular design.** The value of the targeted datasets generated in Aims 1–3 will be amplified enormously by the strategic release of this data through iterative, coordinated SAMPL blind challenges (Figure 2). These blind challenges are designed to test the state of the art, provoke new methodological and force field innovations, allow comparative evaluation of methods, and drive downstream improvements. The new, progressive, targeted nature of the data generated means that SAMPL challenges will now build on one another, and for success in later challenges, participants must build on lessons learned from prior challenges. SAMPL challenges and subsequent data release activities will therefore facilitate rapid cycles of application, learning, and improvement. Each iteration will likely yield its own incremental benefits (e.g., as in Figure 3) for molecular design, in addition to contributing to progress towards our larger goals.

**SAMPL blind challenges.** Challenges will have yearly submission deadlines and involve roughly the same size data sets as prior challenges. The full timeline for SAMPL challenges (Figure 2) will be made available on the website [<https://drugdesigndata.org/about/samp1>] at the outset, allowing participants to plan their work and select what challenges to be involved in. As experimental data for each component becomes available and is curated, input files and challenge details will be made available at least six months prior to the challenge deadline; data not yet available at that time will be held for a subsequent challenge (with the exception of three months for year 1 due to startup timescales). As in prior SAMPLs, submissions will be handled by a web upload service on the SAMPL website (which will be migrated to separate hosting if the D3R effort is not renewed) which validates submissions to ensure that they meet format standards we specify along with the challenge details. As in SAMPL4 and SAMPL5, analysis will also be conducted by our automated Python framework, and results returned automatically online. All participant submissions and methodology descriptions will (as before) be made available publicly on the website, along with participant information (except for participants who specifically request to remain anonymous prior to submission). Aggregate statistics and historical performance will also be made available on our website, along with a record linking publications to historical submissions.

**Our goal is not just to run blind challenges, but to advance modeling by helping participants identify both modeling failures and potential solutions.** To achieve this, we provide guidance to participants as to what known modeling issues we expect may be relevant when providing details on each SAMPL component. For a host-guest system, for example, we might highlight known buffer/salt effects, protonation state challenges, and point out previous work on sampling challenges, with pointers to the relevant experimental work and to modeling work from past SAMPL challenges and elsewhere [142]. This helps participants design their approach. **Additionally, we will run reference calculations using current best practices.** This serves several purposes: It provides a test of the current methods and force fields we select; it helps facilitate learning—we announce what calculations we plan to perform, make input files available in a wide variety of formats [128, 129, 218], and others can repeat our calculations with a different method but same system and force field to compare methods, or swap force field but keep the method and system fixed to compare force fields, etc.; and it allows us to conduct sensitivity analysis, as by varying the conditions of our simulations (protonation state, tautomer, etc., [128]) we can see how much this impacts calculated values and thereby how important it is, even if participants don't do these tests. Reference calculations have, for example, helped us highlight the importance of a small amount of water in cyclohexane for accurately calculating log D values, show how an incorrect tautomer could affect calculated values by many log units [128], and discover that small forcefield modifications could significantly improve results on hydration free energies [126]. To further aid follow-up studies, we will make the input files, results, and simulation workflows used for our reference calculations—along with the data—available via GitHub and Docker Hub.

Physical methods are only valuable if they can reliably outperform alternate methods, so **a new focus of SAMPL6–10 will be selecting quality null models and running them to provide a point of comparison for participants**, going far beyond previous SAMPL nulls [127, 128, 137]).

Following submission and analysis of each SAMPL challenge, challenge results will be released and discussed, with SAMPL workshops allowing more formal presentations on and discussion of results in years 1, 3, and 5. Workshops will run every two years at the request of past participants, and will be co-run and co-hosted with D3R Grand Challenge workshops (see support letter). During the off years, SAMPL challenges will still run, but discussion of and dissemination of results will be via asynchronous means (as discussed below) and a “virtual workshop” consisting of talks and interaction over Google Hangouts or YouTube Live. While coordination with D3R will mostly be at the level of workshops, we will also ensure that SAMPL challenge submission deadlines are offset from D3R deadlines to allow maximum community participation in both efforts. If the D3R effort is not renewed beyond its current funding cycle, we will run SAMPL workshops independently, controlling costs via the model we use for our Workshops on Free Energy Methods in Drug Design—specifically, most participants will pay their own way to the workshop, and we will seek pharmaceutical and software industry sponsorships to defray costs.

**Dissemination of results and data.** Rapid dissemination of results is critical so that new insights can be used in subsequent challenges. We will continue to publish special issues of the *Journal of Computer Aided Molecular Design* (JCAMD) collecting publications related to each year's SAMPL challenges (see Letter of Support). To ensure immediate availability of reports, we will strongly encourage prepublication sharing of results and analysis, including both slides and posters from SAMPL meetings (via F1000 Research) and paper preprints (via bioRxiv). We also want to ensure that participants learn from one another by rapid exchange of ideas outside of formal workshops and meetings. While this has happened in the past—for example, when participants using similar methods work together after the SAMPL meeting to identify the origin of these discrepancies [129, 142, 160, 219, 220]—we hope to accelerate this kind of collaboration. To facilitate more open communication between the community, we will use collaboration software—such as Slack, which facilitates scientific communication for the NASA/JPL Mars Rover teams and NSF antarctic scientific research teams—to build a community discussion platform, facilitating a process of learning from one another more rapidly than normal publication channels.

**Each dataset will have a life cycle of collection, curation, blind challenges, and public dissemination.** In the past, the unfunded nature of SAMPL has forced us to primarily emphasize the *blind challenges* and pre-challenge *curation* aspects, with isolated forays into collection [156, 204]. This work now considers the full life cycle, with Aims 1–3 dealing primarily with collection and pre-challenge curation. Post-challenge, datasets will receive additional curation, then be released as standard test or benchmark sets that allow retrospective evaluation of methodologies on high-quality data [142]. The FreeSolv dataset, for example, includes a large number of calculated and experimental hydration free energies from SAMPL0–4, and provides a standard benchmark dataset for hydration free energy calculations [221]. Post-challenge curation will receive new attention here; in the past, lack of resources has always prevented follow-up experimental work, even when the data clearly indicated it was warranted (such as the puzzling issues with dynamic range for log D values in SAMPL5 [128, 156]). The requested budget will allow follow up experiments motivated by computation when warranted. Dissemination is the final stage in the data life cycle (see Resource Sharing Plan); we will make the data (including primary data, processed data, and our analysis of challenge submissions) available freely and publicly with permanent, citeable DOIs; ensure relevant data is deposited in standard community repositories (e.g. BindingDB [222]); and guarantee data longevity via backup hosting on library archival facilities (such as the UC's DASH (<https://dash.cdlib.org/>)).

We will also push for containerization of tools and methods in conjunction with other efforts such as AutoDesks's Molecular Design Toolkit and the NSF Molecular Sciences (MolSci) initiative. Our vision is that long-term, instead of participants submitting a set of predictions, they would also submit the entire workflow they applied via Docker containers allowing reproducibility and repurposing, ensuring dissemination workflows, not just results.

## COLLABORATION MANAGEMENT PLAN

We have a strong previous history of successful collaboration, with Mobley and Chodera having co-authored roughly a dozen publications and organized several workshops and other initiatives. Mobley, Isaacs, and Gibb have also worked together to coordinate past SAMPL challenges, and Mobley and Gibb a previous NSF workshop. PI Mobley will oversee the project, with teams for the other aims (Aim 1: Mobley & Chodera; Aim 2.1: Isaacs; Aim 2.2: Gibb; Aim 3: Chodera; Aim 4: Mobley & Chodera) involving the other co-investigators as needed. Meetings will consist of a monthly Google Hangout and a yearly in-person planning meeting. Chodera and Mobley will communicate more frequently due to the interlinked nature of their work. Publications are expected to be largely dictated by the overall Timeline, with an experimental publication associated with each challenge component being prepared for distribution to participants along with their results. Conflict resolution is expected to be straightforward, but if any serious difficulties arise, Michael Gilson (UCSD) will arbitrate given our close connections with D3R.

## OUTLOOK

Physical methods have been slow to achieve their promise in binding prediction, in part because truly significant innovations are so hard to recognize due to a lack of standard tests and benchmarks, and in part because of an “applications first” approach which seems to plague our community where we rush to apply our methods to problems of pharmaceutical relevance without ensuring they can tackle simpler, better-understood problems first. Here, we propose an innovative extension of the successful series of SAMPL blind challenges, generating novel experimental data to drive improvement of the methods in our field and help them become pharmaceutically relevant – beginning with relatively simple physical property prediction and progressing to challenging problems in biomolecular recognition via a series of carefully designed intermediate steps. SAMPL already has a strong track record of success, and funding will ensure dramatically increased impact and continued success. The proposed series of carefully tailored challenges will focus our community on a variety of problems which we can realistically resolve in the near term, resulting in dramatic improvements in computational molecular design.

# Subrecipient Statement of Collaborative Intent

## Part I: To be completed by all subrecipients/subcontractors

All subrecipients as well as potential subcontractors who anticipate funding under a federal or non-federal "contract" must complete this form when submitting a proposal to UCI. It provides a checklist of documents and certifications required by prime sponsors and it must be endorsed by the subrecipient's authorized institutional representative prior to proposal submission.

### SUBRECIPIENT INFORMATION

Legal Name: University of Maryland  
Address: Room 3112 Lee Building; 7809 Regents Drive; College Park, MD 20742-5141  
DUNS #: 790934285

Subrecipient PI: Lyle D. Isaacs  
Address: 3341 Chemistry Building; 8051 Regents Dr., College Park, MD 20742-2021  
Email: lisaacs@umd.edu

Authorized Official Name: Katie McKeon  
Address: Room 3112 Lee Building; 7809 Regents Drive; College Park, MD 20742-5141  
Email: oraa@umd.edu

Administrative Contact Name: Cory M. Whitman  
Address: Room 3112 Lee Building; 7809 Regents Drive; College Park, MD 20742-5141  
Email: cwhitma1@umd.edu

### SUBRECIPIENT PROJECT INFORMATION

UCI PI: David Mobley  
Prime Sponsor: NIH

Project Title: Advancing predictive physical modeling through focused development of model systems to drive new modeling innovations  
Total Proposed Amount: \$282,287.84  
Project Period: 04/01/2017 - 03/31/2022

### PROPOSAL DOCUMENTS

The following document are included in our subaward proposal and covered by the certifications below:

- Scope of Work (Required)  
 Budget and Justification (Required)  
 Biosketches
- Cost Sharing Amount (if applicable):  
 Other: Click here to enter text.

### CERTIFICATIONS

Documentation of Subrecipient's approval(s) may be required

#### Subrecipient's Scope of Work Includes:

Human Subjects

If human subjects are involved, have all key personnel completed human subjects training?  Yes  No

Vertebrate Animals

Stem Cells

Recombinant DNA

Dual Use Research of Concern (DURC)

For applicability, please refer to <http://www.phe.gov/s3/dualuse/Documents/durc-policy.pdf>

Large Scale Human or Non-Human Genomic Data (if NIH)

For applicability, please refer to policy at <https://qds.nih.gov/03policy2.html>. Documentation of an approved consent form and Institutional Certification will be required prior to the award, at the "Just in Time" stage.

### SUBRECIPIENT VS. CONTRACTOR DETERMINATION

Check all that apply:

#### Subrecipient

- Performance represents an intellectually significant portion of the overall programmatic effort and is measured against the objectives of the program  
 Will use the funds to carry out a program for a public purpose, as opposed to providing goods or services for the benefit of UCI  
 Is responsible for adhering to applicable program requirements specified in the prime award  
 There is an identified principal investigator for the subrecipient who has responsibility for making programmatic decisions

For the purpose of this proposal, my organization is properly categorized as (check one):  subrecipient  subcontractor as described above.

#### Contractor

- Provides goods or services that are ancillary to the operation of the program identified in the prime award  
 Provides the goods or services purchased with the funds within normal business operations  
 Provides similar goods or services to many different purchasers  
 Is not subject to the compliance requirements of the program as a result of the agreement with UCI  
 Normally operates in a competitive environment

By signing below, I certify that I am the authorized institutional representative and the information and representations made herein are true and accurate. The appropriate programmatic and administrative personnel involved in this application are aware of agency policies in regard to subawards and are prepared to establish the necessary inter-institutional agreements consistent with those policies. Any work begun and/or expenses incurred prior to execution of a subaward agreement are at the subrecipient's own risk.

  
Signature of Subrecipient's Authorized Institutional Official

Takeia M. Bradley, Contract Manager -ORA

Name and Title of Subrecipient's Authorized Institutional Official


# Subrecipient Statement of Collaborative Intent

## Part I: To be completed by all subrecipients/subcontractors

All subrecipients as well as potential subcontractors who anticipate funding under a federal or non-federal "contract" must complete this form when submitting a proposal to UCI. It provides a checklist of documents and certifications required by prime sponsors and it must be endorsed by the subrecipient's authorized institutional representative prior to proposal submission.

<b>SUBRECIPIENT INFORMATION</b>	
Legal Name: The Administrators of the Tulane Educational Fund Address: 6823 St. Charles Ave, New Orleans, LA 70118-5665 DUNS #: 053785812 Subrecipient PI: Bruce Gibb Address: 6823 St. Charles Ave, New Orleans, LA 70118-5665 Email: bgibb@tulane.edu	Authorized Official Name: Norey B. Laug Address: 7029 A Freret Street, New Orleans, LA 70118 Email: norey@tulane.edu Financial Contact Name: Tanya O'Rourke Address: 800 E. Commerce Rd., Suite 203, Harahan, LA 70123 Email: tsteven@tulane.edu
<b>SUBRECIPIENT PROJECT INFORMATION</b>	
UCI PI: David Mobley Prime Sponsor: National Institute of Health (NIH)	Project Title: Advancing predictive physical modeling through focused development of model systems to drive new modeling innovations Total Proposed Amount: \$139,888 Project Period: 07/01/17-06/30/22
<b>PROPOSAL DOCUMENTS</b>	
The following document are included in our subaward proposal and covered by the certifications below:	
<input checked="" type="checkbox"/> Scope of Work (Required) <input checked="" type="checkbox"/> Budget and Justification (Required) <input checked="" type="checkbox"/> Biosketches	<input type="checkbox"/> Cost Sharing Amount (if applicable): <input type="checkbox"/> Other: Click here to enter text.
<b>CERTIFICATIONS</b>	
Documentation of Subrecipient's approval(s) may be required	
Subrecipient's Scope of Work Includes: <input type="checkbox"/> Human Subjects If human subjects are involved, have all key personnel completed human subjects training? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Vertebrate Animals <input type="checkbox"/> Stem Cells <input type="checkbox"/> Recombinant DNA	<input type="checkbox"/> Dual Use Research of Concern (DURC) For applicability, please refer to <a href="http://www.phe.gov/s3/dualuse/Documents/durc-policy.pdf">http://www.phe.gov/s3/dualuse/Documents/durc-policy.pdf</a> <input type="checkbox"/> Large Scale Human or Non-Human Genomic Data (if NIH) For applicability, please refer to policy at <a href="https://qds.nih.gov/03policy2.html">https://qds.nih.gov/03policy2.html</a> . Documentation of an approved consent form and Institutional Certification will be required prior to the award, at the "Just in Time" stage.
<b>SUBRECIPIENT VS. CONTRACTOR DETERMINATION</b>	
Check all that apply:	
<b>Subrecipient</b>	<b>Contractor</b>
<input checked="" type="checkbox"/> Performance represents an intellectually significant portion of the overall programmatic effort and is measured against the objectives of the program <input checked="" type="checkbox"/> Will use the funds to carry out a program for a public purpose, as opposed to providing goods or services for the benefit of UCI <input checked="" type="checkbox"/> Is responsible for adhering to applicable program requirements specified in the prime award <input checked="" type="checkbox"/> There is an identified principal investigator for the subrecipient who has responsibility for making programmatic decisions	<input type="checkbox"/> Provides goods or services that are ancillary to the operation of the program identified in the prime award <input type="checkbox"/> Provides the goods or services purchased with the funds within normal business operations <input type="checkbox"/> Provides similar goods or services to many different purchasers <input type="checkbox"/> Is not subject to the compliance requirements of the program as a result of the agreement with UCI <input type="checkbox"/> Normally operates in a competitive environment
For the purpose of this proposal, my organization is properly categorized as (check one): <input type="checkbox"/> subrecipient <input checked="" type="checkbox"/> subcontractor as described above.	

By signing below, I certify that I am the authorized institutional representative and the information and representations made herein are true and accurate. The appropriate programmatic and administrative personnel involved in this application are aware of agency policies in regard to subawards and are prepared to establish the necessary inter-institutional agreements consistent with those policies. Any work begun and/or expenses incurred prior to execution of a subaward agreement are at the subrecipient's own risk.

  
Signature of Subrecipient's Authorized Institutional Official  
Date: 8/16/16

Norey B. Laug  
Associate Director  
Sponsored Projects Administration

Name and Title of Subrecipient's Authorized Institutional Official

## **Subrecipient Statement of Collaborative Intent**

**Part I: To be completed by all subrecipients/subcontractors**

All subrecipients as well as potential subcontractors who anticipate funding under a federal or non-federal "contract" must complete this form when submitting a proposal to UCI. It provides a checklist of documents and certifications required by prime sponsors and it must be endorsed by the subrecipient's authorized institutional representative prior to proposal submission.

<b>SUBRECIPIENT INFORMATION</b>	
Legal Name: Sloan Kettering Institute for Cancer Research Address: 1275 York Avenue New York, NY 10065-6007 DUNS #: 064931884	Authorized Official Name: Annmarie L. Pacchia, PhD Address: 1275 York Avenue New York, NY 10065-6007 Email: sponsor@mskcc.org
Subrecipient PI: Dr. John Chodera Address: 1275 York Avenue New York, NY 10065-6007 Email: john.chodera@choderlab.org	Financial Contact Name: Annmarie L. Pacchia, PhD Address: 1275 York Avenue New York, NY 10065-6007 Email: sponsor@mskcc.org
<b>SUBRECIPIENT PROJECT INFORMATION</b>	
UCI PI: Dr. David Mobley Prime Sponsor: University of California, Irvine	Project Title: Advancing predictive physical modeling through... Total Proposed Amount: \$864,703 Project Period: 7/1/17-6/30/22
<b>PROPOSAL DOCUMENTS</b>	
The following document are included in our subaward proposal and covered by the certifications below:	
<input checked="" type="checkbox"/> Scope of Work (Required)	<input type="checkbox"/> Cost Sharing Amount (If applicable):
<input checked="" type="checkbox"/> Budget and Justification (Required)	<input type="checkbox"/> Other: Click here to enter text.
<input checked="" type="checkbox"/> BlockSketches	
<b>CERTIFICATIONS</b>	
<i>Documentation of Subrecipient's approval(s) may be required</i>	
Subrecipient's Scope of Work Includes:	<input type="checkbox"/> Dual Use Research of Concern (DURC) For applicability, please refer to <a href="http://www.phe.gov/s3/dualuse/Documents/durc-policy.pdf">http://www.phe.gov/s3/dualuse/Documents/durc-policy.pdf</a>
<input type="checkbox"/> Human Subjects	<input type="checkbox"/> Large Scale Human or Non-Human Genomic Data (If NIH) For applicability, please refer to policy at <a href="https://qds.nih.gov/03policy2.html">https://qds.nih.gov/03policy2.html</a> . Documentation of an approved consent form and Institutional Certification will be required prior to the award, at the "Just in Time" stage.
If human subjects are involved, have all key personnel completed human subjects training? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
<input type="checkbox"/> Vertebrate Animals	
<input type="checkbox"/> Stem Cells	
<input checked="" type="checkbox"/> Recombinant DNA	
<b>SUBRECIPIENT VS. CONTRACTOR DETERMINATION</b>	
Check all that apply:	
<b>Subrecipient</b>	<b>Contractor</b>
<input checked="" type="checkbox"/> Performance represents an intellectually significant portion of the overall programmatic effort and is measured against the objectives of the program	<input type="checkbox"/> Provides goods or services that are ancillary to the operation of the program identified in the prime award
<input checked="" type="checkbox"/> Will use the funds to carry out a program for a public purpose, as opposed to providing goods or services for the benefit of UCI	<input type="checkbox"/> Provides the goods or services purchased with the funds within normal business operations
<input checked="" type="checkbox"/> Is responsible for adhering to applicable program requirements specified in the prime award	<input type="checkbox"/> Provides similar goods or services to many different purchasers
<input checked="" type="checkbox"/> There is an identified principal investigator for the subrecipient who has responsibility for making programmatic decisions	<input type="checkbox"/> Is not subject to the compliance requirements of the program as a result of the agreement with UCI
For the purpose of this proposal, my organization is properly categorized as (check one): <input type="checkbox"/> subrecipient <input type="checkbox"/> subcontractor as described above.	

By signing below, I certify that I am the authorized institutional representative and the information and representations made herein are true and accurate. The appropriate programmatic and administrative personnel involved in this application are aware of agency policies in regard to subawards and are prepared to establish the necessary inter-institutional agreements consistent with those policies. Any work begun and/or expenses incurred prior to execution of a subaward agreement are at the subrecipient's own risk.

1 Jason St. Germain

## Director

**Signature of Subrecipient's Authorized Institutional Official  
Grants & Contracts, ORPA**

Date:

91916

Annmarie L. Pacchla, PhD, Vice President, ORPA

**Name and Title of Subrecipient's Authorized Institutional Official**

# Genentech

A Member of the Roche Group

September 7, 2016

Dear Dr. Mobley and Dr. Chodera,

Genentech is a large pharmaceutical company with interests in a wide range of disease areas. Daniel Ortwine is an experienced computational chemist in the Computational Drug Discovery Group within the Chemistry Department at Genentech, and Baiwei Lin works in our Analytical Chemistry group, specializing in measuring physiochemical properties such as aqueous solubility, pKa, and LogD.

We are very excited to be involved in your proposal, "Advancing predictive physical modeling through focused development of model systems to drive new modeling innovations." As you may be aware, we believe physical modeling is poised to have a real impact on the pharmaceutical drug discovery process, but we also believe there are key challenges the field still needs to resolve to achieve this. The work you propose is absolutely vital to facilitate the necessary advancements.

This letter is to confirm that we are willing to host a student who will help collect experimental data to enable new SAMPL physical property prediction challenges to drive the improvement of these methods. We can provide access to equipment necessary for measuring physical properties that are not typically available to academic laboratories, such as the Sirius T3 (for measurement of pKa, logD, and logS), high-throughput automated shake-flask measurements of logD and logP, and automated membrane permeability assays for compounds available from commercial vendors. We have multiple mechanisms available through which these measurements can be performed. Possibilities include sending a student from your laboratories to perform measurements at Genentech as a visiting scientist, and/or sending a student to us as part of our summer internship program. The latter possibility includes a stipend for focused measurement projects like these.

As you are of course aware, we were already able to do something very similar to this for the SAMPL5 challenge, where – via a summer internship program – we hosted Bas Rustenberg, a student from John Chodera's lab, who measured water-cyclohexane log D values which formed half of the SAMPL5 challenge. We believe we will be able to similarly host academic researchers to help generate data for future SAMPL challenges.

Sincerely,



Daniel Ortwine  
Principal Scientist  
Computational Chemistry



Baiwei Lin  
Scientist  
Analytical Chemistry



September 19, 2016

Dear Drs. Mobley and Chodera:

We write to confirm our enthusiastic support of your proposal, "Advancing predictive physical modeling through focused development of model systems to drive new modeling innovations", and to confirm our willingness to collaborate on the blind challenges you propose.

As Co-Directors of the NIH-funded Drug Design Data Resource (D3R), we work with the pharmaceutical industry and academic labs to obtain high-quality protein-ligand binding data, and we use these data as the basis for blinded prediction challenges that test and drive improvement in methods for pose prediction and affinity calculation. These challenges are informative, as they test the full computational workflow, including preparation of the protein and ligand structures, assignment of protonation states, assignment of force field parameters, and conformational searching and sampling. By the same token, however, they are limited in their ability to assess which aspect of the calculations are the most in need of improvement. Your plan to develop new datasets for simple, model systems, and to use them to continue the SAMPL series of blinded prediction challenges, is strongly complementary to the D3R effort, as the simpler systems can probe specific aspects of the calculations with considerable precision.


Indeed, our efforts are already strongly aligned. Thus, as you know, in 2015-2016, the D3R helped organize the SAMPL5 challenge by coordinating submission of blind predictions for both SAMPL and D3R challenges, and by integrating presentation and discussion of SAMPL and D3R challenges in the March 2016 workshop we held at UC San Diego. The workshop was a tremendous success, as documented by the anonymous post-meeting survey, and it was clear that the SAMPL challenge played an important role in what was learned.

Thus, we are enthusiastic about continuing to cooperate and coordinate, in order to minimize duplication of effort and maximize value to the computational chemistry community. In particular, we look forward to

- co-organizing and co-hosting workshops and webinars centered on SAMPL and D3R challenges
- handling submissions for the SAMPL challenges
- advertising SAMPL challenges by the same channels (e.g., email lists and Twitter) used for D3R
- work together on the science so that the SAMPL and D3R together advance the technology of computer-aided drug design to the maximum possible extent

We wish you the best of luck with your proposal!

Sincerely yours,



Rommie E. Amaro, Ph.D.

Professor and Shuler Scholar, Department of Chemistry and Biochemistry  
Director, National Biomedical Computation Resource  
Co-Director, Drug Design Data Resource



Michael K. Gilson, M.D., Ph.D.

Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences  
Chair in Computer-Aided Drug Design  
Co-Director of the Center for Drug Discovery Innovation  
Co-Director of D3R

# Science for Solutions, LLC

6211 Kaitlyn Court, West Windsor, NJ 08550

Ph & Fx: (609)275-7234

Terry Richard Stouch, PhD, President

tstouch@gmail.com

18 September 2016

David Mobley  
Department of Pharmaceutical Sciences  
147 Bison Modular  
University of California, Irvine  
Irvine, CA 92697

John Chodera  
Assistant Member  
Memorial Sloan-Kettering Cancer Center  
1275 York Ave., Box 357  
New York, NY 10065

Dear Professors Mobley and Chodera:

I'm writing as Senior Editor-in-Chief of the *Journal of Computer Aided Molecular Design* (JCAMD) to express my continued enthusiasm for the SAMPL blind prediction challenge and my support for your plans to continue and expand the challenge via the proposed work, "Advancing predictive physical modeling through focused development of model systems to drive new modeling innovations." Previous SAMPL challenges have provided real benefit to the physical modeling community and have taught us a great deal of relevance to methods for predicting protein-ligand binding, as evidenced by the ongoing interest of pharmaceutical companies in these events. I am convinced your proposed work will do the same.

As you are aware, JCAMD has in the past supported the most recent 4 of the 5 SAMPL challenges by publishing special issues which focus on each iteration and the results of the challenge. For example, we are currently completing construction of the SAMPL5 special issue. Also, as long as SAMPL challenges continue to provide such important insight, this letter also serves to express my willingness to continue to publish SAMPL special issues. Participants would, as they have in the past, submit their papers by a specified deadline timely to the presentation of the results of the Challenge, and we would coordinate reviews and then publication in JCAMD, assuming the work is technically sound.

Previous JCAMD special issues on SAMPL have been well received, well cited, and a substantial service to the field. As one indication, the top ten SAMPL publications have already all been cited more than 50 and as many as over 80 times, per Google Scholar.

I look forward to our continuing our collaboration on the SAMPL challenges.

Sincerely,



Terry Richard Stouch, PhD  
Senior Editor-in-Chief, Journal of Computer-Aided Molecular Design, Springer Publishing  
President, Science for Solutions, LLC  
Consulting: Pharmaceutical Research: Drug Design, Discovery, Technologies, Process, Due Diligence; Computational Sciences; Chemistry, Biochemistry, Biophysics  
American Chemical Society, Division of Computers in Chemistry, past Chair  
University of Maryland, Baltimore, Affiliate Professor, Department of Pharmaceutical Sciences  
Duquesne University, Adjunct Professor Department of Chemistry and Biochemistry, Bayer School of Natural and Environmental Sciences  
American Association for the Advancement of Science (AAAS), Fellow  
International Union of Pure and Applied Chemistry (IUPAC), Fellow



Stouch

Page 1 of 1



2015 Galloping Hill Road  
Kenilworth, NJ 07033

Dear Drs Mobley and Chodera

As you are aware, Tim Rhodes coordinates a group performing routine and in-depth measurements of physical properties, while Brad Sherborne coordinates computational chemistry support for Merck in New Jersey.

We are happy to support your proposal, "Advancing predictive physical modeling through focused development of model systems to drive new modeling innovations", as we believe that physical modeling can continue to increase its impact on pharmaceutical drug discovery and development with based on more fundamental data and benchmarks.

Herein we confirm that we would be willing to host a student from one of your labs to be collecting experimental data that would form the basis of new SAMPL physical property prediction challenges, and would provide access to the required equipment to make those measurements such as Sirius T3 (for pKa, logD and logS), automated shake-flaks measurements of logD, automated membrane permeability assays on commercially available compounds.

Yours sincerely

Tim Rhodes

A handwritten signature in black ink that appears to read "Tim Rhodes".

Brad Sherborne

A handwritten signature in black ink that appears to read "Brad Sherborne".



Pfizer Worldwide Research and  
Development  
Neuroscience Chemistry  
610 Main Street  
Cambridge, MA 02139

---

**Worldwide Research & Development**

September 19, 2016

David Mobley  
Associate Professor  
Department of Pharmaceutical Sciences  
Department of Chemistry  
3134B Natural Sciences I  
University of California, Irvine  
Irvine, CA 92697

Dear Dr. Mobley and Dr. Chodera,

We are very excited to be involved in your proposal, "Advancing predictive physical modeling through focused development of model systems to drive new modeling innovations." As you may be aware, we believe physical modeling is poised to have a real impact on the pharmaceutical drug discovery process, but we also believe there are key challenges remaining to be resolved before it can have the impact it might.

This letter is to confirm that we would like to be involved with facilitating the collection of experimental data to facilitate new SAMPL physical property prediction challenges to drive the improvement of these methods. We expect our involvement will at least involve providing access to equipment you need to measure physical properties, such as our multiplexed capillary electrophoresis measurement of pKa (Shalaeva, J Pharm Sci. 2008;97(7):2581), our RP-HPLC method for measuring partition coefficients (J Med Chem. 2000 Jul 27;43(15):2922-8.), or our method for measuring membrane permeabilities (J Pharm Sci. 2011 Nov;100(11):4974-85) for SAMPL challenges along with help on how to perform these measurements effectively. It is also possible we will be able to facilitate an internship to provide someone who could actually perform the measurements. Otherwise, you would need to provide personnel who would come here and work with us to perform the measurements.

We have seen this model work previously at Genentech for measurement of water-cyclohexane log D values for the SAMPL5 challenge, and we believe a similar model will work well here as well, so we are confident we will be able to support your proposal and future SAMPL challenges in this way.

Very truly yours,

Dr. Xinjun Hou  
Director, Neuroscience and Pain Medicinal Chemistry



Memorial Sloan-Kettering  
Cancer Center

**Dr. John Chodera**  
Assistant Member  
Computational Biology Center  
Sloan-Kettering Institute

18 Sep 2016

To:

**Dr. David L. Mobley**  
**Associate Professor, Department of Pharmaceutical Sciences**  
**University of California, Irvine**

Dear David,

I am writing to express my enthusiastic support for our proposal to utilize blind challenges to drive advancements in quantitative predictive modeling.

As you know, our laboratories have a long history of productive collaboration, and you and I have coauthored 11 publications over the past decade. We have both also been involved in organizing or participating in the SAMPL blind community challenges since their inception in 2007. In the work described in this proposal, we will go far beyond these previous iterations of SAMPL by designing experiments from the very start that focus on current challenges to quantitative physical modeling, rather than primarily reusing datasets that have been collected for different purposes. In this way, we will be able to rapidly drive the community toward solutions in modeling physical effects and significant improvements in accuracy in a manner that has otherwise not been possible.

Our laboratories will share responsibilities for the formation, management, supervision, and execution of industry-academic collaborations to collect physical property datasets in **Aim 1** for use in blind challenges. This model worked very well for the recent SAMPL5 challenge, where a graduate student from my laboratory spent 10 weeks during the summer at Genentech to collect a new experimental dataset of small molecule cyclohexane-water partition coefficients that were used in a blind challenge in which numerous research groups participated, revealing both successes and deficiencies in current approaches to modelign small molecule protonation states, tautomers, and interactions with aqueous and nonpolar environments. Given the high amount of industry support expressed for this project, I expect this Aim to be highly successful with both of our laboratories participating in colloborative partnerships for physical property data collection. Our laboratories will also share the responsibility for the analysis and curation of this data, drawing on our considerable combined expertise in physical property measurement and calculation.

My laboratory will be primarily responsible for the execution of **Aim 3**, in which we will identify and develop new protein:ligand model systems that focus on specific challenges in current predictive physical modeling of small molecule interactions with biomolecular targets. In order to be able to rapidly field timely challenges that address current accuracy-limiting issues, we will develop a novel structural, chemical, and bioinformatics platform for the rapid identification of useful model protein:ligand systems. We fully intend to again draw on our combined expertise regarding the selection of appropriate systems. We will make use of our newly-built automated wetlab facilities to screen these model systems for useful expression, and will automate the collection of high-quality experimental affinity data using the multitude of automated biophysical methods at our disposal (fluorescence, absorbance, ITC, and SPR).

Our laboratories will jointly coordinate, run, and analyze results from blind challenges described in **Aim 4** as future iterations of SAMPL. In addition, our laboratories will share responsibility for performing the reference calculations to accompany these simulations, which makes use of our again considerable combined expertise in both physical property and protein:ligand binding affinity calculation.

This project has the potential to greatly accelerate rate at which quantitative physical modeling makes advances in accuracy, reliability, and expansion of its domain of applicability, all of which will greatly increase the utility and adoption of these techniques throughout academia and industry and aid numerous researchers in their pursuit of rational small molecule ligand design. I very much look forward to continuing our productive collaboration in this regard.

Sincerely,

A handwritten signature in black ink that reads "John D. Chodera". The signature is fluid and cursive, with "John" and "D." being more stylized and "Chodera" being more clearly legible.

John D. Chodera

Assistant Member, Computational Biology Program  
Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center

Assistant Professor of Physiology, Biophysics and Systems Biology Program  
Weill Cornell Graduate School of Medical Sciences

Phone: 646.888.3400  
Email: [john.chodera@choderelab.org](mailto:john.chodera@choderelab.org)

## RESOURCES SHARING PLAN

Aims 1-3 of this work focus on generating reference data tailored for a specific purpose – SAMPL blind prediction challenges. We envision this data going through a life cycle of collection, curation, use in blind challenges, publication, and then post-challenge use as reference data and as part of benchmark sets. Sharing of this data will be particularly vital post-challenge. Additionally, Aim 4 focuses on running blind challenges and reference calculations, which will generate data of a different sort – how different methods perform in these blind prediction challenges, and how they stack up against other methods. Again, dissemination of this data is particularly key.

We plan to make all data collected, including all primary data, available through timely publications. Additionally, we plan to archive all experimental data in easily-accessible machine-readable formats for perpetuity. To ensure broadest dissemination, several different resources will be used. Binding data will be archived in BindingDB, and all data cross-posted or linked to from Alchemy.org. All data will also be posted on the D3R website because of its connection with the SAMPL challenges.

Some specific types of data or products are worth separate attention:

**Software.** All computer software developed for this project will be made freely available through free (libre) open source software licenses (such as LGPL) on online collaborative public code repositories such as GitHub [<http://github.com>], where codes produced by the Mobley and Chodera laboratories are currently hosted [<http://github.com/choderalab/> and <http://github.com/mobleylab/>].

**Experimental datasets.** All experimental data and results will be shared, when practical, through the D3R website, through BindingDB (for binding data) and through online repositories such as GitHub [<http://github.com>], Dryad [<http://datadryad.org/>], FigShare [<http://figshare.com>], and our group websites [<http://www.choderalab.org/data/> and <http://www.mobleylab.org/>]. Primary data will also be provided to the extent possible.

**Simulation datasets.** All simulation and model datasets will be shared, when practical, through the online repositories such as GitHub [<http://github.com>], Dryad [<http://datadryad.org/>], FigShare [<http://figshare.com>], and our group websites [<http://www.choderalab.org/data/> and <http://www.mobleylab.org/>].

**Data on SAMPL results.** Aim 4 involves collection of blind predictions from participants in the SAMPL challenge and analysis of these results. Results will be analyzed and published, with the full set of predictions, method descriptions, and their analysis made available (a) in the supporting information and (b) via a separate GitHub repository; and (c) via the D3R website.

**Simulation protocols, best practices, and benchmark sets.** We will continue to actively support and help maintain the online repository of simulation protocols, best practices, and references for alchemical free energy calculations at the community site alchemy.org. SAMPL challenge results will also contribute to the development of future benchmark systems which will be discussed at <http://github.com/mobleylab/benchmarkssets> and linked to from there.

**Experimental protocols.** In addition to publishing detailed accounts in papers, all experimental protocols for Aims 1 and 3 will be made available online on our group website(s) [<http://choderalab.org> and <http://mobleylab.org>].

**3D printable laboratory parts.** Numerous useful 3D printed parts are fabricated in the Chodera laboratory to aid in our research projects. Electronic printable versions of these parts are made available on both the group website [<http://www.choderalab.org/3dparts/>] and the NIH 3D Print Exchange [<http://3dprint.nih.gov>].

## AUTHENTICATION OF KEY RESOURCES PLAN

### BIOLOGICAL RESOURCES

**Plasmid constructs.** The sequence of engineered plasmid constructs of model proteins received or generated will be authenticated by antibiotic resistance marker and DNA sequencing of inserts in the cloning sites against canonical sequences in UniProt.

**Bacterial cell lines** for expression of recombinant proteins and for molecular biology will be authenticated by their antibiotics profile and their genotype.

### CHEMICAL RESOURCES

**Small molecules (Chodera lab).** Small molecules will be obtained from commercial sources. These compounds will be characterized by HPLC-MS and  $^1\text{H}$ -NMR to verify their identity and purity as appropriate. NMR spectra will be provided as supplementary material for reference.

**Small molecules (Gibb lab).** The purity of purchased speciality chemicals and substrates will be verified primarily by  $^1\text{H}$  NMR and chromatography. Log book notes for individual procedures will include the batch number and stated purity (and if needed, the determined purity) of each reagent utilized.

**Small molecules (Isaacs lab).** Work performed in the Isaacs laboratory will utilize CB[n]-type container compounds that were previously reported along with drug molecules as guests that are commercially available. We will use the published literature procedures to resynthesize the needed container compounds and use spectroscopic methods to verify their identity and purity. Similarly, drug molecules as guest will be verified for identity and purity by analysis of their NMR spectra which will be deposited in the supporting information of the corresponding publications. Samples of all compounds synthesized under this grant will be retained in the Isaacs laboratory at the University of Maryland and will be made available to researchers upon request. Such requests will need to be made to the University of Maryland Office of Technology Commercialization which will execute a standard material transfer agreement with the requestor.

**Recombinantly expressed proteins.** Recombinant proteins will either be produced in-house or obtained from commercial sources. The molecular weight, concentration, and purity of purified His-tagged recombinantly expressed proteins will be verified using a Caliper GXII microfluidic gel electrophoresis instrument. ThermoFluor melts (thermal denaturation scans in the presence of Cypro Orange, a dye that changes fluorescence upon binding to unfolded proteins) performed using a Roche LC480 qPCR machine will be used to verify protein stability in our buffer systems.

**Buffers (Chodera lab).** Buffers used for various biophysical assays are produced in a reproducible fashion by a LabMinds Revo automated buffer maker, which automatically prepares buffers in a reproducible manner, adjusting pH and filtering automatically.

**Buffers (Gibb lab).** Buffers utilized in NMR and ITC titration experiments will be made in-house using ultra-pure water, the purity of which will be verified by on-the-spot conductance measurements.

**Buffers (Overall).** Complete details of all buffers (such as final pH, exact composition of buffer components by mass, manufacturer and lot numbers of all components) are stored online and will be made available as supplementary material.

# PHS Assignment Request Form

**Funding Opportunity Number:** PA-16-160

**Funding Opportunity Title:** NIH Research Project Grant (Parent R01)

## Awarding Component Assignment Request (*optional*)

If you have a preference for an Awarding Component (e.g., NIH Institute/Center) assignment, please use the link below to identify the most appropriate assignment then enter the short abbreviation (e.g., NCI or National Cancer Institute) in "Assign to/Do Not Assign To Awarding Component" sections below. Your first choice should be in column 1. All requests will be considered; however, locus of review is predetermined for some applications and assignment requests cannot always be honored.

*Information about Awarding Components can be found here:*

[https://grants.nih.gov/grants/phs\\_assignment\\_information.htm#AwardingComponents](https://grants.nih.gov/grants/phs_assignment_information.htm#AwardingComponents)

1

2

3

Assign to Awarding Component: NIGMS

Do Not Assign to Awarding Component:

## Study Section Assignment Request (*optional*)

If you have a preference for a study section assignment, please use the link below to identify the most appropriate study section then enter the short abbreviation for that study section in the "Assign to/Do not Assign to Study Section" sections below. Your first choice should be in column 1. All request will be considered; however, locus of review is predetermined for some applications and assignment request cannot always be honored.

For example, you would enter "CAMP" if you wish to request assignment to the Cancer Molecular Pathobiology study section or enter "ZRG1 HDM-R" if you wish to request assignment to the Healthcare Delivery and Methodologies SBIR/STTR panel for informatics. Be careful to accurately capture all formatting (e.g., spaces, hyphens) when you type in the request.

*Information about Study Sections can be found here:*

[https://grants.nih.gov/grants/phs\\_assignment\\_information.htm#StudySection](https://grants.nih.gov/grants/phs_assignment_information.htm#StudySection)

1

2

3

Assign to Study Section:  
(only 20 characters allowed)

Do Not Assign to Study Section:  
(only 20 characters allowed)

## PHS Assignment Request Form

List individuals who should not review your application and why (optional) Only 1000 characters allowed

Identify Scientific areas of expertise needed to review your applications (optional)

Note: Please do not provide names of individuals

1

2

3

4

5

Expertise:

Only 40 characters  
allowed

## Proposal Summary

Proposal Number: Proposal Status:  
Sponsor Deadline: 10/05/2016 Submission Method:  
Submission Type: Application

### INVESTIGATOR DATA

#### PROJECT DIRECTOR / PRINCIPAL INVESTIGATOR CONTACT INFORMATION

Prefix: First Name: <u>DAVID</u>	Middle Name:	Last Name: <u>MOBLEY</u>	Suffix:
Position>Title: <u>Assistant Professor</u>	Organization: <u>The Regents of the University of California, Irvine</u>	Division: <u>DEPARTMENT OF PHARMACEUTICAL S</u>	
Department: <u>PHARMACEUTICAL SCIENCE</u>	Street2: <u></u>	County: <u>Orange</u>	
Street1: <u>3134B Natural Sciences 1</u>	Zip Code: <u>92697-7600</u>	Employee ID: <u>000000963748</u>	
City: <u>Irvine</u>	Fax: <u>(949) 824-2949</u>		
State: <u>CA</u>			
Country: <u>USA</u>			
Phone: <u>(949) 824-6383</u>			
Email: <u>dmobley@uci.edu</u>			

First Budget Period Effort:    Calendar:    Academic: 1.00    Summer:

Status of PI:

Status Waiver Required?

Signed Intellectual Property Waiver Attached?

Signed Conflict of Interest Disclosure Attached?

Agency Certification Documentation Attached?

Cost Sharing Authorization Form Attached?

### SPONSOR DATA

Agency: National Institutes of Health  
Proposal Type  
Sponsor Mechanism: NIH Research Project Grant (Parent R01)  
Sponsor Type:  
Sponsor Code:  
Sponsor Name:  
SubDivision 1:  
SubDivision 2:

### PROJECT DATA

Title of Project: Advancing predictive physical modeling through focused development of model systems to drive new modeling innovations

Is This a Subcontract?

If Yes, who is prime?

Type of Proposal:

Type of Agency:

Kind of Application: New

Previous Grant # or Federal Identifier:

Change in grantee institution?

Type of Project:

### PROJECT ADMINISTRATION

Who is responsible for this research?

Departmental Identification Number:	Primary:	Secondary:
Departmental Name:	Primary:	Secondary:
Primary Dept. Contact Info:		
Account Classification:	Primary:	Secondary:
Other Institutional Code:		
NAICS Code:		

### COMPLIANCE DATA

## Proposal Summary (cont'd)

Are animal subjects used? No  
Is IACUC review pending?  
IACUC Protocol #  
IACUC Approval Date:  
Are human subjects used? No  
Is IRB review pending?  
IRB Protocol #  
IRB Approval Date:  
Does this project involve use of any of the following? Radioactive Material(s), Radiation Producing Devices(s), Recombinant DNA, Biohazardous Chemical(s), Class IIIb or IV Lasers, Other certifications of health, safety and/or environmental compliance.

### BUDGET DATA

Performance Dates	<b>Begin Date</b>	<b>End Date</b>
First Budget Period:	<u>07/01/2017</u>	<u>06/30/2018</u>
Cumulative Budget Period:	<u>07/01/2017</u>	<u>06/30/2022</u>

Cost Sharing Information Committed:	<b>Mandatory</b>	<b>Voluntary</b>
Amount:		
Source:		

Budget Period	<b>Direct Cost</b>	<b>Indirect Cost</b>	<b>Total Cost</b>
Period 1:	<u>319,091</u>	<u>73,439</u>	<u>392,530</u>
Period 2:	<u>327,212</u>	<u>33,924</u>	<u>361,136</u>
Period 3:	<u>349,284</u>	<u>42,803</u>	<u>392,087</u>
Period 4:	<u>358,731</u>	<u>44,853</u>	<u>403,584</u>
Period 5:	<u>367,498</u>	<u>46,023</u>	<u>413,521</u>
Total:	<u>1,721,816</u>	<u>241,042</u>	<u>1,962,858</u>

### AWARD DATA

Award #:      Contract #:      Date:

Budget Period	<b>Direct Cost</b>	<b>Indirect Cost</b>	<b>Total Cost</b>
Period 1:			
Period 2:			
Period 3:			
Period 4:			
Period 5:			
Total:			

### EXPORT CONTROL

1. Will the project involve participation, collaboration or access to information by foreign nationals, defined as: individuals with foreign citizenship, foreign governments, foreign associations and corporations, or foreign political parties? Note: Foreign nationals granted US citizenship, or permanent residence "green card" or granted status as a "protected individual", e.g., political refugees and political asylum holders are "EXEMPT" from deemed export rule.
2. Will the project involve the shipment of equipment, technology, software, materials data or other information?
3. Will the project involve a foreign subcontract or other foreign contractual agreement?

### COMMENTS AND EXPLANATIONS

PLEASE INDICATE ANY SPECIAL INSTRUCTIONS BELOW:

---